[
  {
    "title": "ANK2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ank2/",
    "content": "**ANK2 Gene**\n\nThe ANK2 gene provides instructions for making a protein called ankyrin-B. Ankyrin-B is part of a family of ankyrin proteins, which interact with many other types of proteins in cells throughout the body.\n\n*   **Normal Function**\n    *   Ankyrins help organize the cell's structural framework (the cytoskeleton) and link certain proteins that span the cell membrane to this framework.\n    *   Ankyrins play key roles in important functions including cell movement (migration) and cell growth and division (proliferation).\n    *   The ankyrin-B protein is active in many cell types, particularly in the brain and in heart (cardiac) muscle.\n    *   This protein mainly interacts with ion channels and ion transporters, which are complexes of proteins that move charged atoms (ions) across cell membranes.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Ankyrin-B Syndrome**\n    *   At least ten mutations in the ANK2 gene have been found to cause ankyrin-B syndrome, a condition characterized by a variety of heart problems.\n    *   Most often, mutations in the ANK2 gene lead to abnormalities of the heart's natural pacemaker (the sinoatrial node), a heart rate that is slower than normal (bradycardia), a disruption in the rhythm of the heart (arrhythmia), and an increased risk of fainting (syncope) and sudden death.\n    *   Each of the identified mutations in the ANK2 gene changes a single protein building block (amino acid) in the ankyrin-B protein.\n\n---\n\n**ANK2 Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Category:** general\n\nAs a result of these genetic changes, the ankyrin-B protein cannot target ion channels and ion transporters to their correct locations in cardiac muscle cells. Although the channels and transporters are produced normally by the cell, they are unable to function if they are not inserted correctly into the cell membrane. This loss of functional channels and transporters in the heart disrupts the normal flow of ions, which alters the heart's normal rhythm and leads to the heart problems that can be a part of ankyrin-B syndrome.\n\n**More About This Health Condition**\n\n*   **Autism Spectrum Disorder**: MedlinePlus Genetics provides information about Autism spectrum disorder\n*   **Ankyrin-B Syndrome**: At least ten mutations in the ANK2 gene have been found to cause ankyrin-B syndrome, a condition characterized by a variety of heart problems. Most often, mutations in the ANK2 gene lead to abnormalities of the heart's natural pacemaker (the sinoatrial node), a heart rate that is slower than normal (bradycardia), a disruption in the rhythm of the heart (arrhythmia), and an increased risk of fainting (syncope) and sudden death.\n\n**Other Names for This Gene**\n\n*   ANK2_HUMAN\n*   ankyrin 2\n*   neuronal ankyrin B\n*   ankyrin, brain ankyrin, nonerythroid ankyrin-2, nonerythrocytic brank-2\n*   LQT4\n\n**Additional Information & Resources**\n\n*   **Tests Listed in the Genetic Testing Registry**: Tests of ANK2\n*   **Scientific Articles on PubMed**: PubMed\n*   **Catalog of Genes and Diseases from OMIM**: ANKYRIN 2; ANK2\n\n---\n\n**ANK2 Gene**\n\n**Tests of ANK2**\n\n*   **Scientific Articles on PubMed**\n    *   Chiang CE. Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev. 2004 Jul-Aug;12(4):222-34. doi: 10.1097/01.crd.0000123842.42287.cf. Citation on PubMed\n    *   Cunha SR, Mohler PJ. Obscurin targets ankyrin-B and protein phosphatase 2A to the cardiac M-line. J Biol Chem. 2008 Nov 14;283(46):31968-80. doi: 10.1074/jbc.M806050200. Epub 2008 Sep 9. Citation on PubMed or Free article on PubMed Central\n    *   Groffen AJ, Bikker H, Christiaans I. Long QT Syndrome Overview. 2003 Feb 20 [updated 2024 Mar 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from http://www.ncbi.nlm.nih.gov/books/NBK1129/. Citation on PubMed\n    *   Mohler PJ, Bennett V. Ankyrin-based cardiac arrhythmias: a new class of channelopathies due to loss of cellular targeting. Curr Opin Cardiol. 2005 May;20(3):189-93. doi: 10.1097/01.hco.0000160372.95116.3e. Citation on PubMed\n    *   Mohler PJ, Gramolini AO, Bennett V. Ankyrins. J Cell Sci. 2002 Apr 15;115(Pt 8):1565-6. doi: 10.1242/jcs.115.8.1565. No abstract available. Citation on PubMed\n    *   Mohler PJ, Le Scouarnec S, Denjoy I, Lowe JS, Guicheney P, Caron L, Driskell IM, Schott JJ, Norris K, Leenhardt A, Kim RB, Escande D, Roden DM. Defining the cellular phenotype of \"ankyrin-B syndrome\" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation. 2007 Jan 30;115(4):432-41. doi: 10.1161/CIRCULATIONAHA.106.656512. Epub 2007 Jan 22. Citation on PubMed\n    *   Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003 Feb 6;421(6923):634-9. doi: 10.1038/nature01335. Citation on PubMed\n    *   Mohler PJ, Splawski I, Napolitano C, Bottelli G, Sharpe L, Timothy K, Priori SG, Keating MT, Bennett V. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9137-42. doi: 10.1073/pnas.0402546101. Epub 2004 Jun 3. Citation on PubMed or Free article on PubMed Central\n    *   Sherman J, Tester DJ, Ackerman MJ. Targeted mutational analysis of ankyrin-B in 541 consecutive, unrelated patients referred for long QT syndrome genetic testing and 200 healthy subjects. Heart Rhythm. 2005 Nov;2(11):1218-23. doi: 10.1016/j.hrthm.2005.07.026. Citation on PubMed\n\n**Genomic Location**\n\nThe ANK2 gene is found on chromosome 4.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ANKH gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ankh/",
    "content": "**ANKH Gene**\n\nThe ANKH gene provides instructions for making a protein that is involved in skeletal development. The ANKH protein plays a role in the development and function of cells that build bones (osteoblasts) and cells that break down bone (osteoclasts). Osteoclasts are involved in bone remodeling, a normal process in which old bone is removed and new bone is created to replace it.\n\nIn addition, the ANKH protein transports a molecule called pyrophosphate out of cells to the intricate network of proteins that forms in the spaces between cells (extracellular matrix). This extracellular pyrophosphate helps regulate bone formation by preventing mineralization, the process by which minerals such as calcium and phosphorus are deposited in tissues. The ANKH protein may have other, unknown functions.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Craniometaphyseal Dysplasia**: More than 10 mutations in the ANKH gene have been found to cause autosomal dominant craniometaphyseal dysplasia, a condition characterized by thickening of bones in the skull (cranium) and widening of a region at the end of long bones known as the metaphysis. Some mutations change a single protein building block (amino acid) in the ANKH protein, whereas others insert or delete one or more amino acids in the protein. These changes disrupt the functioning of osteoblasts and osteoclasts. In particular, the maturation (differentiation) of osteoclasts is impaired, which likely disrupts bone remodeling. Reduced breakdown of bone tissue can contribute to the bone thickening characteristic of craniometaphyseal dysplasia. The altered ANKH proteins may also be less able to transport pyrophosphate out of cells. A shortage of extracellular pyrophosphate can increase bone mineralization, which may also contribute to the bone abnormalities.\n\n---\n\n**ANKH Gene**\n\n\\n\\n\n\n*Other Disorders*\n\nAt least five mutations in the ANKH gene have been found to cause a rare hereditary form of a cartilage disorder called calcium pyrophosphate dihydrate deposition disease (CPPDD). CPPDD, also called chondrocalcinosis or pseudogout, is characterized by the accumulation of calcium pyrophosphate dihydrate crystals in the cartilage, the tough but flexible tissue that covers the ends of bones at the joints. The buildup of these crystals weakens cartilage and causes it to break down more easily. The crystals may cause inflammation in the joints, which can be painful.\n\nMost cases of CPPDD occur in people older than 40, are not inherited, and have an unknown cause. However, inherited mutations in the ANKH gene have been shown to cause CPPDD in a few families. In these families, one altered copy of the ANKH gene in each cell is sufficient to cause the condition. Individuals with familial CPPDD caused by ANKH gene mutations typically form crystal deposits within multiple joints during early adulthood. Researchers believe that these mutations lead to elevated pyrophosphate levels in the extracellular matrix. High levels of pyrophosphate result in excessive formation of calcium pyrophosphate dihydrate crystals within joints.\n\nStudies suggest that certain variations (polymorphisms) in the ANKH gene are associated with the normal differences in bone size and shape among individuals. These polymorphisms probably result in slight changes in the activity of the ANKH protein, affecting the levels of pyrophosphate in the extracellular matrix.\n\n\\n\\n\n\n*Craniometaphyseal Dysplasia*\n\nMore than 10 mutations in the ANKH gene have been found to cause autosomal dominant craniometaphyseal dysplasia, a condition characterized by thickening of bones in the skull (cranium) and widening of a region at the end of long bones known as the metaphysis. Some mutations change a single protein building block (amino acid) in the ANKH protein, whereas others insert or delete one or more amino acids in the protein. These changes disrupt the functioning of osteoblasts and osteoclasts. In particular, the maturation (differentiation) of osteoclasts is impaired, which likely disrupts bone remodeling. Reduced breakdown of bone tissue can contribute to the bone thickening characteristic of craniometaphyseal dysplasia. The altered ANKH proteins may also be less able to transport pyrophosphate out of cells. A shortage of extracellular pyrophosphate can increase bone mineralization, which may also contribute to the bone abnormalities.\n\n\\n\\n\n\n*Other Disorders*\n\nAt least five mutations in the ANKH gene have been found to cause a rare hereditary form of a cartilage disorder called calcium pyrophosphate dihydrate deposition disease (CPPDD).\n\n---\n\n**ANKH Gene**\n\nThe **ANKH gene** plays a crucial role in the development and maintenance of cartilage, particularly in regulating the levels of pyrophosphate in the extracellular matrix.\n\n**Calcium Pyrophosphate Dihydrate Deposition Disease (CPPDD)**\n\nAt least five mutations in the ANKH gene have been found to cause a rare hereditary form of a cartilage disorder called calcium pyrophosphate dihydrate deposition disease (CPPDD). CPPDD, also known as chondrocalcinosis or pseudogout, is characterized by the accumulation of calcium pyrophosphate dihydrate crystals in the cartilage. The buildup of these crystals weakens cartilage and causes it to break down more easily.\n\n**Inherited Mutations**\n\nMost cases of CPPDD occur in people older than 40, are not inherited, and have an unknown cause. However, inherited mutations in the ANKH gene have been shown to cause CPPDD in a few families. In these families, one altered copy of the ANKH gene in each cell is sufficient to cause the condition.\n\n**Variations in the ANKH Gene**\n\nStudies suggest that certain variations (polymorphisms) in the ANKH gene are associated with the normal differences in bone size and shape among individuals. These polymorphisms probably result in slight changes in the activity of the ANKH protein, affecting the levels of pyrophosphate in the extracellular matrix.\n\n**Other Names for This Gene**\n\n* ANK\n* ANKH_HUMAN\n* ankylosis, progressive homolog (mouse)\n* FLJ27166\n* HANK\n* MANK\n* progressive ankylosis protein\n* SLC62A1\n\n**References**\n\n* Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem. 2007 May 25;282(21):15872-83.\n* Chen IP, Luxmi R, Kanaujiya J, Hao Z, Reichenberger EJ. Craniometaphyseal Dysplasia Mutations in ANKH Negatively Affect Human Induced Pluripotent Stem Cell Differentiation into Osteoclasts. Stem Cell Reports. 2017 Nov 14;9(5):1369-1376.\n* Chen IP, Wang L, Jiang X, Aguila HL, Reichenberger EJ. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD). Hum Mol Genet. 2011 Mar 1;20(5):948-61.\n* Gurley KA, Reimer RJ, Kingsley DM. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet. 2006 Dec;79(6):1017-29.\n* Korostishevsky M, Vistoropsky Y, Malkin I, Kobyliansky E, Livshits G. Anthropometric and bone-related biochemical factors are associated with different haplotypes of ANKH locus. Ann Hum Biol. 2008 Sep-Oct;35(5):535-46.\n* Malkin I, Dahm S, Suk A, Kobyliansky E, Toliat M, Ruf N, Livshits G, Nurnberg P. Association of ANKH gene polymorphisms with radiographic hand bone size and geometry in a Chuvasha population. Bone. 2005 Feb;36(2):365-73.\n* Malkin I, Ermakov S, Kobyliansky E, Livshits G. Strong association between polymorphisms in ANKH locus and skeletal size traits. Hum Genet. 2006 Aug;120(1):42-51.\n* Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, Leschik G, Uhlmann K, Mischung C, Harrop K, Goldblatt J, Borochowitz ZU, Kotzot D, Westermann F, Mundlos S, Braun HS, Laing N, Tinschert S. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet. 2001 May;28(1):37-41.\n* Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, Reginato A, Shiang R, Wright G, Netter P, Williams C, Kingsley DM. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet. 2002 Oct;71(4):933-40.\n* Reichenberger E, Chen IP. Craniometaphyseal Dysplasia, Autosomal Dominant. 2007 Aug 27 [updated 2020 Jun 11]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n* Reichenberger E, Tiziani V, Watanabe S, Park L, Ueki Y, Santanna C, Baur ST, Shiang R, Grange DK, Beighton P, Gardner J, Hamersma H, Sellars S, Ramesar R, Lidral AC, Sommer A, Raposo do Amaral CM, Gorlin RJ, Mulliken JB, Olsen BR. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001 Jun;68(6):1321-6.\n* Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther. 2005;7(3):R513-25.\n* Williams CJ. The role of ANKH in pathologic mineralization of cartilage. Curr Opin Rheumatol. 2016 Mar;28(2):145-51.\n* Zaka R, Williams CJ. Genetics of chondrocalcinosis. Osteoarthritis Cartilage. 2005 Sep;13(9):745-50.\n* Zaka R, Williams CJ. Role of the progressive ankylosis gene in cartilage mineralization. Curr Opin Rheumatol. 2006 Mar;18(2):181-6.\n\n**Tests Listed in the Genetic Testing Registry**\n\n* Tests of ANKH\n\n**Scientific Articles on PubMed**\n\n* PubMed\n\n**Catalog of Genes and Diseases from OMIM**\n\n* CHONDROCALCINOSIS 2; CCAL2\n* ANKH INORGANIC PYROPHOSPHATE TRANSPORT REGULATOR; ANKH\n\n**Gene and Variant Databases**\n\n* NCBI Gene\n* ClinVar\n\n---\n\n**ANKH Gene**\n\nThe ANKH gene is located on chromosome 5 and plays a crucial role in bone formation and mineralization. Mutations in the ANKH gene have been associated with various skeletal disorders, including craniometaphyseal dysplasia and chondrocalcinosis.\n\n**Research Studies**\n\nSeveral research studies have investigated the relationship between the ANKH gene and skeletal diseases. Some of these studies include:\n\n*   Luxmi R et al. (2017) Craniometaphyseal Dysplasia Mutations in ANKH Negatively Affect Human Induced Pluripotent Stem Cell Differentiation into Osteoclasts.\n*   Chen IP et al. (2011) A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD).\n*   Gurley KA et al. (2006) Biochemical and genetic analysis of ANK in arthritis and bone disease.\n*   Korostishevsky M et al. (2008) Anthropometric and bone-related biochemical factors are associated with different haplotypes of ANKH locus.\n*   Malkin I et al. (2005) Association of ANKH gene polymorphisms with radiographic hand bone size and geometry in a Chuvasha population.\n*   Malkin I et al. (2006) Strong association between polymorphisms in ANKH locus and skeletal size traits.\n*   Nurnberg P et al. (2001) Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia.\n\n**Genomic Location**\n\nThe ANKH gene is found on chromosome 5.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ANKRD11 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ankrd11/",
    "content": "**ANKRD11 Gene**\n\nThe ANKRD11 gene provides instructions for making a protein called ankyrin repeat domain 11 (ANKRD11). As its name suggests, this protein contains multiple regions called ankyrin domains; proteins with these domains help other proteins interact with each other.\n\n**Normal Function**\n\n*   The ANKRD11 protein interacts with certain proteins called histone deacetylases, which are important for controlling gene activity.\n*   Through these interactions, ANKRD11 affects when genes are turned on and off.\n*   For example, ANKRD11 brings together histone deacetylases and other proteins called p160 coactivators. This association regulates the ability of p160 coactivators to turn on gene activity.\n*   ANKRD11 may also enhance the activity of a protein called p53, which controls the growth and division (proliferation) and the self-destruction (apoptosis) of cells.\n\n**Health Conditions Related to Genetic Changes**\n\nSeveral ANKRD11 gene mutations have been found to cause KBG syndrome, a condition characterized by large upper front teeth and other unusual facial features, skeletal abnormalities, and intellectual disability. Most of these mutations lead to an abnormally short ANKRD11 protein, which likely has little or no function.\n\n**References**\n\n*   The ANKRD11 gene provides instructions for making a protein called ankyrin repeat domain 11 (ANKRD11).\n*   As its name suggests, this protein contains multiple regions called ankyrin domains; proteins with these domains help other proteins interact with each other.\n*   The ANKRD11 protein interacts with certain proteins called histone deacetylases, which are important for controlling gene activity.\n*   Through these interactions, ANKRD11 affects when genes are turned on and off.\n*   For example, ANKRD11 brings together histone deacetylases and other proteins called p160 coactivators. This association regulates the ability of p160 coactivators to turn on gene activity.\n*   ANKRD11 may also enhance the activity of a protein called p53, which controls the growth and division (proliferation) and the self-destruction (apoptosis) of cells.\n\n**ANKRD11 Protein**\n\nThe ANKRD11 protein is found in nerve cells (neurons) in the brain. During embryonic development, ANKRD11 helps regulate the proliferation of these cells and development of the brain. Researchers speculate that the protein may also be involved in the ability of neurons to change and adapt over time (plasticity), which is important for learning and memory. ANKRD11 may function in other cells in the body and appears to be involved in normal bone development.\n\n**KBG Syndrome**\n\nSeveral ANKRD11 gene mutations have been found to cause KBG syndrome, a condition characterized by large upper front teeth and other unusual facial features, skeletal abnormalities, and intellectual disability. Most of these mutations lead to an abnormally short ANKRD11 protein, which likely has little or no function. Reduction of this protein's function is thought to underlie the signs and symptoms of the condition. Because ANKRD11 is thought to play an important role in neurons and brain development, researchers speculate that a partial loss of its function may lead to developmental delay and intellectual disability in KBG syndrome. However, the mechanism is not fully known.\n\n---\n\n**ANKRD11 Gene**\n\n**What is the ANKRD11 gene?**\n\nThe ANKRD11 gene provides instructions for making a protein called ankyrin repeat domain-containing protein 11. This protein plays a crucial role in various cellular processes, including cell growth and division.\n\n**How does the ANKRD11 gene affect human health?**\n\nMutations in the ANKRD11 gene have been linked to KBG syndrome, a condition characterized by large upper front teeth and other unusual facial features, skeletal abnormalities, and intellectual disability. The mechanism behind this is not fully understood, but researchers speculate that a partial loss of ANKRD11 function may lead to developmental delay and intellectual disability.\n\n**What are the symptoms of KBG syndrome?**\n\nThe symptoms of KBG syndrome include:\n\n* Large upper front teeth\n* Unusual facial features\n* Skeletal abnormalities\n* Intellectual disability\n\n**What is 16q24.3 microdeletion syndrome?**\n\n16q24.3 microdeletion syndrome is a separate disorder that affects the ANKRD11 gene, along with other nearby genes. People with this type of mutation have similar signs and symptoms to those of KBG syndrome, including unusual facial features and intellectual disability.\n\n**Other names for the ANKRD11 gene**\n\nThe ANKRD11 gene has several other names, including:\n\n* ANCO-1\n* ANCO1\n* Ankyrin repeat domain-containing protein 11\n* Ankyrin repeat-containing cofactor 1\n* LZ16\n* Nasopharyngeal carcinoma susceptibility protein T13\n\n**Additional information and resources**\n\nFor more information on the ANKRD11 gene, you can consult the following resources:\n\n* Tests listed in the Genetic Testing Registry\n* Scientific articles on PubMed\n* Catalog of genes and diseases from OMIM\n\n---\n\n**ANKRD11 Gene**\n\nThe ANKRD11 gene is located on chromosome 16.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Genomic Location**\n\nThe ANKRD11 gene is found on chromosome 16.\n\n**Scientific Articles on PubMed**\n\n* Gallagher D, Voronova A, Zander MA, Cancino GI, Bramall A, Krause MP, Abad C, Tekin M, Neilsen PM, Callen DF, Scherer SW, Keller GM, Kaplan DR, Walz K, Miller FD. Ankrd11 is a chromatin regulator involved in autism that is essential for neural development. Dev Cell. 2015 Jan 12;32(1):31-42.\n* Kim HJ, Cho E, Park JB, Im WY, Kim HJ. A Korean family with KBG syndrome identified by ANKRD11 mutation, and phenotypic comparison of ANKRD11 mutation and 16q24.3 microdeletion. Eur J Med Genet. 2015 Feb;58(2):86-94.\n* Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF. Identification of ANKRD11 as a p53 coactivator. J Cell Sci. 2008 Nov 1;121(Pt 21):3541-52.\n* Sacharow S, Li D, Fan YS, Tekin M. Familial 16q24.3 microdeletion involving ANKRD11 causes a KBG-like syndrome. Am J Med Genet A. 2012 Mar;158A(3):547-52.\n* Sirmaci A, Spiliopoulos M, Brancati F, Powell E, Duman D, Abrams A, Bademci G, Agolini E, Guo S, Konuk B, Kavaz A, Blanton S, Digilio MC, Dallapiccola B, Young J, Zuchner S, Tekin M. Mutations in ANKRD11 cause KBG syndrome, characterized by intellectual disability, skeletal malformations, and macrodontia. Am J Hum Genet. 2011 Aug 12;89(2):289-94.\n* Walz K, Cohen D, Neilsen PM, Foster J 2nd, Brancati F, Demir K, Fisher R, Moffat M, Verbeek NE, Bjorgo K, Lo Castro A, Curatolo P, Novelli G, Abad C, Lei C, Zhang L, Diaz-Horta O, Young JI, Callen DF, Tekin M. Characterization of ANKRD11 mutations in humans and mice related to KBG syndrome. Hum Genet. 2015 Feb;134(2):181-90.\n* Willemsen MH, Fernandez BA, Bacino CA, Gerkes E, de Brouwer AP, Pfundt R, Sikkema-Raddatz B, Scherer SW, Marshall CR, Potocki L, van Bokhoven H, Kleefstra T. Identification of ANKRD11 and ZNF778 as candidate genes for autism and variable cognitive impairment in the novel 16q24.3 microdeletion syndrome. Eur J Hum Genet. 2010 Apr;18(4):429-35.\n* Zhang A, Yeung PL, Li CW, Tsai SC, Dinh GK, Wu X, Li H, Chen JD. Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. J Biol Chem. 2004 Aug 6;279(32):33799-805.\n\n**References**\n\n* Gallagher D, Voronova A, Zander MA, Cancino GI, Bramall A, Krause MP, Abad C, Tekin M, Neilsen PM, Callen DF, Scherer SW, Keller GM, Kaplan DR, Walz K, Miller FD. Ankrd11 is a chromatin regulator involved in autism that is essential for neural development. Dev Cell. 2015 Jan 12;32(1):31-42.\n* Kim HJ, Cho E, Park JB, Im WY, Kim HJ. A Korean family with KBG syndrome identified by ANKRD11 mutation, and phenotypic comparison of ANKRD11 mutation and 16q24.3 microdeletion. Eur J Med Genet. 2015 Feb;58(2):86-94.\n* Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF. Identification of ANKRD11 as a p53 coactivator. J Cell Sci. 2008 Nov 1;121(Pt 21):3541-52.\n* Sacharow S, Li D, Fan YS, Tekin M. Familial 16q24.3 microdeletion involving ANKRD11 causes a KBG-like syndrome. Am J Med Genet A. 2012 Mar;158A(3):547-52.\n* Sirmaci A, Spiliopoulos M, Brancati F, Powell E, Duman D, Abrams A, Bademci G, Agolini E, Guo S, Konuk B, Kavaz A, Blanton S, Digilio MC, Dallapiccola B, Young J, Zuchner S, Tekin M. Mutations in ANKRD11 cause KBG syndrome, characterized by intellectual disability, skeletal malformations, and macrodontia. Am J Hum Genet. 2011 Aug 12;89(2):289-94.\n* Walz K, Cohen D, Neilsen PM, Foster J 2nd, Brancati F, Demir K, Fisher R, Moffat M, Verbeek NE, Bjorgo K, Lo Castro A, Curatolo P, Novelli G, Abad C, Lei C, Zhang L, Diaz-Horta O, Young JI, Callen DF, Tekin M. Characterization of ANKRD11 mutations in humans and mice related to KBG syndrome. Hum Genet. 2015 Feb;134(2):181-90.\n* Willemsen MH, Fernandez BA, Bacino CA, Gerkes E, de Brouwer AP, Pfundt R, Sikkema-Raddatz B, Scherer SW, Marshall CR, Potocki L, van Bokhoven H, Kleefstra T. Identification of ANKRD11 and ZNF778 as candidate genes for autism and variable cognitive impairment in the novel 16q24.3 microdeletion syndrome. Eur J Hum Genet. 2010 Apr;18(4):429-35.\n* Zhang A, Yeung PL, Li CW, Tsai SC, Dinh GK, Wu X, Li H, Chen JD. Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. J Biol Chem. 2004 Aug 6;279(32):33799-805.\n\n**Genomic Location**\n\nThe ANKRD11 gene is found on chromosome 16.\n\n---\n\n**ANKRD11 Gene**\n\n\\n\\n* **What is the ANKRD11 gene?**\n* **How do genetic variations affect the ANKRD11 gene?**\n* **Can the ANKRD11 gene be associated with any specific diseases or conditions?**\n\nNote: The original content has been reformatted to include bold headings and a clear separation of sections. The standalone URLs, code blocks, ads, disclaimers, and repetitive text have been removed while maintaining the medical information and HTML tags.",
    "category": "general"
  },
  {
    "title": "ANO5 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ano5/",
    "content": "**ANO5 Gene**\n\nThe ANO5 gene provides instructions for making a protein called anoctamin-5. While the specific function of this protein is not well understood, it belongs to a family of proteins, called anoctamins, that act as chloride channels.\n\n**Normal Function**\n\n* Chloride channels transport negatively charged chlorine atoms (chloride ions) in and out of cells.\n* They play a key role in a cell's ability to generate and transmit electrical signals.\n* Most anoctamin proteins function as chloride channels that are turned on (activated) in the presence of positively charged calcium atoms (calcium ions).\n* Anoctamin proteins are also involved in maintaining the membrane that surrounds cells and repairing the membrane if it gets damaged.\n\n**Health Conditions Related to Genetic Changes**\n\nThe ANO5 gene is associated with certain health conditions, including:\n\n* **Muscular dystrophy**: Mutations in the ANO5 gene have been linked to various forms of muscular dystrophy.\n* **Myopathy**: The ANO5 gene has also been implicated in myopathies, which are muscle disorders.\n\n**Other Names for This Gene**\n\nThe ANO5 gene is also known as:\n\n* anoctamin 5\n* ANO5\n\n**Additional Information & Resources**\n\nFor more information on the ANO5 gene, please refer to the following resources:\n\n* National Center for Biotechnology Information (NCBI)\n* Online Mendelian Inheritance in Man (OMIM)\n\n**References**\n\nThe following references provide further information on the ANO5 gene:\n\n* [Insert reference citations]\n\n---\n\n**ANO5 Gene**\n\nThe ANO5 gene provides instructions for making a protein called anoctamin-5. While the specific function of this protein is not well understood, it belongs to a family of proteins, called anoctamins, that act as chloride channels.\n\n**Function of Anoctamin-5 Protein**\n\nAnoctamin-5 protein is most abundant in muscles used for movement (skeletal muscles). For the body to move normally, skeletal muscles must tense (contract) and relax in a coordinated way. The regulation of chloride flow within muscle cells plays a role in controlling muscle contraction and relaxation.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Gnathodiaphyseal Dysplasia**: At least three ANO5 gene mutations have been identified in people with a bone disorder called gnathodiaphyseal dysplasia, which leads to fragile bones, jaw problems, and other skeletal abnormalities.\n* **Limb-Girdle Muscular Dystrophy**: More than 40 mutations in the ANO5 gene have been identified in people with limb-girdle muscular dystrophy type 2L. Limb-girdle muscular dystrophy is a group of related disorders characterized by muscle weakness and wasting, particularly in the shoulders, hips, thighs, and upper arms.\n* **Miyoshi Myopathy**: At least 10 mutations in the ANO5 gene have been found to cause Miyoshi myopathy. When caused by mutations in this gene, the condition is also known as distal anoctaminopathy.\n\n**Relationship Between Mutations and Health Conditions**\n\nThe ANO5 gene mutations that cause gnathodiaphyseal dysplasia change single protein building blocks (amino acids) in the anoctamin-5 protein. It is unclear how these mutations lead to the signs and symptoms of gnathodiaphyseal dysplasia, or why they primarily affect bones while other ANO5 gene mutations cause muscle disorders.\n\nThe ANO5 gene mutations identified in people with limb-girdle muscular dystrophy type 2L change single amino acids in the anoctamin-5 protein sequence, disrupt how genetic information is pieced together to make a blueprint for producing the protein, or result in a premature stop signal that leads to an abnormally short protein.\n\nThe effects of the loss of anoctamin-5 are unclear. While chloride is necessary for normal muscle function, it is unknown how a lack of this chloride channel causes the signs and symptoms of Miyoshi myopathy.\n\n---\n\n**ANO5 Gene**\n\nThe ANO5 gene plays a crucial role in bone development and growth.\n\n**Limb-Girdle Muscular Dystrophy**\n\n* More than 40 mutations in the ANO5 gene have been identified in people with limb-girdle muscular dystrophy type 2L.\n* Limb-girdle muscular dystrophy is a group of related disorders characterized by muscle weakness and wasting (atrophy), particularly in the shoulders, hips, thighs, and upper arms.\n* The ANO5 gene mutations identified in people with limb-girdle muscular dystrophy type 2L change single amino acids in the anoctamin-5 protein sequence, disrupt how genetic information is pieced together to make a blueprint for producing the protein, or result in a premature stop signal that leads to an abnormally short protein.\n* One of the mutations adds an extra DNA building block (nucleotide) to the ANO5 gene (written as 191dupA) and is believed to be a relatively common cause of limb-girdle muscular dystrophy in people with northern European ancestry.\n\n**Miyoshi Myopathy**\n\n* At least 10 mutations in the ANO5 gene have been found to cause Miyoshi myopathy.\n* When caused by mutations in this gene, the condition is also known as distal anoctaminopathy.\n* Miyoshi myopathy is a muscle disorder that is characterized by progressive weakness and atrophy of muscles that are away from the center of the body (distal muscles), particularly those in the legs.\n* The ANO5 gene mutations identified in people with Miyoshi myopathy change single amino acids in the anoctamin-5 protein or result in the production of an abnormally short protein that is quickly broken down.\n\n**Relationship Between ANO5 Gene Mutations and Muscle Function**\n\n* ANO5 gene mutations that eliminate or impair the role of the anoctamin-5 protein as a chloride channel likely lead to impaired muscle function, resulting in the signs and symptoms of limb-girdle muscular dystrophy.\n* The effects of the loss of anoctamin-5 are unclear. While chloride is necessary for normal muscle function, it is unknown how a lack of this chloride channel causes the signs and symptoms of Miyoshi myopathy.\n\n---\n\n**ANO5 Gene: MedlinePlus Genetics (Part 4/5)**\n\n**Introduction**\n\nThe ANO5 gene is responsible for producing a protein called anoctamin-5, which plays a crucial role in muscle function. Mutations in the ANO5 gene can lead to various muscular dystrophies, including Miyoshi myopathy and limb-girdle muscular dystrophy.\n\n**Production of Abnormally Short Protein**\n\nIndividuals with ANO5 mutations produce an abnormally short protein that is quickly broken down. This results in little or no anoctamin-5 protein being produced.\n\n**Effects of Loss of Anoctamin-5**\n\nThe effects of the loss of anoctamin-5 are unclear. While chloride is necessary for normal muscle function, it is unknown how a lack of this chloride channel causes the signs and symptoms of Miyoshi myopathy.\n\n**Common Cause of Miyoshi Myopathy**\n\nIn individuals of northern European ancestry, the 191dupA mutation that can cause limb-girdle muscular dystrophy is also a common cause of Miyoshi myopathy. It is not known why the 191dupA mutation can result in different patterns of signs and symptoms.\n\n**Variation of Limb-Girdle Muscular Dystrophy**\n\nMiyoshi myopathy caused by ANO5 gene mutations is likely a variation of limb-girdle muscular dystrophy because it is caused by mutations in the same gene, and in some cases even by the same mutation.\n\n**Other Names for This Gene**\n\n* ANO5_HUMAN\n* anoctamin-5\n* GDD1\n* gnathodiaphyseal dysplasia 1 protein\n* integral membrane protein\n* GDD1\n* LGMD2L\n* TMEM16E\n* transmembrane protein 16E\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry\n* Scientific Articles on PubMed\n* Catalog of Genes and Diseases from OMIM\n* Gene and Variant Databases\n\n**References**\n\n* Bolduc V, Marlow G, Boycott KM, Saleki K, Inoue H, Kroon J, Itakura M, Robitaille Y, Parent L, Baas F, Mizuta K, Kamata N, Richard I, Linssen WH, Mahjneh I, de Visser M, Bashir R, Brais B. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet. 2010 Feb 12;86(2):213-21.\n* Bouquet F, Cossee M, Behin A, Deburgrave N, Romero N, Leturcq F, Eymard B. Miyoshi-like distal myopathy with mutations in anoctamin 5 gene. Rev Neurol (Paris). 2012 Feb;168(2):135-41.\n* Hartzell HC, Yu K, Xiao Q, Chien LT, Qu Z. Anoctamin/TMEM16 family members are Ca2+-activated Cl- channels. J Physiol. 2009 May 15;587(Pt 10):2127-39.\n* Hicks D, Sarkozy A, Muelas N, Koehler K, Huebner A, Hudson G, Chinnery PF, Barresi R, Eagle M, Polvikoski T, Bailey G, Miller J, Radunovic A, Hughes PJ, Roberts R, Krause S, Walter MC, Laval SH, Straub V, Lochmuller H, Bushby K. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain. 2011 Jan;134(Pt 1):171-182.\n* Liewluck T, Winder TL, Dimberg EL, Crum BA, Heppelmann CJ, Wang Y, Bergen HR 3rd, Milone M. ANO5-muscular dystrophy: clinical, pathological and molecular findings. Eur J Neurol. 2013 Oct;20(10):1383-9.\n* Mahjneh I, Jaiswal J, Lamminen A, Somer M, Marlow G, Kiuru-Enari S, Bashir R. A new distal myopathy with mutation in anoctamin 5. Neuromuscul Disord. 2010 Dec;20(12):791-5.\n* Penttila S, Palmio J, Suominen T, Raheem O, Evila A, Muelas Gomez N, Tasca G, Waddell LB, Clarke NF, Barboi A, Hackman P, Udd B. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology. 2012 Mar 20;78(12):897-903.\n* Sarkozy A, Hicks D, Hudson J, Laval SH, Barresi R, Hilton-Jones D, Deschauer M, Harris E, Rufibach L, Hwang E, Bashir R, Walter MC, Krause S, van den Bergh P, Illa I, Penisson-Besnier I, De Waele L, Turnbull D, Guglieri M, Schrank B, Schoser B, Seeger J, Schreiber H, Glaser D, Eagle M, Bailey G, Walters R, Longman C, Norwood F, Winer J, Muntoni F, Hanna M, Roberts M, Bindoff LA, Brierley C, Cooper RG, Cottrell DA, Davies NP, Gibson A, Gorman GS, Hammans S, Jackson AP, Khan A, Lane R, McConville J, McEntagart M, Al-Memar A, Nixon J, Panicker J, Parton M, Petty R, Price CJ, Rakowicz W, Ray P, Schapira AH, Swingler R, Turner C, Wagner KR, Maddison P, Shaw PJ, Straub V, Bushby K, Lochmuller H. ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation. Hum Mutat. 2013 Aug;34(8):1111-8.\n* Tsutsumi S, Kamata N, Vokes TJ, Maruoka Y, Nakakuki K, Enomoto S, Omura K, Amagasa T, Nagayama M, Saito-Ohara F, Inazawa J, Moritani M, Yamaoka T, Inoue H, Itakura M. The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD). Am J Hum Genet. 2004 Jun;74(6):1255-61.\n\n---\n\n**ANO5 Gene**\n\n**Genomic Location**\nThe ANO5 gene is found on chromosome 11.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ANOS1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/anos1/",
    "content": "**ANOS1 Gene**\n\nThe ANOS1 gene, also known as KAL1, provides instructions for making a protein called anosmin-1. This protein is involved in development before birth.\n\n* Found in the extracellular matrix\n* Active in many parts of the developing embryo, including:\n\t+ Respiratory tract\n\t+ Kidneys\n\t+ Digestive system\n\t+ Certain regions of the brain\n\nResearchers are working to determine the functions of anosmin-1. They have discovered that, in the developing brain, this protein is involved in:\n\n* The movement (migration) of nerve cells\n* The outgrowth of axons, which are specialized extensions of nerve cells that transmit nerve impulses\n* Regulating contact between nerve cells (cell adhesion)\n\nAnosmin-1 appears to help control the growth and migration of a group of nerve cells that are specialized to process the sense of smell (olfactory neurons). These nerve cells originate in the developing nose and then migrate together to a structure in the front of the brain called the olfactory bulb, which is critical for the perception of odors.\n\nStudies suggest that anosmin-1 is also involved in the migration of neurons that produce a hormone called gonadotropin-releasing hormone (GnRH). Like olfactory neurons, GnRH-producing neurons migrate from the developing nose to the front of the brain. GnRH controls the production of several hormones that direct sexual development before birth and during puberty. These hormones are important for the normal function of the ovaries in women and testes in men.\n\n\\n\\n\n\n---\n\n**ANOS1 Gene: MedlinePlus Genetics (Part 2/4)**\n\n**Developmental Role of Anosmin-1**\n\nAnosmin-1 plays a crucial role in development before birth. It is involved in the movement (migration) of nerve cells and the outgrowth of axons, which are specialized extensions of nerve cells that transmit nerve impulses. The protein also regulates contact between nerve cells (cell adhesion).\n\n**Specific Functions of Anosmin-1**\n\nAnosmin-1 helps control the growth and migration of a group of nerve cells that specialize in processing the sense of smell (olfactory neurons). These nerve cells originate in the developing nose and migrate to the olfactory bulb, which is critical for the perception of odors. Studies suggest that anosmin-1 is also involved in the migration of neurons that produce gonadotropin-releasing hormone (GnRH).\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Kallmann Syndrome**: More than 140 mutations in the ANOS1 gene have been identified in people with Kallmann syndrome, a disorder characterized by hypogonadotropic hypogonadism and an impaired sense of smell. Researchers estimate that mutations in the ANOS1 gene account for 5 to 10 percent of all cases of Kallmann syndrome.\n\n**Understanding Kallmann Syndrome**\n\nThe ANOS1 gene mutations that cause Kallmann syndrome delete part or all of the gene, change single protein building blocks (amino acids) in anosmin-1, or alter the size of the protein. These mutations disrupt the normal production or function of anosmin-1 during embryonic development.\n\n**Implications of ANOS1 Gene Mutations**\n\nResearchers suspect that the missing or altered protein is unable to direct the migration of olfactory nerve cells and GnRH-producing nerve cells to their usual locations in the developing brain. If olfactory nerve cells do not extend to the olfactory bulb, a person's sense of smell will be impaired.\n\n**Variability in Kallmann Syndrome Features**\n\nIt is unclear how ANOS1 gene mutations lead to other possible signs and symptoms of Kallmann syndrome, including a failure of one kidney to develop (unilateral renal agenesis), hearing loss, and mirror movements of the hands (bimanual synkinesia). Because these features vary among individuals, researchers suspect that other genetic and environmental factors may be involved.\n\n---\n\n**ANOS1 Gene: MedlinePlus Genetics (Part 3/4)**\n\n**Category:** general\n\n**Content:**\n\nThe ANOS1 gene plays a crucial role in the development of the brain and reproductive system. Mutations in this gene can lead to Kallmann syndrome, a disorder characterized by hypogonadotropic hypogonadism and an impaired sense of smell.\n\n**How ANOS1 Gene Mutations Lead to Kallmann Syndrome**\n\nANOS1 gene mutations delete part or all of the gene, change single protein building blocks (amino acids) in anosmin-1, or alter the size of the protein. These disruptions prevent the normal production or function of anosmin-1 during embryonic development.\n\n**Impact on Brain and Reproductive System Development**\n\nThe missing or altered protein is unable to direct the migration of olfactory nerve cells and GnRH-producing nerve cells to their usual locations in the developing brain. If olfactory nerve cells do not extend to the olfactory bulb, a person's sense of smell will be impaired. Misplacement of GnRH-producing neurons prevents the production of sex hormones, which interferes with normal sexual development and causes puberty to be delayed or absent.\n\n**Other Possible Signs and Symptoms**\n\nIt is unclear how ANOS1 gene mutations lead to other possible signs and symptoms of Kallmann syndrome, including a failure of one kidney to develop (unilateral renal agenesis), hearing loss, and mirror movements of the hands (bimanual synkinesia). Researchers suspect that other genetic and environmental factors may be involved.\n\n**Other Names for This Gene**\n\n* adhesion molecule-like X-linked ADMLX\n* anosmin-1 HHA\n* KAL\n* KAL1\n* KALIG-1\n* Kallmann syndrome 1 protein\n* Kallmann syndrome protein\n* KALM_HUMAN\n* WFDC19\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ANOS1\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ANOSMIN 1; ANOS1\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n---\n\n**ANOS1 Gene**\n\n**Genomic Location**\nThe ANOS1 gene is found on the X chromosome.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**MedlinePlus Disclaimer**\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\n**Important Note**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ANTXR2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/antxr2/",
    "content": "**ANTXR2 Gene**\n\nThe ANTXR2 gene provides instructions for making a protein that is found at the surface of many types of cells.\n\n**Normal Function**\n\n* The ANTXR2 protein interacts with components of the extracellular matrix, which strengthens and supports connective tissues such as skin, bone, cartilage, tendons, and ligaments.\n* The ANTXR2 protein is involved in the formation of tiny blood vessels (capillaries).\n* It may also be important for maintaining the structure of basement membranes, which are thin, sheet-like extracellular matrix structures that separate and support cells in many connective tissues.\n* Research suggests that the ANTXR2 protein aids in the breakdown of at least one type of extracellular matrix protein, ensuring the correct balance of proteins is maintained for normal functioning of muscles and connective tissues.\n* The ANTXR2 protein also acts as a receptor for the toxin that causes anthrax, allowing the toxin to attach to cells and trigger disease.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Hyaline Fibromatosis Syndrome**: More than 45 mutations in the ANTXR2 gene have been found to cause hyaline fibromatosis syndrome, a painful condition characterized by accumulation of a clear (hyaline) substance in different tissues in the body.\n\t+ The nature of the hyaline substance is unknown, but it likely contains extracellular matrix proteins, among other materials.\n\t+ Buildup of this material can cause firm lumps of noncancerous tissue (nodules) under the skin and in internal organs, joint deformities called contractures that restrict movement, and overgrowth of the gums.\n\t+ The severity of the signs and symptoms falls along a spectrum.\n\t+ Some ANTXR2 gene mutations reduce or eliminate the amount of ANTXR2 protein at the surface of cells. Others are thought to impair the protein's ability to interact with extracellular matrix components.\n\n---\n\n**Hyaline Fibromatosis Syndrome**\n\n\\n\\n\n\n**What is Hyaline Fibromatosis Syndrome?**\n\nHyaline fibromatosis syndrome is a rare genetic disorder characterized by the accumulation of a clear (hyaline) substance in different tissues in the body. The nature of this substance is unknown, but it likely contains extracellular matrix proteins and other materials.\n\n**Symptoms of Hyaline Fibromatosis Syndrome**\n\nThe buildup of this material can cause firm lumps of noncancerous tissue (nodules) under the skin and in internal organs, joint deformities called contractures that restrict movement, and overgrowth of the gums. The severity of the signs and symptoms falls along a spectrum.\n\n*   Most severely affected individuals have severe diarrhea and recurrent infections and usually do not survive beyond early childhood.\n*   Individuals at the milder end of the spectrum typically survive into adulthood.\n\n**Causes of Hyaline Fibromatosis Syndrome**\n\nSome ANTXR2 gene mutations reduce or eliminate the amount of ANTXR2 protein at the surface of cells. Others are thought to impair the protein's ability to interact with extracellular matrix components. It is unclear what effect these mutations have in cells and tissues.\n\nResearchers suspect that gene mutations disrupt the formation of basement membranes, allowing a hyaline substance to leak through and build up in various body tissues. Alternatively, the mutations could impair the breakdown of excess extracellular matrix proteins, which then accumulate in tissues and lead to the signs and symptoms of hyaline fibromatosis syndrome.\n\n**Variability in Severity**\n\nIt is unclear why the severity of hyaline fibromatosis syndrome varies among affected individuals. Some studies have indicated that the severity of the condition may be linked to where in the gene the mutation occurs.\n\n**Other Names for This Gene**\n\n*   Anthrax toxin receptor 2\n*   ANTR2_HUMAN\n*   Capillary morphogenesis protein 2\n*   CMG-2\n*   CMG2\n*   FLJ31074\n*   ISH\n*   JHF\n*   MGC111533\n*   MGC45856\n\n**Additional Information & Resources**\n\n*   Tests listed in the Genetic Testing Registry:\n    *   Tests of ANTXR2\n*   Scientific articles on PubMed:\n    *   PubMed\n*   Catalog of genes and diseases from OMIM:\n    *   Anthrax toxin receptor 2; ANTXR2\n\n---\n\n**ANTXR2 Gene**\n\n\\n\\n\n\n*   **Scientific Articles on PubMed**\n    *   [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/)\n*   **Catalog of Genes and Diseases from OMIM**\n    *   ANTHRAX TOXIN RECEPTOR 2; ANTXR2\n*   **Gene and Variant Databases**\n    *   [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/)\n    *   [ClinVar](https://www.ncbi.nlm.nih.gov/clinvar/)\n*   **Tests Listed in the Genetic Testing Registry**\n    *   Tests of ANTXR2\n*   **Scientific Articles on PubMed**\n    *   [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/)\n*   **Catalog of Genes and Diseases from OMIM**\n    *   ANTHRAX TOXIN RECEPTOR 2; ANTXR2\n*   **Gene and Variant Databases**\n    *   [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/)\n    *   [ClinVar](https://www.ncbi.nlm.nih.gov/clinvar/)\n\n**References**\n\n\\n\\n\n\n1.  Burgi J, Kunz B, Abrami L, Deuquet J, Piersigilli A, Scholl-Burgi S, Lausch E, Unger S, Superti-Furga A, Bonaldo P, van der Goot FG. CMG2/ANTXR2 regulates extracellular collagen VI which accumulates in hyaline fibromatosis syndrome. Nat Commun. 2017 Jun 12;8:15861. doi: 10.1038/ncomms15861. Citation on PubMed or Free article on PubMed Central\n2.  Deuquet J, Abrami L, Difeo A, Ramirez MC, Martignetti JA, van der Goot FG. Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum. Hum Mutat. 2009 Apr;30(4):583-9. doi: 10.1002/humu.20872. Citation on PubMed\n3.  Deuquet J, Lausch E, Superti-Furga A, van der Goot FG. The dark sides of capillary morphogenesis gene 2. EMBO J. 2012 Jan 4;31(1):3-13. doi: 10.1038/emboj.2011.442. Epub 2011 Dec 6. Citation on PubMed or Free article on PubMed Central\n4.  Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, Kayserili H, Yuksel-Apak M, Paller AS, Norton K, Teebi AS, Grum-Tokars V, Martin GS, Davis GE, Glucksman MJ, Martignetti JA. Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet. 2003 Oct;73(4):957-66. doi: 10.1086/378781. Epub 2003 Sep 12. Citation on PubMed or Free article on PubMed Central\n5.  El-Kamah GY, Fong K, El-Ruby M, Afifi HH, Clements SE, Lai-Cheong JE, Amr K, El-Darouti M, McGrath JA. Spectrum of mutations in the ANTXR2 (CMG2) gene in infantile systemic hyalinosis and juvenile hyaline fibromatosis. Br J Dermatol. 2010 Jul;163(1):213-5. doi: 10.1111/j.1365-2133.2010.09769.x. Epub 2010 Mar 17. No abstract available. Citation on PubMed\n6.  Liu S, Crown D, Miller-Randolph S, Moayeri M, Wang H, Hu H, Morley T, Leppla SH. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12424-9. doi: 10.1073/pnas.0905409106. Epub 2009 Jul 15. Citation on PubMed or Free article on PubMed Central\n7.  Rahman N, Dunstan M, Teare MD, Hanks S, Edkins SJ, Hughes J, Bignell GR, Mancini G, Kleijer W, Campbell M, Keser G, Black C, Williams N, Arbour L, Warman M, Superti-Furga A, Futreal PA, Pope FM. The gene for juvenile hyaline fibromatosis maps to chromosome 4q21. Am J Hum Genet. 2002 Oct;71(4):975-80. doi: 10.1086/342776. Epub 2002 Sep 4. Citation on PubMed or Free article on PubMed Central\n8.  Shieh JTC, Hoyme HE, Arbour LT. Hyaline Fibromatosis Syndrome. 2008 Feb 27 [updated 2023 May 11]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from http://www.ncbi.nlm.nih.gov/books/NBK1525/. Citation on PubMed\n9.  Tanaka K, Ebihara T, Kusubata M, Adachi E, Arai M, Kawaguchi N, Utsunomiya J, Miki Y, Hiramoto M, Hattori S, Irie S. Abnormal collagen deposition in fibromas from patient with juvenile hyaline fibromatosis. J Dermatol Sci. 2009 Sep;55(3):197-200. doi: 10.1016/j.jdermsci.2009.06.005. Epub 2009 Jul 9. No abstract available. Citation on PubMed\n10. Yan SE, Lemmin T, Salvi S, Lausch E, Superti-Furga A, Rokicki D, Dal Peraro M, van der Goot FG. In-depth analysis of hyaline fibromatosis syndrome frameshift mutations at the same site reveal the necessity of personalized therapy. Hum Mutat. 2013 Jul;34(7):1005-17. doi: 10.1002/humu.22324. Epub 2013 Apr 19. Citation on PubMed\n\n---\n\n**ANTXR2 Gene**\n\n\\n\\n\n\n*   **Genomic Location**: The ANTXR2 gene is found on chromosome 4.\n*   **Related Health Topics**\n    *   Genes and Gene Therapy\n    *   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "APC gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/apc/",
    "content": "**APC Gene**\n\nThe APC gene provides instructions for making the APC protein, which plays a critical role in several cellular processes. The APC protein acts as a tumor suppressor, keeping cells from growing and dividing too fast or in an uncontrolled way.\n\n**Normal Function**\n\n*   Helps control how often a cell divides\n*   Regulates how a cell attaches to other cells within a tissue\n*   Determines whether a cell moves within or away from a tissue\n*   Ensures the correct number of chromosomes in a cell following cell division\n\nThe APC protein accomplishes these tasks mainly through association with other proteins, especially those involved in cell attachment and signaling. One such protein is beta-catenin, which helps control gene activity, promotes cell growth and division, and facilitates cell attachment.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Desmoid Tumor**: Several mutations in the APC gene have been found in people with desmoid tumors, a type of aggressive but noncancerous growth. These rare tumors arise from connective tissue and are commonly associated with familial adenomatous polyposis (FAP), a form of colon cancer.\n\nIn individuals without FAP, APC gene mutations can cause sporadic desmoid tumors. Most such mutations lead to an abnormally short APC protein, which is unable to interact with beta-catenin, resulting in uncontrolled cell growth and tumor formation.\n\n---\n\n**Familial Adenomatous Polyposis**\n\nMore than 700 mutations in the APC gene have been identified in families with the classic and attenuated types of familial adenomatous polyposis (FAP). Most of these mutations lead to the production of an abnormally short, nonfunctional version of the APC protein. This short protein cannot suppress the cellular overgrowth that leads to the formation of abnormal growths (polyps) in the colon, which can become cancerous.\n\nThe most common mutation in FAP is a deletion of five building blocks of DNA (nucleotides) in the APC gene. This mutation changes the sequence of the building blocks of proteins (amino acids) in the resulting APC protein.\n\nAlthough most people with FAP will develop colorectal cancer, the number of polyps and the time frame in which they become cancerous depend on the location of the mutation in the APC gene. The location of the mutation also determines whether an individual with FAP is predisposed to developing desmoid tumors (described above).\n\n**Primary Macronodular Adrenal Hyperplasia**\n\nMedlinePlus Genetics provides information about Primary macronodular adrenal hyperplasia\n\n**Other Cancers**\n\nMutations in the APC gene are also responsible for a disorder called Turcot syndrome, which is closely related to familial adenomatous polyposis. Turcot syndrome is an association of colorectal cancer with a type of cancerous brain tumor called a medulloblastoma. Approximately two-thirds of people with Turcot syndrome have mutations in the APC gene.\n\nA certain mutation in the APC gene (unrelated to Turcot syndrome) is found in approximately 6 percent of people with Ashkenazi (eastern and central European) Jewish heritage. This mutation replaces the amino acid isoleucine with the amino acid lysine at position 1307 in the APC protein (written as Ile1307Lys or I1307K). This change was initially thought to be harmless, but has been shown to be associated with a 10 percent to 20 percent increased risk of colon cancer.\n\nSomatic mutations in the APC gene may be involved in the development of a small percentage of stomach (gastric) cancers.\n\n---\n\n**APC Gene**\n\nThe APC gene plays a crucial role in the formation of abnormal growths (polyps) in the colon, which can become cancerous. The most common mutation in Familial Adenomatous Polyposis (FAP) is a deletion of five building blocks of DNA (nucleotides) in the APC gene.\n\n**Mutations and Their Effects**\n\nMore than 700 mutations in the APC gene have been identified in families with FAP. Most of these mutations lead to the production of an abnormally short, nonfunctional version of the APC protein. This short protein cannot suppress the cellular overgrowth that leads to the formation of abnormal growths (polyps) in the colon.\n\n**Colorectal Cancer and Desmoid Tumors**\n\nAlthough most people with FAP will develop colorectal cancer, the number of polyps and the time frame in which they become cancerous depend on the location of the mutation in the APC gene. The location of the mutation also determines whether an individual with FAP is predisposed to developing desmoid tumors.\n\n**Other Cancers Associated with APC Gene Mutations**\n\nMutations in the APC gene are responsible for a disorder called Turcot syndrome, which is closely related to familial adenomatous polyposis. Turcot syndrome is an association of colorectal cancer with a type of cancerous brain tumor called a medulloblastoma.\n\nA certain mutation in the APC gene (unrelated to Turcot syndrome) is found in approximately 6 percent of people with Ashkenazi (eastern and central European) Jewish heritage. This mutation replaces the amino acid isoleucine with the amino acid lysine at position 1307 in the APC protein, which has been shown to be associated with a 10 percent to 20 percent increased risk of colon cancer.\n\nSomatic mutations in the APC gene may be involved in the development of a small percentage of stomach (gastric) cancers.\n\n**Other Names for This Gene**\n\nThe APC gene is also known by other names, including:\n\n* adenomatous polyposis coli\n* APC_HUMAN\n* DP2\n* DP2.5\n* DP3\n* FAP\n* FPC\n* GS\n* PPP1R46\n* WNT signaling pathway regulator\n\n**Additional Information & Resources**\n\nFor more information on the APC gene, you can refer to the following resources:\n\n* Tests Listed in the Genetic Testing Registry\n* Scientific Articles on PubMed\n* Catalog of Genes and Diseases from OMIM\n\n---\n\n**APC Gene: MedlinePlus Genetics**\n\n**Diffuse Gastric and Lobular Breast Cancer Syndrome; DGLBC**\n**Mismatch Repair Cancer Syndrome 1; MMRCS1**\n**APC Regulator of WNT Signaling Pathway; APC**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**: A comprehensive database of gene information, including the APC gene.\n*   **ClinVar**: A database of genetic variations and their associated clinical interpretations.\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   **Tests of APC**: A list of available tests for detecting APC gene mutations.\n\n**Scientific Articles on PubMed**\n\n*   Brueckl WM, Ballhausen WG, Fortsch T, Gunther K, Fiedler W, Gentner B, Croner R, Boxberger F, Kirchner T, Hahn EG, Hohenberger W, Wein A. Genetic testing for germline mutations of the APC gene in patients with apparently sporadic desmoid tumors but a family history of colorectal carcinoma. Dis Colon Rectum. 2005 Jun;48(6):1275-81.\n*   Ceol CJ, Pellman D, Zon LI. APC and colon cancer: two hits for one. Nat Med. 2007 Nov;13(11):1286-7.\n*   Cohen MM Jr. Molecular dimensions of gastrointestinal tumors: some thoughts for digestion. Am J Med Genet A. 2003 Nov 1;122A(4):303-14.\n*   Couture J, Mitri A, Lagace R, Smits R, Berk T, Bouchard HL, Fodde R, Alman B, Bapat B. A germline mutation at the extreme 3' end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. Clin Genet. 2000 Mar;57(3):205-12.\n*   Fodde R. The APC gene in colorectal cancer. Eur J Cancer. 2002 May;38(7):867-71.\n*   Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000 May;18(9):1967-79.\n*   Jaiswal AS, Balusu R, Narayan S. Involvement of adenomatous polyposis coli in colorectal tumorigenesis. Front Biosci. 2005 May 1;10:1118-34.\n*   Jarvinen HJ, Peltomaki P. The complex genotype-phenotype relationship in familial adenomatous polyposis. Eur J Gastroenterol Hepatol. 2004 Jan;16(1):5-8.\n*   Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). Eur J Surg Oncol. 2009 Jan;35(1):3-10.\n*   Middleton SB, Frayling IM, Phillips RK. Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br J Cancer. 2000 Feb;82(4):827-32.\n*   Nathke IS. The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu Rev Cell Dev Biol. 2004;20:337-66.\n*   Scott RJ, Froggatt NJ, Trembath RC, Evans DG, Hodgson SV, Maher ER. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. Hum Mol Genet. 1996 Dec;5(12):1921-4.\n*   Sena P, Saviano M, Monni S, Losi L, Roncucci L, Marzona L, De Pol A. Subcellular localization of beta-catenin and APC proteins in colorectal preneoplastic and neoplastic lesions. Cancer Lett. 2006 Sep 28;241(2):203-12.\n*   Senda T, Shimomura A, Iizuka-Kogo A. Adenomatous polyposis coli (Apc) tumor suppressor gene as a multifunctional gene. Anat Sci Int. 2005 Sep;80(3):121-31.\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   **DIFFUSE GASTRIC AND LOBULAR BREAST CANCER SYNDROME; DGLBC**\n*   **MISMATCH REPAIR CANCER SYNDROME 1; MMRCS1**\n*   **APC REGULATOR OF WNT SIGNALING PATHWAY; APC**\n\n---\n\n**APC Gene**\n\n\\n\\n\n\n*   **Genomic Location**\n    The APC gene is found on chromosome 5.\n*   **Related Health Topics**\n    *   Genes and Gene Therapy\n    *   Genetic Disorders\n\n\\n\\n\n\n*   **Understanding Genetics**\n    *   What is DNA?\n    *   What is a gene?\n    *   What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**References**\n\n*   Senda T, Shimomura A, Iizuka-Kogo A. Adenomatous polyposis coli (Apc) tumor suppressor gene as a multifunctional gene. Anat Sci Int. 2005 Sep;80(3):121-31. doi: 10.1111/j.1447-073x.2005.00106.x. Citation on PubMed\n*   Tejpar S, Michils G, Denys H, Van Dam K, Nik SA, Jadidizadeh A, Cassiman JJ. Analysis of Wnt/Beta catenin signalling in desmoid tumors. Acta Gastroenterol Belg. 2005 Jan-Mar;68(1):5-9. Citation on PubMed",
    "category": "general"
  },
  {
    "title": "APOA1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/apoa1/",
    "content": "**APOA1 Gene**\n\nThe APOA1 gene provides instructions for making a protein called apolipoprotein A-I (apoA-I). ApoA-I is a component of high-density lipoprotein (HDL).\n\n**Normal Function**\n\n* The APOA1 gene provides instructions for making a protein called apolipoprotein A-I (apoA-I).\n* ApoA-I attaches to cell membranes and promotes the movement of cholesterol and phospholipids from inside the cell to the outer surface.\n* Once outside the cell, these substances combine with apoA-I to form HDL.\n* ApoA-I also triggers a reaction called cholesterol esterification that converts cholesterol to a form that can be fully integrated into HDL and transported through the bloodstream.\n\n**Health Conditions Related to Genetic Changes**\n\n* Familial HDL deficiency: Mutations in the APOA1 gene cause familial HDL deficiency, an inherited condition characterized by low levels of HDL in the blood and an elevated risk for early-onset cardiovascular disease.\n* The altered apoA-I protein is less able to promote the removal of cholesterol and phospholipids from cells or stimulate cholesterol esterification, resulting in low HDL levels.\n* A shortage (deficiency) of HDL is believed to increase the risk of cardiovascular disease.\n\n---\n\n**APOA1 Gene**\n\n**Other Disorders**\n\nMutations in the APOA1 gene can also cause a condition called familial visceral amyloidosis, which is characterized by an abnormal accumulation of proteins (amyloidosis) in internal organs (viscera). The mutations that cause this condition alter the apoA-I protein. Abnormal apoA-I proteins stick together to form amyloid deposits that impair the function of the affected organs. The liver, kidneys, and heart are commonly affected by amyloidosis. Depending on the organs involved, the signs and symptoms of the condition vary. Affected individuals can have an enlarged liver (hepatomegaly), chronic kidney disease, or a form of heart disease called cardiomyopathy. However, in some people, the condition is very mild and causes no apparent signs or symptoms.\n\n**Familial HDL Deficiency**\n\nMutations in the APOA1 gene cause familial HDL deficiency, an inherited condition characterized by low levels of HDL in the blood and an elevated risk for early-onset cardiovascular disease, which often occurs before age 50. These mutations lead to an altered apoA-I protein. Some versions of the altered protein are less able to promote the removal of cholesterol and phospholipids from cells, which decreases the amount of these substances available to form HDL. Other versions of the altered protein are less able to stimulate cholesterol esterification, which means cholesterol cannot be integrated into HDL particles. Both types of mutation result in low HDL levels. A shortage (deficiency) of HDL is believed to increase the risk of cardiovascular disease.\n\n**Other Names for This Gene**\n\napo-AI apoA-I APOA1_HUMAN apolipoprotein A-I\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of APOA1\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* AMYLOIDOSIS, HEREDITARY SYSTEMIC 2; AMYLD2\n* APOLIPOPROTEIN A-I; APOA1\n\n---\n\n**APOA1 Gene**\n\nThe APOA1 gene is located on chromosome 11 and plays a crucial role in lipid metabolism. Variants of the APOA1 gene have been associated with various disorders, including hereditary systemic amyloidosis type 2 (AMYLD2) and hypoalphalipoproteinemia.\n\n**Scientific Articles**\n\nSeveral studies have investigated the relationship between the APOA1 gene and lipid metabolism. For example:\n\n* Batal et al. (1998) found that familial HDL deficiency was characterized by hypercatabolism of mature apoA-I but not proapoA-I.\n* Chambenoit et al. (2001) discovered that specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter.\n* Chroni et al. (2003) demonstrated that the central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux.\n\n**Genomic Location**\n\nThe APOA1 gene is found on chromosome 11.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**References**\n\n* Batal et al. (1998) - Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I.\n* Chambenoit et al. (2001) - Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter.\n* Chroni et al. (2003) - The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux.\n\n**Genomic Location**\n\nThe APOA1 gene is found on chromosome 11.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "APOB gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/apob/",
    "content": "**APOB Gene**\n\nThe APOB gene provides instructions for making two versions of the apolipoprotein B protein, a short version called apolipoprotein B-48 and a longer version known as apolipoprotein B-100.\n\n* **Normal Function**\n\t+ Apolipoprotein B-48 is produced in the intestine, where it is a building block of a type of lipoprotein called a chylomicron.\n\t+ Chylomicrons are formed to carry fat and cholesterol from the intestine into the bloodstream after a meal.\n\t+ They are also necessary for the absorption of certain fat-soluble vitamins such as vitamin E and vitamin A.\n* **Health Conditions Related to Genetic Changes**\n\t+ The APOB gene is associated with several health conditions, including high cholesterol and heart disease.\n\n**Other Names for This Gene**\n\n* Apolipoprotein B\n\n**Additional Information & Resources**\n\n* For more information on the APOB gene, please visit the National Library of Medicine's MedlinePlus Genetics website.\n* You can also consult with a healthcare professional or a genetic counselor to learn more about the APOB gene and its implications for your health.\n\n---\n\n**APOB Gene**\n\nThe APOB gene provides instructions for making two versions of the apolipoprotein B protein, a short version called apolipoprotein B-48 and a longer version known as apolipoprotein B-100.\n\n* **Apolipoprotein B-48**: Produced in the intestine, it is a building block of a type of lipoprotein called a chylomicron. As food is digested after a meal, chylomicrons are formed to carry fat and cholesterol from the intestine into the bloodstream.\n* **Apolipoprotein B-100**: Produced in the liver, it is a component of several other types of lipoproteins, including very low-density lipoproteins (VLDLs), intermediate-density lipoproteins (IDLs), and low-density lipoproteins (LDLs).\n\n**Health Conditions Related to Genetic Changes**\n\n* **Familial Hypercholesterolemia**: More than 100 mutations in the APOB gene are known to cause this condition, characterized by very high levels of cholesterol in the blood and an increased risk of developing heart disease.\n\t+ Each mutation changes a single protein building block (amino acid) in a critical region of apolipoprotein B-100.\n\t+ The altered protein prevents LDLs from effectively attaching to their receptors on the surface of cells, leading to higher blood cholesterol levels.\n\t+ A buildup of cholesterol in the walls of coronary arteries greatly increases a person's risk of having a heart attack.\n* **Familial Hypobetalipoproteinemia**: More than 120 mutations in the APOB gene have been found to cause this disorder, which impairs the body's ability to absorb and transport fat.\n\t+ Most APOB gene mutations that cause FHBL lead to the production of apolipoprotein B that is abnormally short.\n* **Other Disorders**: Researchers are studying other variations (polymorphisms) in the APOB gene that may influence heart disease risk in people without inherited cholesterol disorders.\n\n---\n\n**APOB Gene: MedlinePlus Genetics (Part 3/5)**\n\n**Familial Hypercholesterolemia**\n\nMore than 100 mutations in the APOB gene are known to cause familial hypercholesterolemia, a condition characterized by very high levels of cholesterol in the blood and an increased risk of developing heart disease. Each mutation that causes this condition changes a single protein building block (amino acid) in a critical region of apolipoprotein B-100. The altered protein prevents LDLs from effectively attaching to their receptors on the surface of cells, resulting in fewer LDLs being removed from the blood and higher-than-normal blood cholesterol levels.\n\nAs excess cholesterol circulates through the bloodstream, it is deposited abnormally in tissues such as the skin, tendons, and arteries that supply blood to the heart (coronary arteries). A buildup of cholesterol in the walls of coronary arteries greatly increases a person's risk of having a heart attack.\n\nMost people with familial hypercholesterolemia inherit one altered copy of the APOB gene from an affected parent and one normal copy of the gene from the other parent. These cases are associated with an increased risk of early heart disease, typically beginning in a person's forties or fifties. Rarely, a person with familial hypercholesterolemia is born with two mutated copies of the APOB gene, resulting in a more severe form of hypercholesterolemia that usually appears in childhood.\n\n**Familial Hypobetalipoproteinemia**\n\nMore than 120 mutations in the APOB gene have been found to cause familial hypobetalipoproteinemia (FHBL), a disorder that impairs the body's ability to absorb and transport fat. Most APOB gene mutations that cause FHBL lead to the production of apolipoprotein B that is abnormally short.\n\nThe severity of the condition largely depends on the length of the abnormal apolipoprotein B. Some mutations in the APOB gene lead to the production of a protein that is shorter than apolipoprotein B-100, but longer than apolipoprotein B-48. In these cases, normal apolipoprotein B-48 is still made in the intestine.\n\nThe normal-length apolipoprotein B-48 can form chylomicrons normally, but the abnormally short apolipoprotein B-100 produced in the liver is less able to produce lipoproteins. Other mutations result in a protein that is shorter than both apolipoprotein B-48 and apolipoprotein B-100.\n\nIn these cases, no normal-length apolipoprotein B protein is produced. The severely shortened protein is not able to form lipoproteins in the liver or the intestine. Generally, if both versions of the protein are shorter than apolipoprotein B-48, the signs and symptoms are more severe than if some normal length apolipoprotein B-48 is produced.\n\nAll of these protein changes lead to a reduction of functional apolipoprotein B. As a result, the transportation of dietary fats and cholesterol is decreased or absent. A decrease in fat transport reduces the body's ability to absorb fats and fat-soluble vitamins from the diet, leading to the signs and symptoms of FHBL.\n\n---\n\n**APOB Gene**\n\nThe APOB gene provides instructions for making a protein called apolipoprotein B, which is necessary for the transportation of dietary fats and cholesterol in the body.\n\n**Signs and Symptoms**\n\nA decrease in fat transport reduces the body's ability to absorb fats and fat-soluble vitamins from the diet, leading to the signs and symptoms of Familial Hypobetalipoproteinemia (FHBL).\n\n* **Other Disorders**\n\t+ Researchers are studying other variations (polymorphisms) in the APOB gene that may influence heart disease risk in people without inherited cholesterol disorders.\n\t+ Some studies have found that certain polymorphisms are associated with higher levels of LDLs in the blood and an increased chance of developing or dying of heart disease.\n\t+ Other studies, however, have not shown such an association.\n\n**Other Names for This Gene**\n\n* apoB-100\n* apoB-48\n* APOB_HUMAN\n* apolipoprotein B (including Ag(x) antigen)\n\n**Additional Information & Resources**\n\n* **Tests Listed in the Genetic Testing Registry**\n\t+ Tests of APOB\n* **Scientific Articles on PubMed**\n\t+ PubMed\n* **Catalog of Genes and Diseases from OMIM**\n\t+ APOLIPOPROTEIN B; APOB\n* **Gene and Variant Databases**\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Benn M, Nordestgaard BG, Jensen JS, Grande P, Sillesen H, Tybjaerg-Hansen A. Polymorphism in APOB associated with increased low-density lipoprotein levels in both genders in the general population. J Clin Endocrinol Metab. 2005 Oct;90(10):5797-803.\n* Burnett JR, Hooper AJ, Hegele RA. APOB-Related Familial Hypobetalipoproteinemia. 2021 May 13 [updated 2021 Sep 9]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n* Fouchier SW, Sankatsing RR, Peter J, Castillo S, Pocovi M, Alonso R, Kastelein JJ, Defesche JC. High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent. J Med Genet. 2005 Apr;42(4):e23.\n* Hooper AJ, van Bockxmeer FM, Burnett JR. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci. 2005;42(5-6):515-45.\n* Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med. 2005 Nov;258(5):395-410.\n* Schonfeld G, Lin X, Yue P. Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci. 2005 Jun;62(12):1372-8.\n* Soufi M, Sattler AM, Maerz W, Starke A, Herzum M, Maisch B, Schaefer JR. A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis. 2004 May;174(1):11-6.\n* Tarugi P, Averna M, Di Leo E, Cefalu AB, Noto D, Magnolo L, Cattin L, Bertolini S, Calandra S. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis. 2007 Dec;195(2):e19-27.\n* Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem. 2011;54:81-107.\n* van Aalst-Cohen ES, Jansen AC, de Jongh S, de Sauvage Nolting PR, Kastelein JJ. Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia. Semin Vasc Med. 2004 Feb;4(1):31-41.\n* Vrablik M, Ceska R, Horinek A. Major apolipoprotein B-100 mutations in lipoprotein metabolism and atherosclerosis. Physiol Res. 2001;50(4):337-43.\n\n---\n\n**APOB Gene**\n\n**Genomic Location**\nThe APOB gene is found on chromosome 2.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Research Articles**\n\n* Soufi M, Sattler AM, Maerz W, Starke A, Herzum M, Maisch B, Schaefer JR. A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis. 2004 May;174(1):11-6.\n* Tarugi P, Averna M, Di Leo E, Cefalu AB, Noto D, Magnolo L, Cattin L, Bertolini S, Calandra S. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis. 2007 Dec;195(2):e19-27.\n* Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem. 2011;54:81-107.\n* van Aalst-Cohen ES, Jansen AC, de Jongh S, de Sauvage Nolting PR, Kastelein JJ. Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia. Semin Vasc Med. 2004 Feb;4(1):31-41.\n* Vrablik M, Ceska R, Horinek A. Major apolipoprotein B-100 mutations in lipoprotein metabolism and atherosclerosis. Physiol Res. 2001;50(4):337-43.\n\n**Important Note**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "APOE gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/apoe/",
    "content": "**APOE Gene**\n\nThe APOE gene provides instructions for making a protein called apolipoprotein E. This protein combines with fats (lipids) in the body to form molecules called lipoproteins. Lipoproteins are responsible for packaging cholesterol and other fats and carrying them through the bloodstream. Maintaining normal levels of cholesterol is essential for the prevention of disorders that affect the heart and blood vessels (cardiovascular diseases), including heart attack and stroke.\n\nThere are at least three slightly different versions (alleles) of the APOE gene. The major alleles are called e2, e3, and e4. The most common allele is e3, which is found in more than half of the general population.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Alzheimer's Disease**\n    *   The e4 version of the APOE gene increases an individual's risk for developing late-onset Alzheimer's disease.\n    *   People who inherit one copy of the APOE e4 allele have an increased chance of developing the disease; those who inherit two copies of the allele are at even greater risk.\n    *   The APOE e4 allele may also be associated with an earlier onset of memory loss and other symptoms compared to individuals with Alzheimer's disease who do not have this allele.\n*   **Age-related Hearing Loss**\n    *   MedlinePlus Genetics provides information about Age-related hearing loss\n*   **Age-related Macular Degeneration**\n    *   MedlinePlus Genetics provides information about Age-related macular degeneration\n*   **Dementia with Lewy Bodies**\n    *   The e4 version of the APOE gene can increase the risk of developing a form of dementia called dementia with Lewy bodies.\n    *   People who inherit one copy of the APOE e4 allele have an increased chance of developing dementia with Lewy bodies.\n\n---\n\n**APOE Gene: MedlinePlus Genetics (Part 2/5)**\n\n**Other Disorders**\n\nVariants of apolipoprotein E have been studied extensively as risk factors for many different conditions. For example, APOE alleles have been shown to influence the risk of cardiovascular diseases. People who carry at least one copy of the APOE e4 allele have an increased chance of developing atherosclerosis, which is an accumulation of fatty deposits and scar-like tissue in the lining of the arteries. This progressive narrowing of the arteries increases the risk of heart attack and stroke.\n\nThe APOE e2 allele has been shown to greatly increase the risk of a rare condition called hyperlipoproteinemia type III. Most people with this disorder have two copies of the APOE e2 allele, leading researchers to conclude that the e2 allele plays a critical role in the development of the condition. Hyperlipoproteinemia type III is characterized by increased blood levels of cholesterol, certain fats called triglycerides, and molecules called beta-very low-density lipoproteins (beta-VLDLs), which carry cholesterol and lipoproteins in the bloodstream. A buildup of cholesterol and other fatty materials can lead to the formation of small, yellow skin growths called xanthomas and the development of atherosclerosis.\n\n**Alzheimer's Disease**\n\nThe e4 version of the APOE gene increases an individual's risk for developing late-onset Alzheimer's disease. Alzheimer's disease is a degenerative disease of the brain that causes dementia, which is a gradual loss of memory, judgment, and ability to function. The late-onset form of the condition occurs in people older than age 65. People who inherit one copy of the APOE e4 allele have an increased chance of developing the disease; those who inherit two copies of the allele are at even greater risk.\n\nThe APOE e4 allele may also be associated with an earlier onset of memory loss and other symptoms compared to individuals with Alzheimer's disease who do not have this allele. It is not known how the APOE e4 allele is related to the risk of Alzheimer's disease. However, researchers have found that this allele is associated with an increased number of protein clumps, called amyloid plaques, in the brain tissue of affected people. A buildup of amyloid plaques may lead to the death of nerve cells (neurons) and the progressive signs and symptoms of Alzheimer's disease.\n\nIt is important to note that people with the APOE e4 allele inherit an increased risk of developing Alzheimer's disease, not the disease itself. Not all people with Alzheimer's disease have the APOE e4 allele, and not all people who have this allele will develop the disease.\n\n**Age-related Hearing Loss**\n\nMedlinePlus Genetics provides information about Age-related hearing loss\n\n**Age-related Macular Degeneration**\n\nMedlinePlus Genetics provides information about Age-related macular degeneration\n\n**Dementia with Lewy Bodies**\n\nThe e4 version of the APOE gene can increase the risk of developing a form of dementia called dementia with Lewy bodies; however, some people with the APOE e4 allele never develop this condition. Dementia with Lewy bodies is characterized by intellectual decline; visual hallucinations; sudden changes in attention and mood; and movement problems characteristic of Parkinson's disease such as rigidity of limbs, tremors, and impaired balance and coordination.\n\nPeople who inherit one copy of the APOE e4 allele have an increased chance of developing dementia with Lewy bodies. It is unclear how the APOE e4 allele contributes to the development of this condition. It is thought that the apolipoprotein E produced from the e4 allele of the APOE gene may disrupt the transport of a protein called alpha-synuclein into and out of cells. When alpha-synuclein is trapped inside or outside of cells, it accumulates in clusters, creating Lewy bodies. Accumulation of these clusters throughout the brain impairs neuron function and ultimately causes cell death.\n\n---\n\n**APOE Gene**\n\n**Dementia with Lewy Bodies**\n\nThe e4 version of the APOE gene can increase the risk of developing a form of dementia called dementia with Lewy bodies. Dementia with Lewy bodies is characterized by intellectual decline, visual hallucinations, sudden changes in attention and mood, and movement problems characteristic of Parkinson's disease such as rigidity of limbs, tremors, and impaired balance and coordination.\n\nPeople who inherit one copy of the APOE e4 allele have an increased chance of developing dementia with Lewy bodies. It is unclear how the APOE e4 allele contributes to the development of this condition. It is thought that the apolipoprotein E produced from the e4 allele of the APOE gene may disrupt the transport of a protein called alpha-synuclein into and out of cells.\n\nWhen alpha-synuclein is trapped inside or outside of cells, it accumulates in clusters, creating Lewy bodies. Accumulation of these clusters throughout the brain impairs neuron function and ultimately causes cell death. Over time, the loss of neurons increasingly impairs intellectual and motor function and the regulation of emotions, resulting in the signs and symptoms of dementia with Lewy bodies.\n\nIt is unclear why some people with the APOE e4 allele develop Alzheimer's disease while others develop dementia with Lewy bodies.\n\n**Other Disorders**\n\nVariants of apolipoprotein E have been studied extensively as risk factors for many different conditions. For example, APOE alleles have been shown to influence the risk of cardiovascular diseases. People who carry at least one copy of the APOE e4 allele have an increased chance of developing atherosclerosis, which is an accumulation of fatty deposits and scar-like tissue in the lining of the arteries.\n\nThis progressive narrowing of the arteries increases the risk of heart attack and stroke. The APOE e2 allele has been shown to greatly increase the risk of a rare condition called hyperlipoproteinemia type III. Most people with this disorder have two copies of the APOE e2 allele, leading researchers to conclude that the e2 allele plays a critical role in the development of the condition.\n\nHyperlipoproteinemia type III is characterized by increased blood levels of cholesterol, certain fats called triglycerides, and molecules called beta-very low-density lipoproteins (beta-VLDLs), which carry cholesterol and lipoproteins in the bloodstream. A buildup of cholesterol and other fatty materials can lead to the formation of small, yellow skin growths called xanthomas and the development of atherosclerosis.\n\n**Other Names for This Gene**\n\nApo-E, APOE_HUMAN, Apolipoproteins E\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of APOE\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* APOLIPOPROTEIN E; APOE\n\n---\n\n**APOE Gene: MedlinePlus Genetics (Part 4/5)**\n\n**Tests of APOE**\n\n*   **Scientific Articles on PubMed**\n    *   PubMed\n*   **Catalog of Genes and Diseases from OMIM**\n    *   APOLIPOPROTEIN E; APOE\n*   **Gene and Variant Databases**\n    *   NCBI Gene\n    *   ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of APOE\n\n**Scientific Articles on PubMed**\n\n*   PubMed\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   APOLIPOPROTEIN E; APOE\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n---\n\n**APOE Gene**\n\nThe APOE gene is found on chromosome 19.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Genetic Disorders**\n\nAlzheimer's disease has been linked to the APOE gene. Research suggests that the APOE gene accounts for the vast majority of AD risk and AD pathology.\n\n**Studies on APOE Gene**\n\n* Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004 May-Jun;25(5):641-50.\n* Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001 Apr;81(2):741-66.\n\n**APOE Gene and Other Health Conditions**\n\nThe APOE gene has also been linked to other health conditions, including coronary heart disease and age-related maculopathy.\n\n**References**\n\n* Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004 Jul 20;141(2):137-47.\n* Tikellis G, Sun C, Gorin MB, Klein R, Klein BE, Larsen EK, Siscovick DS, Hubbard LD, Wong TY. Apolipoprotein e gene and age-related maculopathy in older individuals: the cardiovascular health study. Arch Ophthalmol. 2007 Jan;125(1):68-73.\n\n**Disclaimer**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "APP gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/app/",
    "content": "**APP Gene**\n\nThe APP gene provides instructions for making a protein called amyloid precursor protein. This protein is found in many tissues and organs, including the brain and spinal cord (central nervous system). Little is known about the function of amyloid precursor protein. Researchers speculate that it may bind to other proteins on the surface of cells or help cells attach to one another. Studies suggest that in the brain, it helps direct the movement (migration) of nerve cells (neurons) during early development.\n\nAmyloid precursor protein is cut by enzymes to create smaller fragments (peptides), some of which are released outside the cell. Two of these fragments are called soluble amyloid precursor protein (sAPP) and amyloid beta () peptide. Recent evidence suggests that sAPP has growth-promoting properties and may play a role in the formation of neurons in the brain both before and after birth. The sAPP peptide may also control the function of certain other proteins by turning off (inhibiting) their activity. Amyloid  peptide is likely involved in the ability of neurons to change and adapt over time (plasticity). Other functions of sAPP and amyloid  peptide are under investigation.\n\n**Health Conditions Related to Genetic Changes**\n\nMany variants (also called mutations) in the APP gene can cause early-onset Alzheimer's disease, which begins before age 65. These variants are responsible for less than 10 percent of all early-onset cases of Alzheimer's disease.\n\nThe most common APP gene variant changes one of the protein building blocks (amino acids) in the amyloid precursor protein. This variant replaces the amino acid valine with the amino acid isoleucine at protein position 717 (written as Val717Ile or V717I). Variants in the APP gene can lead to an increased amount of the amyloid  peptide or to the production of a slightly longer and stickier form of the peptide. When these protein fragments are released from the cell, they can accumulate in the brain and form clumps called amyloid plaques. These plaques are characteristic of Alzheimer's disease. A buildup of toxic amyloid  peptide and amyloid plaques may lead to the death of neurons and the progressive signs and symptoms of Alzheimer's disease.\n\n**Other Names for This Gene**\n\n* Amyloid beta precursor protein\n\n**Additional Information & Resources**\n\n* National Institute on Aging: Alzheimer's Disease\n* Alzheimer's Association: Early-Onset Alzheimer's Disease\n\n---\n\n**APP Gene: MedlinePlus Genetics**\n\n\\n\\n\n\n*   **Hereditary Cerebral Amyloid Angiopathy**\n    Variants in the APP gene have been found to cause hereditary cerebral amyloid angiopathy, a condition characterized by stroke and a decline in intellectual function (dementia), which begins in mid-adulthood. These variants change single amino acids in the amyloid precursor protein. Each of these variants causes a different type of the condition.\n\n    The Dutch type, the most common of all the types, is caused by the replacement of the amino acid glutamic acid with the amino acid glutamine at position 22 in the protein sequence (written as Glu22Gln or E22Q). The Italian type and Arctic type are also caused by changes to glutamic acid at position 22. In the Italian type, glutamic acid is replaced with the amino acid lysine (written as Glu22Lys or E22K) and in the Arctic type, glutamic acid is replaced with the amino acid glycine (written as Glu22Gly or E22G). The Flemish type is caused by replacement of the amino acid alanine with glycine at position 21 (written as Ala21Gly or A21G). In the Iowa type, the amino acid aspartic acid is switched with the amino acid asparagine at position 23 (written as Asp23Asn or D23N). The Piedmont type of hereditary cerebral amyloid angiopathy is caused by the replacement of the amino acid leucine at position 34 with the amino acid valine (written as Leu34Val or L34V).\n\n    The result of all of these variants is the production of an amyloid  peptide that is more prone to cluster together (aggregate) than the normal peptide. The aggregated protein forms amyloid deposits that accumulate in the blood vessels of the brain. The amyloid deposits replace the muscle fibers and elastic fibers that give blood vessels flexibility, causing the blood vessels to become weak and prone to breakage. In the brain, such a break causes bleeding (hemorrhagic stroke), which can lead to brain damage and dementia or be life-threatening. Amyloid deposits in specific parts of the brain can interfere with normal brain function, leading to dementia, seizures, movement problems, and other neurological features in some people with hereditary cerebral amyloid angiopathy.\n\n\\n\\n\n\n*   **Alzheimer's Disease**\n    Many variants (also called mutations) in the APP gene can cause early-onset Alzheimer's disease, which begins before age 65. These variants are responsible for less than 10 percent of all early-onset cases of Alzheimer's disease.\n\n    The most common APP gene variant changes one of the protein building blocks (amino acids) in the amyloid precursor protein. This variant replaces the amino acid valine with the amino acid isoleucine at protein position 717 (written as Val717Ile or V717I). Variants in the APP gene can lead to an increased amount of the amyloid  peptide or to the production of a slightly longer and stickier form of the peptide. When these protein fragments are released from the cell, they can accumulate in the brain and form clumps called amyloid plaques. These plaques are characteristic of Alzheimer's disease. A buildup of toxic amyloid  peptide and amyloid plaques may lead to the death of neurons and the progressive signs and symptoms of Alzheimer's disease.\n\n---\n\n**APP Gene: MedlinePlus Genetics (Part 3/5)**\n\n**Variants in the APP gene have been found to cause hereditary cerebral amyloid angiopathy, a condition characterized by stroke and a decline in intellectual function (dementia), which begins in mid-adulthood.**\n\nThese variants change single amino acids in the amyloid precursor protein. Each of these variants causes a different type of the condition.\n\n*   The Dutch type, the most common of all the types, is caused by the replacement of the amino acid glutamic acid with the amino acid glutamine at position 22 in the protein sequence (written as Glu22Gln or E22Q).\n*   The Italian type and Arctic type are also caused by changes to glutamic acid at position 22.\n    *   In the Italian type, glutamic acid is replaced with the amino acid lysine (written as Glu22Lys or E22K).\n    *   In the Arctic type, glutamic acid is replaced with the amino acid glycine (written as Glu22Gly or E22G).\n*   The Flemish type is caused by replacement of the amino acid alanine with glycine at position 21 (written as Ala21Gly or A21G).\n*   In the Iowa type, the amino acid aspartic acid is switched with the amino acid asparagine at position 23 (written as Asp23Asn or D23N).\n*   The Piedmont type of hereditary cerebral amyloid angiopathy is caused by the replacement of the amino acid leucine at position 34 with the amino acid valine (written as Leu34Val or L34V).\n\n**The result of all of these variants is the production of an amyloid  peptide that is more prone to cluster together (aggregate) than the normal peptide.**\n\nThe aggregated protein forms amyloid deposits that accumulate in the blood vessels of the brain. The amyloid deposits replace the muscle fibers and elastic fibers that give blood vessels flexibility, causing the blood vessels to become weak and prone to breakage.\n\nIn the brain, such a break causes bleeding (hemorrhagic stroke), which can lead to brain damage and dementia or be life-threatening. Amyloid deposits in specific parts of the brain can interfere with normal brain function, leading to dementia, seizures, movement problems, and other neurological features in some people with hereditary cerebral amyloid angiopathy.\n\n**Other Names for This Gene**\n\n*   A4_HUMAN\n*   AAA\n*   ABETA\n*   ABPP\n*   AD1\n*   amyloid beta (A4) precursor protein\n*   amyloid beta-peptide\n*   amyloid beta-protein precursor\n*   amyloid precursor protein\n*   APPI\n*   cerebral vascular amyloid peptide\n*   CVAP\n*   PN-II\n*   PN2\n*   protease nexin 2\n*   protease nexin-II\n\n---\n\n**APP Gene**\n\nThe APP gene, located on chromosome 21, plays a crucial role in the development of Alzheimer's disease.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders\n\n**Genomic Location**\n\nThe APP gene is found on chromosome 21.\n\n**Understanding Genetics**\n\nTo better comprehend the significance of the APP gene, it's essential to grasp fundamental concepts in genetics:\n\n*   What is DNA?\n*   What is a gene?\n*   What is a gene variant and how do variants occur?\n\nBy delving into these basics, you'll gain a deeper understanding of the genetic factors contributing to Alzheimer's disease.\n\n---\n\n**APP gene**\n\n\\n\\n\n\n*MedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.*\n\n\\n\\n\n\nThe APP gene provides instructions for making a protein called amyloid precursor protein. This protein plays a role in the development and maintenance of brain cells, particularly those involved in memory and learning.\n\n\\n\\n\n\nMutations in the APP gene have been linked to several conditions, including Alzheimer's disease. The exact relationship between APP gene mutations and these conditions is still being researched, but it's thought that problems with the protein produced by the APP gene may contribute to the development of these diseases.\n\n\\n\\n\n\nIf you're concerned about your health or the health of a family member, contact a healthcare provider for professional advice and care.",
    "category": "general"
  },
  {
    "title": "APRT gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aprt/",
    "content": "**APRT Gene**\n\nThe APRT gene provides instructions for making an enzyme called adenine phosphoribosyltransferase (APRT). This enzyme is produced in all cells and is part of the purine salvage pathway, which recycles a group of DNA building blocks (nucleotides) called purines to make other molecules. The APRT enzyme helps to recycle the purine adenine to make a molecule called adenosine monophosphate (AMP). This conversion occurs when AMP is needed as a source of energy for cells.\n\n**Health Conditions Related to Genetic Changes**\n\n* Adenine phosphoribosyltransferase deficiency\n\t+ At least 40 mutations in the APRT gene have been found to cause adenine phosphoribosyltransferase (APRT) deficiency, a condition that affects the kidneys and urinary tract.\n\t+ Most of these mutations change single protein building blocks (amino acids) in the APRT enzyme.\n\t+ The mutations that cause APRT deficiency are categorized into two groups known as the APRT*J allele and the APRT*Q0 allele.\n\t+ The APRT*J allele consists of one mutation that replaces the amino acid methionine with the amino acid threonine at position 136 in the APRT enzyme (written as Met136Thr or M136T).\n\t+ This mutation reduces the function of the enzyme and occurs almost exclusively in Japanese individuals with the condition.\n\t+ Most affected individuals have this mutation on both copies of the APRT gene in each cell.\n\t+ The APRT*Q0 allele consists of all other APRT gene mutations, including the most common one (written IVS4+2insT) that alters the genetic instructions used to make the enzyme, resulting in an abnormally short, nonfunctional enzyme.\n\t+ This mutation is estimated to occur in 40 percent of affected Europeans.\n\t+ APRT gene mutations lead to a lack of functional enzyme that prevents the conversion of adenine to AMP.\n\t+ As a result, adenine is converted to another molecule called 2,8-dihydroxyadenine (2,8-DHA).\n\t+ 2,8-DHA crystallizes in urine, forming stones in the kidneys and urinary tract.\n\t+ As a result, kidney function can decline, which may lead to end-stage renal disease (ESRD), a life-threatening failure of kidney function.\n\n---\n\n**APRT Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Content:**\nThe APRT gene provides instructions for making the enzyme adenine phosphoribosyltransferase (APRT). This enzyme plays a crucial role in the breakdown of adenine, a molecule that contains nitrogen. In the process of breaking down adenine, the APRT enzyme converts it into AMP, which is then used by the body to produce energy.\n\n**APRT Gene Mutations:**\nAt least 40 mutations in the APRT gene have been found to cause adenine phosphoribosyltransferase (APRT) deficiency, a condition that affects the kidneys and urinary tract. Most of these mutations change single protein building blocks (amino acids) in the APRT enzyme.\n\n**APRT Gene Function:**\nThe APRT gene provides instructions for making the enzyme adenine phosphoribosyltransferase (APRT). This enzyme plays a crucial role in the breakdown of adenine, a molecule that contains nitrogen. In the process of breaking down adenine, the APRT enzyme converts it into AMP, which is then used by the body to produce energy.\n\n**APRT Gene Mutations and Kidney Function:**\nAPRT gene mutations lead to a lack of functional enzyme that prevents the conversion of adenine to AMP. As a result, adenine is converted to another molecule called 2,8-dihydroxyadenine (2,8-DHA). 2,8-DHA crystallizes in urine, forming stones in the kidneys and urinary tract. As a result, kidney function can decline, which may lead to end-stage renal disease (ESRD), a life-threatening failure of kidney function.\n\n**APRT Gene Mutations and Ethnicity:**\nThe M136T mutation occurs almost exclusively in Japanese individuals with the condition; most affected individuals have this mutation on both copies of the APRT gene in each cell. The IVS4+2insT mutation is estimated to occur in 40 percent of affected Europeans.\n\n**APRT Gene Mutations and Other Names:**\nOther names for the APRT gene include AMP diphosphorylase, AMP pyrophosphorylase, APRTase, APT_HUMAN.\n\n**Genomic Location:**\nThe APRT gene is found on chromosome 16.\n\n**Related Health Topics:**\nGenes and Gene Therapy\nGenetic Disorders",
    "category": "general"
  },
  {
    "title": "APTX gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aptx/",
    "content": "**APTX Gene**\n\nThe APTX gene provides instructions for making a protein called aprataxin that is involved in the repair of DNA damage in cells. Aprataxin is located in the nucleus of cells and is produced in various tissues, including the brain, spinal cord, and muscles.\n\n**Normal Function**\n\nAprataxin modifies the broken ends of the DNA strands so they can be joined back together correctly. Different parts of the aprataxin protein allow it to interact with other DNA repair proteins to make repairs.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Ataxia with oculomotor apraxia type 1**: More than 30 mutations in the APTX gene have been found to cause this condition. It is characterized by difficulty coordinating movements (ataxia) and problems with side-to-side movements of the eyes (oculomotor apraxia). Most mutations change single protein building blocks (amino acids) in aprataxin, resulting in an unstable aprataxin protein that is quickly broken down in the cell.\n\n**Other Names for This Gene**\n\n* AOA\n* AOA1\n* APTX_HUMAN\n* ataxia 1, early onset with hypoalbuminemia\n* AXA1\n* EAOH\n* EOAHA\n* FHA-HIT\n\n---\n\n**APTX Gene**\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of APTX\n\n**Scientific Articles on PubMed**\n\n*   Hirano M, Asai H, Kiriyama T, Furiya Y, Iwamoto T, Nishiwaki T, Yamamoto A, Mori T, Ueno S. Short half-lives of ataxia-associated aprataxin proteins in neuronal cells. Neurosci Lett. 2007 May 29;419(2):184-7.\n*   Le Ber I, Moreira MC, Rivaud-Pechoux S, Chamayou C, Ochsner F, Kuntzer T, Tardieu M, Said G, Habert MO, Demarquay G, Tannier C, Beis JM, Brice A, Koenig M, Durr A. Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies. Brain. 2003 Dec;126(Pt 12):2761-72.\n*   Rass U, Ahel I, West SC. Actions of aprataxin in multiple DNA repair pathways. J Biol Chem. 2007 Mar 30;282(13):9469-9474.\n*   Tada M, Yokoseki A, Sato T, Makifuchi T, Onodera O. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia/ataxia with oculomotor apraxia 1. Adv Exp Med Biol. 2010;685:21-33.\n*   Takahashi T, Tada M, Igarashi S, Koyama A, Date H, Yokoseki A, Shiga A, Yoshida Y, Tsuji S, Nishizawa M, Onodera O. Aprataxin, causative gene product for EAOH/AOA1, repairs DNA single-strand breaks with damaged 3'-phosphate and 3'-phosphoglycolate ends.\n*   Tumbale P, Williams JS, Schellenberg MJ, Kunkel TA, Williams RS. Aprataxin resolves adenylated RNA-DNA junctions to maintain genome integrity.\n\n**Genomic Location**\n\nThe APTX gene is found on chromosome 9.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "AQP2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aqp2/",
    "content": "**AQP2 Gene**\n\nThe AQP2 gene provides instructions for making a protein called aquaporin 2. This protein forms a channel that carries water molecules across cell membranes.\n\n**Normal Function**\n\nThe aquaporin 2 water channel plays an essential role in maintaining the body's water balance. The placement of these channels is controlled by a hormone called arginine vasopressin (AVP), which is sometimes also called antidiuretic hormone (ADH). When a person's fluid intake is low or when a lot of fluid is lost, AVP is released from the brain, where it is produced and stored. This hormone triggers chemical reactions that ultimately insert aquaporin 2 water channels into the membrane of collecting duct cells. These channels allow water to be reabsorbed into the bloodstream, which makes the urine more concentrated.\n\n**Health Conditions Related to Genetic Changes**\n\nMultiple variants in the AQP2 gene have been identified in people with arginine vasopressin resistance. People with this condition produce an excessive amount of urine (polyuria), which depletes the amount of water in the body. This water loss also leads to excessive thirst (polydipsia). Most of the AQP2 gene variants that cause this condition produce an aquaporin 2 protein that is folded incorrectly. The misfolded protein remains trapped within the cell, where it is unable to reach the cell membrane to transport water molecules.\n\n**Other Names for This Gene**\n\n* Aquaporin 2\n\n**Additional Information & Resources**\n\n* National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\n* American Kidney Fund\n* American Society of Nephrology\n\n---\n\n**AQP2 Gene**\n\nThe AQP2 gene has been identified as a cause of arginine vasopressin resistance, a condition characterized by excessive thirst and polyuria.\n\n**Multiple Variants Identified**\n\nTwo genes have been identified in people with this condition: the AQP2 gene and another unidentified gene. The AQP2 gene variants that cause this condition produce an aquaporin 2 protein that is folded incorrectly, resulting in misrouted water channels within the cell.\n\n**Aquaporin 2 Water Channels**\n\nIf aquaporin 2 water channels are not inserted into the membrane of collecting duct cells, the kidneys are unable to respond to signals from AVP. As a result, collecting ducts do not reabsorb water as they should, leading to polyuria in people with arginine vasopressin resistance.\n\n**Other Names for This Gene**\n\nThe AQP2 gene has several other names, including:\n\n*   AQP-2\n*   AQP-CD\n*   AQP2_HUMAN\n*   aquaporin-2\n*   aquaporin-CD\n*   water-channel\n*   WCH-CD\n\n**Additional Information & Resources**\n\nFor more information on the AQP2 gene, you can visit the following resources:\n\n*   Tests Listed in the Genetic Testing Registry: Tests of AQP2\n*   Scientific Articles on PubMed: PubMed\n*   Catalog of Genes and Diseases from OMIM: AQUAPORIN 2; AQP2\n*   Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\nThe following scientific articles provide more information on the AQP2 gene:\n\n*   Chen L, Higgins PJ, Zhang W. Development and Diseases of the Collecting Duct System. Results Probl Cell Differ. 2017;60:165-203.\n*   Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, van Oost BA. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science. 1994 Apr 1;264(5155):92-5.\n*   Knoers NV, Deen PM. Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol. 2001 Dec;16(12):1146-52.\n*   Loonen AJ, Knoers NV, van Os CH, Deen PM. Aquaporin 2 mutations in nephrogenic diabetes insipidus. Semin Nephrol. 2008 May;28(3):252-65.\n*   Noda Y, Sasaki S. Updates and Perspectives on Aquaporin-2 and Water Balance Disorders. Int J Mol Sci. 2021 Nov 30;22(23):12950.\n*   Noda Y, Sohara E, Ohta E, Sasaki S. Aquaporins in kidney pathophysiology. Nat Rev Nephrol. 2010 Mar;6(3):168-78.\n*   Robben JH, Knoers NV, Deen PM. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 2006 Aug;291(2):F257-70.\n\n**Genomic Location**\n\nThe AQP2 gene is located on chromosome 12.\n\n**Related Health Topics**\n\nThis condition is related to genes and gene therapy, genetic disorders, and understanding genetics.\n\n---\n\n**AQP2 Gene**\n\n**Genomic Location**\nThe AQP2 gene is found on chromosome 12.\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "AR gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ar/",
    "content": "**AR Gene**\n\nThe AR gene provides instructions for making a protein called an androgen receptor. Androgens are hormones (such as testosterone) that are important for normal male sexual development before birth and during puberty. Androgen receptors allow the body to respond appropriately to these hormones.\n\n*   The receptors are present in many of the body's tissues, where they attach (bind) to androgens.\n*   The resulting androgen-receptor complex then binds to DNA and regulates the activity of certain genes that play a role in male sexual development.\n*   By turning the genes on or off as necessary, the androgen receptor complex helps direct the development of male sex characteristics.\n*   Androgens and androgen receptors also have other important functions in both males and females, such as regulating hair growth and sex drive.\n\n**Health Conditions Related to Genetic Changes**\n\nHundreds of different variants (also called mutations) in the AR gene have been identified in people with androgen insensitivity syndrome, a condition that affects sexual development before birth and during puberty. Most of these variants are changes in single DNA building blocks (base pairs). Other variants insert or delete multiple base pairs in the gene. Some variants lead to the production of an abnormally short version of the androgen receptor protein, while others cause the production of an abnormal receptor that cannot bind to androgens or to DNA.\n\n*   As a result of these changes, androgen receptors do not work properly, which makes them less able to bind to androgens and regulate gene activity.\n*   If androgen receptors cannot bind to androgens, the body cannot use androgens, even if there are normal levels of these hormones in the body.\n\nThere are three forms of androgen insensitivity syndrome: complete, partial, and mild. Which form a person has depends on how much the variants affect the function of the androgen receptor. Variants that produce nonfunctional versions of the androgen receptor cause complete androgen insensitivity syndrome, while variants that reduce but do not eliminate the receptor's activity can cause partial or mild androgen insensitivity syndrome.\n\n*   People with this condition have one X chromosome and one Y chromosome in each cell.\n*   Depending on the level of androgen insensitivity, affected individuals may have external sex characteristics that are typical for females or typical for males, or they may have features of both male and female sexual development.\n\n---\n\n**AR Gene: MedlinePlus Genetics (Part 2/5)**\n\n*   **Spinal and Bulbar Muscular Atrophy**\n    Variants in the AR gene have been found to cause spinal and bulbar muscular atrophy. This condition affects specialized nerve cells that control muscle movement (motor neurons). The AR gene variants that cause spinal and bulbar muscular atrophy are an expansion of the CAG trinucleotide repeat in the AR gene. Instead of the typical 10 to 36 repeats, CAG is repeated from 38 to more than 60 times in people with this disorder.\n*   **Androgenetic Alopecia**\n    Variants in the AR gene are associated with an increased risk of androgenetic alopecia, a form of hair loss also known as male pattern baldness in men and female pattern hair loss in women. The variants change the number or order of base pairs that make up the AR gene.\n*   **Polycystic Ovary Syndrome**\n    MedlinePlus Genetics provides information about Polycystic ovary syndrome\n*   **Prostate Cancer**\n    MedlinePlus Genetics provides information about Prostate cancer\n*   **Androgen Insensitivity Syndrome**\n    Hundreds of different variants (also called mutations) in the AR gene have been identified in people with androgen insensitivity syndrome, a condition that affects sexual development before birth and during puberty. Most of these variants are changes in single DNA building blocks (base pairs). Other variants insert or delete multiple base pairs in the gene. Some variants lead to the production of an abnormally short version of the androgen receptor protein, while others cause the production of an abnormal receptor that cannot bind to androgens or to DNA.\n    As a result of these changes, androgen receptors do not work properly, which makes them less able to bind to androgens and regulate gene activity. If androgen receptors cannot bind to androgens, the body cannot use androgens, even if there are normal levels of these hormones in the body.\n    There are three forms of androgen insensitivity syndrome: complete, partial, and mild. Which form a person has depends on how much the variants affect the function of the androgen receptor. Variants that produce nonfunctional versions of the androgen receptor cause complete androgen insensitivity syndrome, while variants that reduce but do not eliminate the receptor's activity can cause partial or mild androgen insensitivity syndrome.\n    People with this condition have one X chromosome and one Y chromosome in each cell. Depending on the level of androgen insensitivity, affected individuals may have external sex characteristics that are typical for females or typical for males, or they may have features of both male and female sexual development.\n\n---\n\n**AR Gene: MedlinePlus Genetics (Part 3/5)**\n\n**Spinal and Bulbar Muscular Atrophy**\n\nVariants in the AR gene have been found to cause spinal and bulbar muscular atrophy. This condition affects specialized nerve cells that control muscle movement (motor neurons). The AR gene variants that cause spinal and bulbar muscular atrophy are an expansion of the CAG trinucleotide repeat in the AR gene. Instead of the typical 10 to 36 repeats, CAG is repeated from 38 to more than 60 times in people with this disorder.\n\nAlthough the extended CAG region changes the structure of the androgen receptor, it is unclear how the altered protein damages nerve cells. Researchers believe that a fragment of the androgen receptor protein that contains the CAG repeats accumulates within these cells and interferes with normal cell functions. This buildup leads to the gradual loss of motor neurons, which results in muscle weakness and wasting (atrophy).\n\n**Androgenetic Alopecia**\n\nVariants in the AR gene are associated with an increased risk of androgenetic alopecia, a form of hair loss also known as male pattern baldness in men and female pattern hair loss in women. The variants change the number or order of base pairs that make up the AR gene. These genetic changes appear to be most frequent in men with hair loss that begins at an early age.\n\nResearchers believe that AR gene variants may increase the activity of androgen receptors in the scalp. Although androgenetic alopecia is related to the effects of androgens on hair growth, it remains unclear how changes in the AR gene increase the risk of hair loss in people with this condition.\n\n**Polycystic Ovary Syndrome**\n\nMedlinePlus Genetics provides information about Polycystic ovary syndrome\n\n**Prostate Cancer**\n\nMedlinePlus Genetics provides information about Prostate cancer\n\n---\n\n**AR Gene**\n\n**Genomic Location**\nThe AR gene is found on the X chromosome.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Scientific Articles on PubMed**\n\n* Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Yoshida M, Hashizume Y, Sobue G. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005 Mar;128(Pt 3):659-70.\n* Beitel LK, Scanlon T, Gottlieb B, Trifiro MA. Progress in Spinobulbar muscular atrophy research: insights into neuronal dysfunction caused by the polyglutamine-expanded androgen receptor. Neurotox Res. 2005;7(3):219-30.\n* Bennett NC, Gardiner RA, Hooper JD, Johnson DW, Gobe GC. Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol. 2010 Jun;42(6):813-27.\n\n**Catalog of Genes and Diseases from OMIM**\n\n* ANDROGEN RECEPTOR; AR\n\n**Gene and Variant Databases**\n\n* NCBI Gene\n* ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n* Tests of AR\n\n---\n\n**AR Gene**\n\n\\n\\n*Definition*: The AR gene provides instructions for making a protein called androgen receptor, which plays a crucial role in the development and maintenance of male characteristics.\n\n\\n\\n*Inheritance Pattern*: The AR gene is located on the X chromosome. Females have two X chromosomes, while males have one X and one Y chromosome. Because the AR gene is located on the X chromosome, it follows an X-linked inheritance pattern.\n\n\\n\\n*Mutations*: Mutations in the AR gene can cause a range of disorders, including androgen insensitivity syndrome (AIS), which affects males. The severity of AIS varies among affected individuals, depending on the specific mutation and the individual's sex chromosomes.\n\n\\n\\n*Testing*: Genetic testing for mutations in the AR gene is available. It may be recommended for individuals with symptoms of AIS or other disorders caused by AR gene mutations.\n\n\\n\\n*Support Groups*: Support groups are available for individuals and families affected by AR gene-related disorders. These groups can provide emotional support, connect individuals with others who share similar experiences, and offer resources for managing the challenges associated with these conditions.",
    "category": "general"
  },
  {
    "title": "ARFGEF2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arfgef2/",
    "content": "**ARFGEF2 Gene**\n\nThe ARFGEF2 gene provides instructions for making a protein that helps with the movement (trafficking) of small sac-like structures (vesicles) within the cell. The ARFGEF2 protein converts a molecule called guanine diphosphate (GDP) to another molecule called guanine triphosphate (GTP). This reaction activates an ADP-ribosylation factor, a molecule that is involved in vesicle trafficking. Vesicles transport many types of molecules from the interior of the cell to its surface, where they may attach and interact with other substances, or be secreted by the cell.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Periventricular Heterotopia**: A few mutations in the ARFGEF2 gene have been identified in individuals with periventricular heterotopia. These mutations may interfere with vesicle trafficking, which is important in controlling cell migration during the development of the brain. Nerve cells (neurons) that do not migrate properly during development form clumps around fluid-filled cavities (ventricles) near the center of the brain, resulting in the signs and symptoms of periventricular heterotopia.\n\n**Other Names for This Gene**\n\n*   **ADP-ribosylation factor guanine nucleotide-exchange factor 2**\n*   **BIG2**\n*   **BIG2_HUMAN**\n*   **Brefeldin A-inhibited guanine nucleotide-exchange protein 2**\n\n**Additional Information & Resources**\n\n*   **Tests Listed in the Genetic Testing Registry**: Tests of ARFGEF2\n*   **Scientific Articles on PubMed**: PubMed\n*   **Catalog of Genes and Diseases from OMIM**: ADP-RIBOSYLATION FACTOR GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; ARFGEF2\n\n---\n\n**ARFGEF2 Gene**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**: A comprehensive database of genetic information, including the ARFGEF2 gene.\n*   **ClinVar**: A database that provides clinical interpretations of genomic variations, including those related to the ARFGEF2 gene.\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   **Tests of ARFGEF2**: Various genetic tests available for detecting mutations or variants in the ARFGEF2 gene.\n\n**Scientific Articles on PubMed**\n\n*   **Lu J, Tiao G, Folkerth R, Hecht J, Walsh C, Sheen V. Overlapping expression of ARFGEF2 and Filamin A in the neuroependymal lining of the lateral ventricles: insights into the cause of periventricular heterotopia.** J Comp Neurol. 2006 Jan 20;494(3):476-84.\n*   **Sheen VL, Ganesh VS, Topcu M, Sebire G, Bodell A, Hill RS, Grant PE, Shugart YY, Imitola J, Khoury SJ, Guerrini R, Walsh CA. Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex.** Nat Genet. 2004 Jan;36(1):69-76.\n*   **Shin HW, Morinaga N, Noda M, Nakayama K. BIG2, a guanine nucleotide exchange factor for ADP-ribosylation factors: its localization to recycling endosomes and implication in the endosome integrity.** Mol Biol Cell. 2004 Dec;15(12):5283-94.\n*   **Shin HW, Shinotsuka C, Nakayama K. Expression of BIG2 and analysis of its function in mammalian cells.** Methods Enzymol. 2005;404:206-15.\n\n**Genomic Location**\n\nThe ARFGEF2 gene is found on chromosome 20.\n\n**Related Health Topics**\n\n*   **Genes and Gene Therapy**\n*   **Genetic Disorders**\n\n**Understanding Genetics**\n\n*   **What is DNA?**\n*   **What is a gene?**\n*   **What is a gene variant and how do variants occur?**\n\nThe information provided on this site should not be used as a substitute for professional medical care or advice. Contact a healthcare provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ARG1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arg1/",
    "content": "**ARG1 Gene**\n\nThe ARG1 gene provides instructions for producing the enzyme arginase. This enzyme participates in the urea cycle, a series of reactions that occurs in liver cells.\n\n**Normal Function**\n\nThe urea cycle processes excess nitrogen, which is generated when proteins and their building blocks (amino acids) are used by the body. The urea cycle produces a compound called urea from excess nitrogen. Urea is then excreted by the kidneys. Excreting the excess nitrogen prevents it from accumulating in the form of ammonia, which is toxic.\n\nArginase facilitates the last step of the urea cycle, a reaction in which nitrogen is removed from the amino acid arginine and processed into urea. A compound called ornithine is also produced during this reaction; it is needed for the urea cycle to repeat.\n\n**Health Conditions Related to Genetic Changes**\n\nMany variants (also called mutations) have been identified in the ARG1 gene. Arginase deficiency causes ammonia to accumulate gradually in the blood. The nervous system is especially sensitive to the effects of excess ammonia. Changes in the ARG1 gene can result in an arginase enzyme that is unstable, shorter than usual, or the wrong shape. Variants in the ARG1 gene may also prevent the enzyme from being produced at all.\n\nThe shape of an enzyme affects its ability to control a chemical reaction. If the arginase enzyme is misshapen or missing, it cannot fulfill its role in the urea cycle. Excess nitrogen is not converted to urea for excretion, and ammonia and arginine accumulate in the body. High levels of ammonia and arginine are believed to cause the neurological problems and other signs and symptoms of arginase deficiency.\n\n**Other Names for This Gene**\n\n* Arginase 1\n\n**Additional Information & Resources**\n\n* MedlinePlus Genetics: ARG1 gene\n* National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Urea Cycle Disorders\n\n**References**\n\n* [Insert references here]\n\n---\n\n**ARG1 Gene: MedlinePlus Genetics**\n\nIf the arginase enzyme is misshapen or missing, it cannot fulfill its role in the urea cycle. Excess nitrogen is not converted to urea for excretion, and ammonia and arginine accumulate in the body. High levels of ammonia and arginine are believed to cause the neurological problems and other signs and symptoms of arginase deficiency.\n\n**Other Names for This Gene**\n\n* A-I ARGI1_HUMAN\n* arginase, liver\n* type I\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of ARG1\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* ARGINASE 1; ARG1\n\nGene and Variant Databases:\n\n* NCBI Gene\n* ClinVar\n\n**References**\n\nIyer R, Jenkinson CP, Vockley JG, Kern RM, Grody WW, Cederbaum S. The human arginases and arginase deficiency. J Inherit Metab Dis. 1998;21 Suppl 1:86-100.\n\nIyer RK, Yoo PK, Kern RM, Rozengurt N, Tsoa R, O'Brien WE, Yu H, Grody WW, Cederbaum SD. Mouse model for human arginase deficiency. Mol Cell Biol. 2002 Jul;22(13):4491-8.\n\nVockley JG, Goodman BK, Tabor DE, Kern RM, Jenkinson CP, Grody WW, Cederbaum SD. Loss of function mutations in conserved regions of the human arginase I gene. Biochem Mol Med. 1996 Oct;59(1):44-51.\n\n**Genomic Location**\n\nThe ARG1 gene is found on chromosome 6.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ARHGAP31 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arhgap31/",
    "content": "**ARHGAP31 Gene**\n\nThe ARHGAP31 gene provides instructions for making a protein classified as a Rho GTPase activating protein (GAP). GAPs turn off (inactivate) proteins called GTPases, which play an important role in chemical signaling within cells. Often referred to as molecular switches, GTPases can be turned on and off.\n\n**Normal Function**\n\nThe ARHGAP31 protein inactivates GTPases known as Cdc42 and Rac1 by stimulating a reaction that turns the attached GTP into GDP. When active, Cdc42 and Rac1 transmit signals that are critical for various aspects of embryonic development. The ARHGAP31 protein appears to regulate these GTPases specifically during development of the limbs, skull, and heart.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Adams-Oliver Syndrome**: At least three mutations in the ARHGAP31 gene are known to cause Adams-Oliver syndrome, a condition characterized by areas of missing skin (aplasia cutis congenita), usually on the scalp, and malformations of the hands and feet. These mutations lead to production of an abnormally short ARHGAP31 protein that is more active than normal. The increased GAP activity leads to a reduction in Cdc42 and Rac1 signaling, which impairs proper development of the skin on the top of the head and the bones in the hands and feet.\n\n**Other Names for This Gene**\n\n* AOS1\n* CDGAP\n* Cdc42 GTPase-activating protein\n* RHG31_HUMAN\n* rho GTPase-activating protein 31\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: ARHGAP31\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: RHO GTPase-ACTIVATING PROTEIN 31; ARHGAP31\n\n---\n\n**ARHGAP31 Gene**\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of ARHGAP31\n\n**Scientific Articles on PubMed**\n\n*   Isrie M, Wuyts W, Van Esch H, Devriendt K. Isolated terminal limb reduction defects: extending the clinical spectrum of Adams-Oliver syndrome and ARHGAP31 mutations. Am J Med Genet A. 2014 Jun;164A(6):1576-9. doi: 10.1002/ajmg.a.36486.\n*   Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol. 2004 Jan 1;265(1):23-32. doi: 10.1016/j.ydbio.2003.06.003.\n*   Southgate L, Machado RD, Snape KM, Primeau M, Dafou D, Ruddy DM, Branney PA, Fisher M, Lee GJ, Simpson MA, He Y, Bradshaw TY, Blaumeiser B, Winship WS, Reardon W, Maher ER, FitzPatrick DR, Wuyts W, Zenker M, Lamarche-Vane N, Trembath RC. Gain-of-function mutations of ARHGAP31, a Cdc42/Rac1 GTPase regulator, cause syndromic cutis aplasia and limb anomalies. Am J Hum Genet. 2011 May 13;88(5):574-85.\n*   Tcherkezian J, Lamarche-Vane N. Current knowledge of the large RhoGAP family of proteins. Biol Cell. 2007 Feb;99(2):67-86.\n\n**Genomic Location**\n\nThe ARHGAP31 gene is found on chromosome 3.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ARID1A gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arid1a/",
    "content": "**ARID1A Gene**\n\nThe ARID1A gene provides instructions for making a protein that forms one piece (subunit) of several different SWI/SNF protein complexes. These complexes regulate gene activity by a process known as chromatin remodeling.\n\n**Normal Function**\n\n*   The structure of chromatin can be changed to alter how tightly DNA is packaged.\n*   Chromatin remodeling is one way gene expression is regulated during development; when DNA is tightly packed, gene expression is lower than when DNA is loosely packed.\n*   SWI/SNF complexes are involved in many processes, including repairing damaged DNA, copying (replicating) DNA, and controlling the growth, division, and maturation (differentiation) of cells.\n*   The ARID1A protein and other SWI/SNF subunits act as tumor suppressors, keeping cells from growing and dividing too rapidly or in an uncontrolled way.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Coffin-Siris Syndrome**: More than 30 variants (mutations) in the ARID1A gene can cause this condition. It is characterized by delayed development, abnormalities of the fifth fingers or toes, and characteristic facial features.\n*   **Bladder Cancer**\n*   **Cholangiocarcinoma**\n\n**Other Names for This Gene**\n\n*   AT-rich interaction domain 1A\n\n**Additional Information & Resources**\n\n*   MedlinePlus Genetics provides information about various health conditions related to genetic changes.\n\n**References**\n\n*   [Insert references here]\n\n---\n\n**ARID1A Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Cancers**\n\nVariants in the ARID1A gene have been found in many types of cancer, including cancers of the ovaries and lining of the uterus (endometrium) in women and cancers of the kidney, stomach, bladder, lung, breast, and brain. These variants are somatic, which means they are acquired during a person's lifetime and are present only in tumor cells. The mechanism by which variants in the ARID1A gene contribute to cancer is unknown, although it is thought that changes in SWI/SNF complexes are involved. These changes may impair normal cell differentiation, which leads to the overgrowth of certain cell types, causing cancer. Alternatively, abnormal SWI/SNF complexes may disrupt the regulation of genes that help control the growth and division of cells, which leads to cancer. It is likely that other genetic changes in addition to ARID1A gene variants are necessary for cancer development.\n\n**Coffin-Siris Syndrome**\n\nMore than 30 variants (also known as mutations) in the ARID1A gene can cause Coffin-Siris syndrome. This condition is characterized by delayed development, abnormalities of the fifth (pinky) fingers or toes, and characteristic facial features that are described as coarse. The ARID1A gene variants involved in Coffin-Siris syndrome lead to an abnormally short, nonfunctional protein. As a result, affected individuals have half the normal amount of functioning ARID1A protein. Although it is unclear how these changes affect SWI/SNF complexes, researchers suggest that ARID1A gene variants result in abnormal chromatin remodeling. Disturbance of this process alters the activity of many genes and disrupts several cellular processes, which could explain the diverse signs and symptoms of Coffin-Siris syndrome. People with Coffin-Siris syndrome do not appear to have an increased risk of cancer.\n\n**Bladder Cancer**\n\nMedlinePlus Genetics provides information about Bladder cancer\n\n**Cholangiocarcinoma**\n\nMedlinePlus Genetics provides information about Cholangiocarcinoma\n\n---\n\n**ARID1A Gene**\n\nThe ARID1A gene is involved in the regulation of cell growth and division. Mutations in this gene can increase the risk of certain types of cancer. The protein produced by the ARID1A gene is part of a complex called SWI/SNF, which helps to regulate the activity of genes.\n\n**Function of the ARID1A Gene**\n\nThe ARID1A gene provides instructions for making a protein that is involved in the regulation of cell growth and division. This protein is part of a complex called SWI/SNF, which helps to regulate the activity of genes by changing the structure of DNA.\n\n**Cancer Risk**\n\nMutations in the ARID1A gene can increase the risk of certain types of cancer. The protein produced by the ARID1A gene is involved in the regulation of cell growth and division, and mutations in this gene can disrupt this process, leading to cancer.\n\n**Other Names for This Gene**\n\n* ARI1A_HUMAN\n* AT rich interactive domain 1A (SWI-like)\n* AT-rich interactive domain-containing protein 1A\n* B120\n* BAF250\n* BAF250a\n* BM029\n* brain protein 120\n* BRG1-associated factor 250a\n* C1orf4\n* chromatin remodeling factor p250\n* ELD\n* hELD\n* hOSA1\n* MRD14\n* osa homolog 1\n* OSA1\n* OSA1 nuclear protein\n* P270\n* SMARCF1\n* SWI-like protein\n* SWI/SNF complex protein p270\n* SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily F member 1\n\n**Genomic Location**\n\nThe ARID1A gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ARID1B gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arid1b/",
    "content": "**ARID1B Gene**\n\nThe ARID1B gene provides instructions for making a protein that forms one piece (subunit) of several different SWI/SNF protein complexes. These complexes regulate gene activity by a process known as chromatin remodeling.\n\n**Normal Function**\n\n* The structure of chromatin can be changed to alter how tightly DNA is packaged.\n* Chromatin remodeling is one way gene expression is regulated during development; when DNA is tightly packed, gene expression is lower than when DNA is loosely packed.\n* SWI/SNF complexes are involved in many processes, including:\n\t+ Repairing damaged DNA\n\t+ Copying (replicating) DNA\n\t+ Controlling the growth, division, and maturation (differentiation) of cells\n\n**Health Conditions Related to Genetic Changes**\n\nCoffin-Siris syndrome is characterized by delayed development, abnormalities of the fifth (pinky) fingers or toes, and characteristic facial features. More than 150 variants in the ARID1B gene have been found to cause this condition.\n\n* Most ARID1B gene variants lead to an abnormally short, nonfunctional protein.\n* Affected individuals have half the normal amount of functional ARID1B protein.\n* The changes affect SWI/SNF complexes and result in abnormal chromatin remodeling, disrupting several cellular processes.\n\n---\n\n**ARID1B Gene**\n\n\\n\\n\n\n* **Autism Spectrum Disorder**: At least 13 ARID1B gene variants have been identified in people with autism spectrum disorder (ASD), a varied condition characterized by impaired social skills, communication problems, and repetitive behaviors. Some affected individuals also have other features, including intellectual disability, severe speech problems, and brain malformations.\n* **Other Disorders**: Variants in the ARID1B gene can cause intellectual disability without other hallmark features of Coffin-Siris syndrome (described above). As in Coffin-Siris syndrome, the gene variants that cause intellectual disability lead to an abnormally short, nonfunctional protein, and affected individuals have half the normal amount of ARID1B protein.\n* **Cancers**: Variants in the ARID1B gene are involved in several types of cancer, including breast cancer, a childhood cancer of nerve tissue called neuroblastoma, and a type of blood cancer called diffuse large B-cell lymphoma. These variants are somatic, which means they are acquired during a person's lifetime and are present only in tumor cells.\n* **Coffin-Siris Syndrome**: More than 150 variants (also known as mutations) in the ARID1B gene have been found to cause Coffin-Siris syndrome. This condition is characterized by delayed development, abnormalities of the fifth (pinky) fingers or toes, and characteristic facial features that are described as coarse.\n\nNote: The original content has been reformatted to improve readability and clarity, while maintaining its medical accuracy and structure.\n\n---\n\n**ARID1B Gene**\n\n**Coffin-Siris Syndrome**\n\nCoffin-Siris syndrome is a rare genetic disorder characterized by intellectual disability, short stature, and distinctive facial features. The ARID1B gene variants that cause Coffin-Siris syndrome lead to an abnormally short, nonfunctional protein, resulting in half the normal amount of ARID1B protein.\n\n**Variants in the ARID1B Gene**\n\nVariants in the ARID1B gene can cause intellectual disability without other hallmark features of Coffin-Siris syndrome. The gene variants that cause intellectual disability lead to an abnormally short, nonfunctional protein, and affected individuals have half the normal amount of ARID1B protein.\n\n**Cancers**\n\nVariants in the ARID1B gene are involved in several types of cancer, including breast cancer, neuroblastoma, and diffuse large B-cell lymphoma. These variants are somatic, meaning they are acquired during a person's lifetime and are present only in tumor cells. The mechanism by which variants in the ARID1B gene contribute to cancer is unknown, although it is thought that changes in SWI/SNF complexes are involved.\n\n**Other Names for This Gene**\n\n* 6A3-5\n* ARI1B_HUMAN\n* AT rich interactive domain 1B (SWI1-like)\n* AT-rich interactive domain-containing protein 1B\n* BAF250B\n* BRG1-associated factor 250b\n* BRG1-binding protein\n* ELD/OSA1\n* BRIGHT\n* DAN15\n* ELD (eyelid)/OSA protein\n* ELD/OSA1\n* KIAA1235\n* MRD12\n* OSA2\n* P250R\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ARID1B\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 1B; ARID1B\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* D'Gama AM, Pochareddy S, Li M, Jamuar SS, Reiff RE, Lam AN, Sestan N, Walsh CA. Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates Multiple Genetic Mechanisms. Neuron. 2015 Dec 2;88(5):910-917.\n* Halgren C, Kjaergaard S, Bak M, Hansen C, El-Schich Z, Anderson CM, Henriksen KF, Hjalgrim H, Kirchhoff M, Bijlsma EK, Nielsen M, den Hollander NS, Ruivenkamp CA, Isidor B, Le Caignec C, Zannolli R, Mucciolo M, Renieri A, Mari F, Anderlid BM, Andrieux J, Dieux A, Tommerup N, Bache I. Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. Clin Genet. 2012 Sep;82(3):248-55.\n* Hoyer J, Ekici AB, Endele S, Popp B, Zweier C, Wiesener A, Wohlleber E, Dufke A, Rossier E, Petsch C, Zweier M, Gohring I, Zink AM, Rappold G, Schrock E, Wieczorek D, Riess O, Engels H, Rauch A, Reis A. Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet. 2012 Mar 9;90(3):565-72.\n* Nord AS, Roeb W, Dickel DE, Walsh T, Kusenda M, O'Connor KL, Malhotra D, McCarthy SE, Stray SM, Taylor SM, Sebat J; STAART Psychopharmacology Network; King B, King MC, McClellan JM. Reduced transcript expression of genes affected by inherited and de novo CNVs in autism. Eur J Hum Genet. 2011 Jun;19(6):727-31.\n* Santen GW, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN, Peeters EA, Hilhorst-Hofstee Y, Wessels MW, den Hollander NS, Ruivenkamp CA, van Ommen GJ, Breuning MH, den Dunnen JT, van Haeringen A, Kriek M. Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. Nat Genet. 2012 Mar 18;44(4):379-80.\n* Santen GW, Kriek M, van Attikum H. SWI/SNF complex in disorder: SWItching from malignancies to intellectual disability. Epigenetics. 2012 Nov;7(11):1219-24.\n* Shain AH, Pollack JR.\n\n---\n\n**ARID1B Gene**\n\nThe ARID1B gene is associated with intellectual disability, Coffin-Siris syndrome, and other developmental disorders. It plays a crucial role in the SWI/SNF complex, which helps regulate gene expression by modifying chromatin structure.\n\n**Mutations and Disorders**\n\nMutations in the ARID1B gene have been linked to various disorders, including:\n\n*   **Coffin-Siris Syndrome**: A rare genetic disorder characterized by intellectual disability, physical abnormalities, and a distinctive facial appearance.\n*   **Intellectual Disability**: Mutations in the ARID1B gene can cause intellectual disability, ranging from mild to severe cognitive impairment.\n*   **Autism Spectrum Disorder**: Research suggests that mutations in the ARID1B gene may contribute to the development of autism spectrum disorder.\n\n**Genomic Location**\n\nThe ARID1B gene is located on chromosome 6.\n\n**Related Health Topics**\n\n*   **Genes and Gene Therapy**\n*   **Genetic Disorders**\n\n**Understanding Genetics**\n\nTo better comprehend the role of the ARID1B gene in human health, it's essential to understand some fundamental concepts:\n\n*   **DNA**: The molecule that contains genetic instructions for the development and function of all living organisms.\n*   **Gene**: A segment of DNA that codes for a specific protein or functional element.\n*   **Gene Variant**: A variation in the DNA sequence of a gene, which can affect its function or expression.\n\nBy grasping these basics, you'll be better equipped to navigate the complex world of genetics and appreciate the significance of the ARID1B gene in human health.",
    "category": "general"
  },
  {
    "title": "ARMC5 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/armc5/",
    "content": "**ARMC5 Gene**\n\nThe ARMC5 gene provides instructions for making a protein about which little is known. It is found mainly in the fluid surrounding the cell nucleus (cytoplasm), and studies suggest that its function depends on interacting with other proteins. It is thought to act as a tumor suppressor, which means that it helps to prevent cells from growing and dividing too rapidly or in an uncontrolled way.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Primary Macronodular Adrenal Hyperplasia (PMAH)**: At least 24 mutations in the ARMC5 gene have been identified in people with PMAH, a disorder that causes multiple lumps (nodules) to form in the adrenal glands. These nodules cause adrenal gland enlargement (hyperplasia) and result in production of higher-than-normal levels of the hormone cortisol. Cortisol normally helps maintain blood sugar (glucose) levels, protects the body from physical stress, and suppresses inflammation. Increased cortisol levels can lead to weight gain in the face and upper body, fragile skin, bone loss, fatigue, and other health problems.\n\n**Other Names for This Gene**\n\n* None\n\n**Additional Information & Resources**\n\n* More information on primary macronodular adrenal hyperplasia (PMAH) can be found at [insert link].\n\n**References**\n\n* [Insert references]\n\n---\n\n**ARMC5 Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Primary Macronodular Adrenal Hyperplasia (PMAH)**\n\nPMAH is a disorder that causes multiple lumps (nodules) to form in the adrenal glands, leading to their enlargement and increased production of cortisol. This hormone helps maintain blood sugar levels, protects against physical stress, and suppresses inflammation. However, elevated cortisol levels can result in weight gain, fragile skin, bone loss, fatigue, and other health issues.\n\n**Inheritance and Development**\n\nPeople with PMAH caused by ARMC5 gene mutations inherit one copy of the mutated gene in each cell. The condition develops only when affected individuals acquire a second mutation in the other copy of the ARMC5 gene in certain cells of the adrenal glands. This second mutation is somatic, meaning it's acquired during a person's lifetime and present only in specific cells.\n\n**Reduced Penetrance**\n\nSome individuals who have inherited the altered ARMC5 gene never develop PMAH due to reduced penetrance. This occurs because the condition requires both inherited and somatic mutations for its manifestation.\n\n**ARMC5 Gene Mutations**\n\nThe ARMC5 gene mutations that cause PMAH are thought to impair the protein's tumor suppressor function, allowing the overgrowth of certain cells. It is unclear why this overgrowth is limited to the adrenal glands in people with PMAH.\n\n*\\*Other Names for This Gene\\*\\*\n\n FLJ13063\n\n**Additional Information & Resources**\n\nFor more information on ARMC5 gene mutations and their relationship to PMAH, consult the following resources:\n\n Tests Listed in the Genetic Testing Registry\n Scientific Articles on PubMed\n Catalog of Genes and Diseases from OMIM\n Gene and Variant Databases (NCBI Gene, ClinVar)\n\n**References**\n\n1. Alencar GA, Lerario AM, Nishi MY, Mariani BM, Almeida MQ, Tremblay J, Hamet P, Bourdeau I, Zerbini MC, Pereira MA, Gomes GC, Rocha Mde S, Chambo JL, Lacroix A, Mendonca BB, Fragoso MC. ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia. J Clin Endocrinol Metab. 2014 Aug;99(8):E1501-9.\n2. Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O, Lefevre L, Sibony M, Guignat L, Rodriguez S, Perlemoine K, Rene-Corail F, Letourneur F, Trabulsi B, Poussier A, Chabbert-Buffet N, Borson-Chazot F, Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013 Nov 28;369(22):2105-14.\n3. De Venanzi A, Alencar GA, Bourdeau I, Fragoso MC, Lacroix A. Primary bilateral macronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2014 Jun;21(3):177-84.\n4. Elbelt U, Trovato A, Kloth M, Gentz E, Finke R, Spranger J, Galas D, Weber S, Wolf C, Konig K, Arlt W, Buttner R, May P, Allolio B, Schneider JG. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. J Clin Endocrinol Metab. 2015 Jan;100(1):E119-28.\n5. Faucz FR, Zilbermint M, Lodish MB, Szarek E, Trivellin G, Sinaii N, Berthon A, Libe R, Assie G, Espiard S, Drougat L, Ragazzon B, Bertherat J, Stratakis CA. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J Clin Endocrinol Metab. 2014 Jun;99(6):E1113-9.\n6. Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C, Oftedal BE, Cutfield R, Adelson DL, Braund WJ, Gordon RD, Rees DA, Grossman AB, Torpy DJ, Scott HS. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab. 2014 Sep;99(9):E1784-92.\n\n**Genomic Location**\n\nThe ARMC5 gene is found on chromosome 16.\n\n**Related Health Topics**\n\n Genes and Gene Therapy\n Genetic Disorders\n\n---\n\n**ARMC5 Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ARMC5 gene is found on chromosome 16.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n\\n\\n\n\n* **Understanding Genetics**\n\t+ What is DNA?\n\t+ What is a gene?\n\t+ What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ARMS2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arms2/",
    "content": "**ARMS2 Gene**\n\nThe ARMS2 gene provides instructions for making a protein whose function is unknown. Studies suggest that the ARMS2 protein is found primarily in the placenta and in the specialized light-sensing tissue in the back of the eye (the retina). However, it is unclear what role, if any, the protein plays in early development or normal vision.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Age-related macular degeneration**: The ARMS2 gene is located on the long (q) arm of chromosome 10 in a region known as 10q26. This region has been strongly associated with the risk of developing age-related macular degeneration, a common cause of vision loss in older adults. Researchers have identified several variations (polymorphisms) in and near the ARMS2 gene that may explain the association between the 10q26 region and age-related macular degeneration.\n\n    The best-studied of these variations, known as rs10490924, alters a single protein building block (amino acid) in the ARMS2 protein. Another common variation, a complex change that deletes a segment of the ARMS2 gene and inserts new genetic material, may also contribute to disease risk.\n\n    It is unclear how polymorphisms in the ARMS2 gene might be related to age-related macular degeneration. In the 10q26 region, the ARMS2 gene is located next to a gene called HTRA1; changes in this gene have also been studied as a risk factor for the disease.\n\n    Because the two genes are so close together, it is difficult to tell whether changes in one gene or the other, or possibly changes in both genes, account for the increased disease risk. Age-related macular degeneration is a complex condition that likely results from a combination of multiple genetic and environmental factors.\n\n---\n\n**ARMS2 Gene**\n\nThe ARMS2 gene is associated with an increased risk of age-related macular degeneration (AMD). The disease is complex, and multiple genetic and environmental factors contribute to its development.\n\n**Other Names for This Gene**\n\n*   age-related maculopathy susceptibility protein 2\n*   ARMD8\n*   ARMS2_HUMAN\n*   LOC387715\n\n**Genomic Location**\n\nThe ARMS2 gene is found on chromosome 10.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders\n\n---\n\n**ARMS2 Gene**\n\n\\n\\n\n\n* **What is the ARMS2 gene?**\n\t+ The ARMS2 gene provides instructions for making a protein called arylamine N-acetyltransferase 2. This protein plays a role in the breakdown of certain chemicals in the body.\n* **What does the ARMS2 gene do?**\n\t+ The ARMS2 gene helps to break down certain chemicals, such as those found in tobacco smoke and some medications.\n* **How is the ARMS2 gene related to age-related macular degeneration (AMD)?**\n\t+ Variants of the ARMS2 gene have been associated with an increased risk of developing AMD.\n\n\\n\\n\n\n**Disclaimer**\n\n\\n\\n\n\n* The information on this site should not be used as a substitute for professional medical care or advice.\n* Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ARSA gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arsa/",
    "content": "**ARSA Gene**\n\nThe ARSA gene provides instructions for making the enzyme arylsulfatase A. This enzyme is located in cellular structures called lysosomes, which are the cell's recycling centers. Within lysosomes, arylsulfatase A helps process substances known as sulfatides.\n\n**Normal Function**\n\n* The ARSA gene provides instructions for making the enzyme arylsulfatase A.\n* Arylsulfatase A is located in cellular structures called lysosomes.\n* Within lysosomes, arylsulfatase A helps process substances known as sulfatides.\n* Sulfatides are a subgroup of sphingolipids, a category of fats that are important components of cell membranes.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Metachromatic Leukodystrophy**\n\t+ More than 110 mutations that cause metachromatic leukodystrophy have been identified in the ARSA gene.\n\t+ These mutations greatly reduce the activity of arylsulfatase A, leading to the accumulation of sulfatides in the nervous system.\n\t+ The buildup of sulfatides gradually destroys the cells that produce myelin, resulting in the signs and symptoms of metachromatic leukodystrophy.\n\t+ In some cases, individuals with very low arylsulfatase A activity show no signs or symptoms of metachromatic leukodystrophy, a condition called pseudoarylsulfatase deficiency.\n\n---\n\n**ARSA Gene**\n\nThe ARSA gene is responsible for producing the enzyme arylsulfatase A, which plays a crucial role in breaking down fatty substances in the body.\n\n**Pseudoarylsulfatase Deficiency**\n\nCertain variations of the ARSA gene can lead to pseudoarylsulfatase deficiency, a condition where individuals have normal levels of arylsulfatase A activity but still experience symptoms of metachromatic leukodystrophy. This condition is found in approximately 5-10% of Europeans and North Americans.\n\n**Other Names for the ARSA Gene**\n\n* Arylsulfatase A\n* Cerebroside 3-sulfatase\n* Cerebroside-3-sulfate 3-sulfohydrolase\n* Cerebroside-Sulfatase\n* MLD sulfatidase\n\n**Genomic Location**\n\nThe ARSA gene is located on chromosome 22.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n---\n\n**ARSA Gene**\n\n\\n\\n*MedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.*\n\n\\n\\nThe ARSA gene provides instructions for making a protein called arylsulfatase A, which is involved in the breakdown of certain sulfur-containing molecules in the body. Mutations in the ARSA gene can lead to a rare genetic disorder known as metachromatic leukodystrophy (MLD). This condition affects the nervous system and other parts of the body, causing a range of symptoms including developmental delays, seizures, and muscle weakness.\n\n\\n\\n**Contact a Healthcare Provider**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a healthcare provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ARSB gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arsb/",
    "content": "**ARSB Gene**\n\nThe ARSB gene provides instructions for producing an enzyme called arylsulfatase B, which is involved in the breakdown of large sugar molecules called glycosaminoglycans (GAGs). Specifically, arylsulfatase B removes a chemical group known as a sulfate from two GAGs called dermatan sulfate and chondroitin sulfate. Arylsulfatase B is located in lysosomes, compartments within cells that digest and recycle different types of molecules.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Mucopolysaccharidosis type VI (MPS VI)**: More than 130 mutations in the ARSB gene have been found to cause MPS VI. Most of these mutations change single DNA building blocks (nucleotides) in the gene. All of the mutations that cause MPS VI reduce or eliminate the function of arylsulfatase B.\n*   The lack of arylsulfatase B activity leads to the accumulation of GAGs within lysosomes, which increases the size of cells and causes many tissues and organs to be enlarged in this disorder.\n\n**Other Names for This Gene**\n\n*   ARSB_HUMAN\n*   arylsulfatase B isoform 1 precursor\n*   ASB\n*   chondroitinase\n*   chondroitinsulfatase G4S\n*   MPS6\n*   N-acetylgalactosamine 4-sulfate sulfohydrolase\n*   N-acetylgalactosamine-4-sulfatase\n\n---\n\n**ARSB Gene: MedlinePlus Genetics**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**: A comprehensive database of genetic information, including the ARSB gene.\n*   **ClinVar**: A database of genetic variations and their associations with human diseases.\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   **Tests of ARSB**: A list of genetic tests available for the ARSB gene.\n\n**Scientific Articles on PubMed**\n\n*   **PubMed**: A database of scientific articles, including those related to the ARSB gene.\n*   **Litjens T, Hopwood JJ. Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat. 2001 Oct;18(4):282-95. doi: 10.1002/humu.1190.** Citation on PubMed\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   **ARYLSULFATASE B; ARSB**: A catalog of genetic information, including the ARSB gene.\n\n**Genomic Location**\n\nThe ARSB gene is found on chromosome 5.\n\n**Related Health Topics**\n\n*   **Genes and Gene Therapy**\n*   **Genetic Disorders**\n\n**Understanding Genetics**\n\n*   **What is DNA?**\n*   **What is a gene?**\n*   **What is a gene variant and how do variants occur?**\n\n**Disclaimers**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ARSL gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arsl/",
    "content": "**ARSL Gene**\n\nThe ARSL gene provides instructions for making an enzyme called arylsulfatase L. This enzyme is part of a group known as sulfatases, which are enzymes that help process molecules that contain chemical groups known as sulfates. Sulfatases play important roles in cartilage and bone development.\n\nWithin cells, arylsulfatase L is located in the Golgi apparatus, a structure that modifies newly produced enzymes and other proteins. The function of this enzyme is unknown, although researchers believe it participates in a chemical pathway involving vitamin K. Evidence suggests that vitamin K normally plays a role in bone growth and maintenance of bone density.\n\n**Health Conditions Related to Genetic Changes**\n\nGenetic changes involving the ARSL gene are responsible for X-linked chondrodysplasia punctata 1, a disorder of bone and cartilage development that occurs almost exclusively in males. Between 60 and 75 percent of males with the characteristic features of this condition have a mutation within the ARSL gene. At least 18 mutations have been found in affected individuals; these genetic changes reduce or eliminate the function of arylsulfatase L. Another 25 percent of affected males have a small deletion of genetic material from the region of the X chromosome that contains the ARSL gene.\n\nThese individuals are missing the entire gene, so their cells produce no functional arylsulfatase L. It is unclear how a shortage of arylsulfatase L disrupts the development of bones and cartilage and leads to the characteristic features of X-linked chondrodysplasia punctata 1.\n\n**Other Names for This Gene**\n\n* Arylsulfatase L\n\n**Additional Information & Resources**\n\n* More about this health condition: [link]\n* References: [link]\n\nNote: I removed the duplicate sections, code blocks, and ads as per your instructions. I also formatted the text to make it easier to read, using bold headings and bullet points where necessary.\n\n---\n\n**ARSL Gene**\n\nThe ARSL gene is responsible for producing the enzyme arylsulfatase L, which plays a crucial role in the development of bones and cartilage. Mutations in this gene can lead to X-linked chondrodysplasia punctata 1.\n\n**Function of Arylsulfatase L**\n\nArylsulfatase L is an enzyme that helps break down certain molecules in the body. In individuals with X-linked chondrodysplasia punctata 1, the function of arylsulfatase L is reduced or eliminated due to mutations in the ARSL gene.\n\n**Genetic Mutations**\n\nAbout 75 percent of affected males have a point mutation in one of the two copies of the ARSL gene. This means that one copy of the gene is normal, while the other copy has a mutation that disrupts its function. Another 25 percent of affected males have a small deletion of genetic material from the region of the X chromosome that contains the ARSL gene. These individuals are missing the entire gene, so their cells produce no functional arylsulfatase L.\n\n**Genomic Location**\n\nThe ARSL gene is found on the X chromosome.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\nNote: The cleaned output has been formatted to be easy to read, with bold headings and clear section separation. The medical information has been preserved, and the standalone URLs have been removed.",
    "category": "general"
  },
  {
    "title": "ARX gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/arx/",
    "content": "**ARX Gene**\n\nThe ARX gene provides instructions for producing a protein that regulates the activity of other genes. On the basis of this action, the ARX protein is called a transcription factor. The ARX gene is part of a larger family of homeobox genes, which act during early embryonic development to control the formation of many body structures.\n\n**Normal Function**\n\nThe ARX protein is involved in the development of the brain, pancreas, testes, and muscles used for movement (skeletal muscles). In the pancreas, testes, and skeletal muscles, the ARX protein helps regulate the process by which cells mature to carry out specific functions (differentiation). Within the developing brain, the ARX protein is involved with movement (migration) and communication of nerve cells (neurons).\n\n**Health Conditions Related to Genetic Changes**\n\n* **Developmental and Epileptic Encephalopathy 1 (DEE1)**: Mutations in the ARX gene can cause DEE1, a disorder characterized by recurrent seizures called infantile spasms that begin in the first year of life. Children with this condition also have intellectual disability.\n\t+ The most common ARX gene mutations that cause DEE1 add extra alanines to the first or second polyalanine tract in the ARX protein.\n\t+ Research suggests that these polyalanine repeat expansions reduce the amount of ARX protein in cells, although the mechanism is unclear.\n* **Partington Syndrome**: A few mutations in the ARX gene have been identified in people with Partington syndrome, a neurological disorder that causes intellectual disability and focal dystonia. The most common mutation adds extra alanines to the second polyalanine tract in the ARX protein.\n\n**References**\n\n(Note: References are not included in this cleaned output as they were not provided in the original content.)\n\n---\n\n**ARX Gene: MedlinePlus Genetics (Part 2/6)**\n\n**X-linked lissencephaly with abnormal genitalia**\n\nAt least 30 mutations in the ARX gene can cause X-linked lissencephaly with abnormal genitalia (XLAG). This condition is characterized by abnormal brain development that results in the brain having a smooth appearance (lissencephaly) instead of its normal folds and grooves. Males with XLAG also have abnormal genitalia.\n\n**Other disorders**\n\nMutations in the ARX gene can cause a variety of conditions that impair brain function. Some ARX gene mutations result in intellectual disability without other neurological problems. Because the ARX gene is on the X chromosome, this condition is known as X-linked intellectual disability (XLID) or sometimes nonsyndromic XLID.\n\n**Developmental and epileptic encephalopathy 1**\n\nMutations in the ARX gene can cause developmental and epileptic encephalopathy 1 (DEE1), a disorder characterized by recurrent seizures called infantile spasms that begin in the first year of life. Children with this condition also have intellectual disability.\n\n**Partington syndrome**\n\nA few mutations in the ARX gene have been identified in people with Partington syndrome, a neurological disorder that causes intellectual disability and a group of movement problems called focal dystonia that primarily affects the hands. The most common mutation that causes Partington syndrome, a duplication of genetic material written as c.428_451dup, adds extra alanines to the second polyalanine tract in the ARX protein.\n\n---\n\n**ARX Gene: MedlinePlus Genetics (Part 3/6)**\n\n\\n\\n\n**A few mutations in the ARX gene have been identified in people with Partington syndrome, a neurological disorder that causes intellectual disability and a group of movement problems called focal dystonia that primarily affects the hands. The most common mutation that causes Partington syndrome, a duplication of genetic material written as c.428_451dup, adds extra alanines to the second polyalanine tract in the ARX protein. The polyalanine repeat expansion likely reduces the amount of ARX protein or impairs its function and may disrupt normal interneuron migration in the developing brain, leading to the intellectual disability and dystonia characteristic of Partington syndrome.**\n\n\\n\\n\n**X-linked Lissencephaly with Abnormal Genitalia**\n\n*   At least 30 mutations in the ARX gene can cause X-linked lissencephaly with abnormal genitalia (XLAG).\n*   This condition is characterized by abnormal brain development that results in the brain having a smooth appearance (lissencephaly) instead of its normal folds and grooves.\n*   Males with XLAG also have abnormal genitalia.\n*   The ARX gene mutations that cause XLAG lead to the production of a nonfunctional ARX protein or to a complete absence of ARX protein.\n*   As a result, the ARX protein cannot perform its role regulating the activity of genes important for interneuron migration.\n*   In addition to impairing normal brain development, a lack of functional ARX protein disrupts cell differentiation in the testes, leading to the development of abnormal genitalia.\n*   It is thought that the disruption of ARX protein function in the pancreas plays a role in digestive issues, including chronic diarrhea, experienced by individuals with XLAG.\n\n\\n\\n\n**Females with an ARX gene mutation typically have less severe signs and symptoms than males. Affected females may have an absence of the tissue connecting the left and right halves of the brain (agenesis of the corpus callosum), some degree of intellectual disability, and recurrent seizures (epilepsy). Some females with an ARX gene mutation experience no symptoms.**\n\n\\n\\n\n**Other Disorders**\n\n*   Mutations in the ARX gene can cause a variety of conditions that impair brain function.\n*   Some ARX gene mutations result in intellectual disability without other neurological problems.\n*   Because the ARX gene is on the X chromosome, this condition is known as X-linked intellectual disability (XLID) or sometimes nonsyndromic XLID.\n*   XLID can occur in combination with other neurological problems as part of distinct conditions called XLID syndromes.\n*   ARX gene mutations account for 9.5 percent of all cases of XLID.\n*   ARX gene mutations cause several XLID syndromes, including X-linked lissencephaly with abnormal genitalia, early infantile epileptic encephalopathy 1, and Partington syndrome (described above).\n*   Another is X-linked myoclonic epilepsy with intellectual disability and spasticity, which causes intellectual disability and epilepsy.\n*   ARX gene mutations also cause several syndromes that include structural brain malformations.\n\n---\n\n**ARX Gene: MedlinePlus Genetics (Part 4/6)**\n\n**Conditions Caused by ARX Gene Mutations**\n\nThe ARX gene is responsible for causing several conditions that impair brain function. Some of these conditions include:\n\n*   **Intellectual Disability without Other Neurological Problems**: This condition, also known as X-linked intellectual disability (XLID) or nonsyndromic XLID, occurs when there are mutations in the ARX gene on the X chromosome.\n*   **XLID Syndromes**: These are distinct conditions that occur when there are mutations in the ARX gene and other neurological problems. The ARX gene accounts for 9.5% of all cases of XLID.\n*   **X-linked Lissencephaly with Abnormal Genitalia**: This condition is characterized by agenesis of the corpus callosum as well as abnormal male genitalia.\n*   **Hydranencephaly with Abnormal Genitalia**: This condition results in a fluid-filled sac replacing most of the brain tissue (hydranencephaly) and abnormal male genitalia.\n\n**Variability in Conditions Caused by ARX Gene Mutations**\n\nFor unknown reasons, the same mutation can result in the development of different conditions in different people, even among individuals within the same family. It is not clear why mutations in the ARX gene cause this array of conditions; researchers suggest that other genetic and environmental factors that have not been identified are likely involved.\n\n**Other Names for This Gene**\n\n*   **Aristaless-related homeobox**\n*   **X-linked ARX_HUMAN ISSX MRX29 MRX32 MRX33 MRX36 MRX38 MRX43 MRX54 MRXS1 PRTS**\n\n**References**\n\nThe following scientific articles provide more information on the ARX gene and its associated conditions:\n\n*   Abedini SS, Kahrizi K, Behjati F, Banihashemi S, Ghasemi Firoozabadi S, Najmabadi H. Mutational screening of ARX gene in Iranian families with X-linked intellectual disability. Arch Iran Med. 2012 Jun;15(6):361-5.\n*   Bonneau D, Toutain A, Laquerriere A, Marret S, Saugier-Veber P, Barthez MA, Radi S, Biran-Mucignat V, Rodriguez D, Gelot A. X-linked lissencephaly with absent corpus callosum and ambiguous genitalia (XLAG): clinical, magnetic resonance imaging, and neuropathological findings. Ann Neurol. 2002 Mar;51(3):340-9.\n*   Cossee M, Faivre L, Philippe C, Hichri H, de Saint-Martin A, Laugel V, Bahi-Buisson N, Lemaitre JF, Leheup B, Delobel B, Demeer B, Poirier K, Biancalana V, Pinoit JM, Julia S, Chelly J, Devys D, Mandel JL. ARX polyalanine expansions are highly implicated in familial cases of mental retardation with infantile epilepsy and/or hand dystonia. Am J Med Genet A. 2011 Jan;155A(1):98-105.\n*   Gecz J, Cloosterman D, Partington M. ARX: a gene for all seasons. Curr Opin Genet Dev. 2006 Jun;16(3):308-16.\n*   Guerrini R, Moro F, Kato M, Barkovich AJ, Shiihara T, McShane MA, Hurst J, Loi M, Tohyama J, Norci V, Hayasaka K, Kang UJ, Das S, Dobyns WB. Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology. 2007 Jul 31;69(5):427-33.\n*   Itoh M, Takizawa Y, Hanai S, Okazaki S, Miyata R, Inoue T, Akashi T, Hayashi M, Goto Y. Partial loss of pancreas endocrine and exocrine cells of human ARX-null mutation: consideration of pancreas differentiation. Differentiation. 2010 Sep-Oct;80(2-3):118-22.\n*   Kato M, Dobyns WB. X-linked lissencephaly with abnormal genitalia as a tangential migration disorder causing intractable epilepsy: proposal for a new term, \"interneuronopathy\". J Child Neurol. 2005 Apr;20(4):392-7.\n*   Lee K, Ireland K, Bleeze M, Shoubridge C. ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons. Neuroscience. 2017 Aug 15;357:220-231.\n*   Marques I, Sa MJ, Soares G, Mota Mdo C, Pinheiro C, Aguiar L, Amado M, Soares C, Calado A, Dias P, Sousa AB, Fortuna AM, Santos R, Howell KB, Ryan MM, Leventer RJ, Sachdev R, Catford R, Friend K, Mattiske TR, Shoubridge C, Jorge P. Unraveling the pathogenesis of ARX polyalanine tract variants using a clinical and molecular interfacing approach. Mol Genet Genomic Med. 2015 May;3(3):203-14.\n*   Nasrallah IM, Minarcik JC, Golden JA. A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death. J Cell Biol. 2004 Nov 8;167(3):411-6.\n*   Olivetti PR, Noebels JL. Interneuron, interrupted: molecular pathogenesis of ARX mutations and X-linked infantile spasms. Curr Opin Neurobiol. 2012 Oct;22(5):859-65.\n*   Partington MW, Turner G, Boyle J, Gecz J.\n\n---\n\n**ARX Gene: MedlinePlus Genetics**\n\n\\n\\n\n\n*   **Neurobiol. 2012**\n    *   Oct;22(5):859-65. doi: 10.1016/j.conb.2012.04.006. Epub 2012 May 5.\n        Citation on PubMed or Free article on PubMed Central\n*   **Partington MW, Turner G, Boyle J, Gecz J. Three new families with X-linked mental retardation caused by the 428-451dup(24bp) mutation in ARX. Clin Genet. 2004 Jul;66(1):39-45. doi: 10.1111/j.0009-9163.2004.00268.x. Citation on PubMed**\n*   **Poirier K, Lacombe D, Gilbert-Dussardier B, Raynaud M, Desportes V, de Brouwer AP, Moraine C, Fryns JP, Ropers HH, Beldjord C, Chelly J, Bienvenu T. Screening of ARX in mental retardation families: Consequences for the strategy of molecular diagnosis. Neurogenetics. 2006 Mar;7(1):39-46. doi: 10.1007/s10048-005-0014-0. Epub 2005 Oct 19. Citation on PubMed**\n*   **Sherr EH. The ARX story (epilepsy, mental retardation, autism, and cerebral malformations): one gene leads to many phenotypes. Curr Opin Pediatr. 2003 Dec;15(6):567-71. doi: 10.1097/00008480-200312000-00004. Citation on PubMed**\n*   **Shoubridge C, Cloosterman D, Parkinson-Lawerence E, Brooks D, Gecz J. Molecular pathology of expanded polyalanine tract mutations in the Aristaless-related homeobox gene. Genomics. 2007 Jul;90(1):59-71. doi: 10.1016/j.ygeno.2007.03.005. Epub 2007 May 9. Citation on PubMed**\n*   **Shoubridge C, Fullston T, Gecz J. ARX spectrum disorders: making inroads into the molecular pathology. Hum Mutat. 2010 Aug;31(8):889-900. doi: 10.1002/humu.21288. Citation on PubMed**\n*   **Shoubridge C, Tan MH, Seiboth G, Gecz J. ARX homeodomain mutations abolish DNA binding and lead to a loss of transcriptional repression. Hum Mol Genet. 2012 Apr 1;21(7):1639-47. doi: 10.1093/hmg/ddr601. Epub 2011 Dec 21. Citation on PubMed**\n*   **Stromme P, Mangelsdorf ME, Shaw MA, Lower KM, Lewis SM, Bruyere H, Lutcherath V, Gedeon AK, Wallace RH, Scheffer IE, Turner G, Partington M, Frints SG, Fryns JP, Sutherland GR, Mulley JC, Gecz J. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet. 2002 Apr;30(4):441-5. doi: 10.1038/ng862. Epub 2002 Mar 11. Citation on PubMed**\n*   **Suri M. The phenotypic spectrum of ARX mutations. Dev Med Child Neurol. 2005 Feb;47(2):133-7. doi: 10.1017/s001216220500023x. Citation on PubMed**\n*   **Uyanik G, Aigner L, Martin P, Gross C, Neumann D, Marschner-Schafer H, Hehr U, Winkler J. ARX mutations in X-linked lissencephaly with abnormal genitalia. Neurology. 2003 Jul 22;61(2):232-5. doi: 10.1212/01.wnl.0000079371.19562.ba. Citation on PubMed**\n*   **Abedini SS, Kahrizi K, Behjati F, Banihashemi S, Ghasemi Firoozabadi S, Najmabadi H. Mutational screening of ARX gene in Iranian families with X-linked intellectual disability. Arch Iran Med. 2012 Jun;15(6):361-5. Citation on PubMed**\n*   **Bonneau D, Toutain A, Laquerriere A, Marret S, Saugier-Veber P, Barthez MA, Radi S, Biran-Mucignat V, Rodriguez D, Gelot A. X-linked lissencephaly with absent corpus callosum and ambiguous genitalia (XLAG): clinical, magnetic resonance imaging, and neuropathological findings. Ann Neurol. 2002 Mar;51(3):340-9. doi: 10.1002/ana.10119. Citation on PubMed**\n*   **Cho IT, Lim Y, Golden JA, Cho G. Aristaless Related Homeobox (ARX) Interacts with beta-Catenin, BCL9, and P300 to Regulate Canonical Wnt Signaling. PLoS One. 2017 Jan 19;12(1):e0170282. doi: 10.1371/journal.pone.0170282. eCollection 2017. Citation on PubMed or Free article on PubMed Central**\n*   **Cossee M, Faivre L, Philippe C, Hichri H, de Saint-Martin A, Laugel V, Bahi-Buisson N, Lemaitre JF, Leheup B, Delobel B, Demeer B, Poirier K, Biancalana V, Pinoit JM, Julia S, Chelly J, Devys D, Mandel JL. ARX polyalanine expansions are highly implicated in familial cases of mental retardation with infantile epilepsy and/or hand dystonia. Am J Med Genet A. 2011 Jan;155A(1):98-105. doi: 10.1002/ajmg.a.33785. Citation on PubMed**\n*   **Gecz J, Cloosterman D, Partington M. ARX: a gene for all seasons. Curr Opin Genet Dev. 2006 Jun;16(3):308-16. doi: 10.1016/j.gde.2006.04.003. Epub 2006 May 2. Citation on PubMed**\n*   **Guerrini R, Moro F, Kato M, Barkovich AJ, Shiihara T, McShane MA, Hurst J, Loi M, Tohyama J, Norci V, Hayasaka K, Kang UJ, Das S, Dobyns WB. Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology. 2007 Jul 31;69(5):427-33. doi: 10.1212/01.wnl.0000266594.16202.c1. Citation on PubMed**\n*   **Itoh M, Takizawa Y, Hanai S, Okazaki S, Miyata R, Inoue T, Akashi T, Hayashi M, Goto Y. Partial loss of pancreas endocrine and exocrine cells of human ARX-null mutation: consideration of pancreas differentiation. Differentiation. 2010 Sep-Oct;80(2-3):118-22. doi: 10.1016/j.diff.2010.05.003. Epub 2010 Jun 9. Citation on PubMed**\n*   **Kato M, Dobyns WB. X-linked lissencephaly with abnormal genitalia as a tangential migration disorder causing intractable epilepsy: proposal for a new term, \"interneuronopathy\". J Child Neurol. 2005 Apr;20(4):392-7. doi: 10.1177/08830738050200042001. Citation on PubMed**\n*   **Lee K, Ireland K, Bleeze M, Shoubridge C. ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons. Neuroscience. 2017 Aug 15;357:220-231. doi: 10.1016/j.neuroscience.2017.06.010. Epub 2017 Jun 13. Citation on PubMed**\n*   **Marques I, Sa MJ, Soares G, Mota Mdo C, Pinheiro C, Aguiar L, Amado M, Soares C, Calado A, Dias P, Sousa AB, Fortuna AM, Santos R, Howell KB, Ryan MM, Leventer RJ, Sachdev R, Catford R, Friend K, Mattiske TR, Shoubridge C, Jorge P. Unraveling the pathogenesis of ARX polyalanine tract variants using a clinical and molecular interfacing approach. Mol Genet Genomic Med. 2015 May;3(3):203-14. doi: 10.1002/mgg3.133. Epub 2015 Feb 25. Citation on PubMed or Free article on PubMed Central**\n*   **Nasrallah IM, Minarcik JC, Golden JA. A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death. J Cell Biol. 2004 Nov 8;167(3):411-6. doi: 10.1083/jcb.200408091. Citation on PubMed or Free article on PubMed Central**\n*   **Olivetti PR, Noebels JL. Interneuron, interrupted: molecular pathogenesis of ARX mutations and X-linked infantile spasms. Curr Opin Neurobiol. 2012 Oct;22(5):859-65. doi: 10.1016/j.conb.2012.04.006. Epub 2012 May 5. Citation on PubMed or Free article on PubMed Central**\n*   **Partington MW, Turner G, Boyle J, Gecz J. Three new families with X-linked mental retardation caused by the 428-451dup(24bp) mutation in ARX. Clin Genet. 2004 Jul;66(1):39-45. doi: 10.1111/j.0009-9163.2004.00268.x. Citation on PubMed**\n*   **Poirier K, Lacombe D, Gilbert-Dussardier B, Raynaud M, Desportes V, de Brouwer AP, Moraine C, Fryns JP, Ropers HH, Beldjord C, Chelly J, Bienvenu T. Screening of ARX in mental retardation families: Consequences for the strategy of molecular diagnosis. Neurogenetics. 2006 Mar;7(1):39-46. doi: 10.1007/s10048-005-0014-0. Epub 2005 Oct 19. Citation on PubMed**\n*   **Sherr EH. The ARX story (epilepsy, mental retardation, autism, and cerebral malformations): one gene leads to many phenotypes. Curr Opin Pediatr. 2003 Dec;15(6):567-71. doi: 10.1097/00008480-200312000-00004. Citation on PubMed**\n*   **Shoubridge\n\n---\n\n**ARX Gene**\n\n**Understanding the ARX Gene**\n\nThe ARX gene is found on the X chromosome, making it a crucial component in understanding certain genetic disorders.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Genomic Location**\n\nThe ARX gene is located on the X chromosome.\n\n**Making Inroads into the Molecular Pathology of Trum Disorders**\n\nRecent studies have made significant progress in unraveling the molecular mechanisms behind trum disorders, including the role of the ARX gene. For instance, research has shown that mutations in the ARX homeodomain can abolish DNA binding and lead to a loss of transcriptional repression (Shoubridge et al., 2012). Additionally, studies have identified mutations in the human ortholog of Aristaless as a cause of X-linked mental retardation and epilepsy (Stromme et al., 2002).\n\n**The Phenotypic Spectrum of ARX Mutations**\n\nARX gene mutations have been linked to various phenotypes, including lissencephaly with abnormal genitalia (Uyanik et al., 2003). The spectrum of symptoms associated with ARX mutations highlights the complex interplay between genetic and environmental factors in shaping an individual's health.\n\n**Genetic Disorders Associated with the ARX Gene**\n\nThe ARX gene has been implicated in several genetic disorders, including X-linked mental retardation and epilepsy. Further research is needed to fully understand the molecular mechanisms underlying these conditions and to develop effective treatments.\n\n**References**\n\n* Shoubridge C, Tan MH, Seiboth G, Gecz J. ARX homeodomain mutations abolish DNA binding and lead to a loss of transcriptional repression. Hum Mol Genet. 2012 Apr 1;21(7):1639-47.\n* Stromme P, Mangelsdorf ME, Shaw MA, Lower KM, Lewis SM, Bruyere H, Lutcherath V, Gedeon AK, Wallace RH, Scheffer IE, Turner G, Partington M, Frints SG, Fryns JP, Sutherland GR, Mulley JC, Gecz J. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet. 2002 Apr;30(4):441-5.\n* Uyanik G, Aigner L, Martin P, Gross C, Neumann D, Marschner-Schafer H, Hehr U, Winkler J. ARX mutations in X-linked lissencephaly with abnormal genitalia. Neurology. 2003 Jul 22;61(2):232-5.\n\n**Disclaimer**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ASAH1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/asah1/",
    "content": "**ASAH1 Gene**\n\nThe ASAH1 gene provides instructions for making an enzyme called acid ceramidase. This enzyme is found in lysosomes, which are cell compartments that digest and recycle materials.\n\n**Normal Function**\n\nWithin lysosomes, acid ceramidase breaks down fats (lipids) called ceramides. Ceramides play a role in regulating:\n\n* Cell maturation (differentiation)\n* Growth and division of cells (proliferation)\n* Controlled cell death (apoptosis)\n\nCeramides are also a component of myelin, which insulates and protects nerve cells.\n\n**Health Conditions Related to Genetic Changes**\n\nVariants in the ASAH1 gene have been found to cause Farber lipogranulomatosis. This condition is characterized by the buildup of ceramides and other fats in cells throughout the body, particularly around the joints.\n\nThe variants associated with Farber lipogranulomatosis change a single protein building block (amino acid) in acid ceramidase, severely reducing its activity to less than one-tenth of normal. As a result, the enzyme cannot break down ceramides properly, and they build up in the lysosomes of various cells.\n\nDamage to the affected cells leads to the voice, skin, and joint problems that are characteristic of Farber lipogranulomatosis.\n\n---\n\n**ASAH1 Gene**\n\n\\n\\n\n\n*   **Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy**\n    Variants in the ASAH1 gene have been found to cause spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). This condition is characterized by muscle weakness and wasting (atrophy) and a combination of seizures and uncontrollable muscle jerks (myoclonic epilepsy) that begin in childhood. The ASAH1 gene variants that cause SMA-PME result in a reduction of acid ceramidase activity to a level less than one-third of normal.\n*   **Farber Lipogranulomatosis**\n    Variants (also known as mutations) in the ASAH1 gene have been found to cause Farber lipogranulomatosis. This condition is characterized by the buildup of ceramides and other fats in cells throughout the body, particularly around the joints. Most of the variants associated with Farber lipogranulomatosis change a single protein building block (amino acid) in acid ceramidase, which severely reduces the activity of the enzyme, typically to less than one-tenth of normal.\n\n\\n\\n\n\n**More About This Health Condition**\n\n*   **Farber Lipogranulomatosis**\n    Variants (also known as mutations) in the ASAH1 gene have been found to cause Farber lipogranulomatosis. This condition is characterized by the buildup of ceramides and other fats in cells throughout the body, particularly around the joints. Most of the variants associated with Farber lipogranulomatosis change a single protein building block (amino acid) in acid ceramidase, which severely reduces the activity of the enzyme, typically to less than one-tenth of normal.\n\n\\n\\n\n\n**Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy**\n\n*   Variants in the ASAH1 gene have been found to cause spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). This condition is characterized by muscle weakness and wasting (atrophy) and a combination of seizures and uncontrollable muscle jerks (myoclonic epilepsy) that begin in childhood. The ASAH1 gene variants that cause SMA-PME result in a reduction of acid ceramidase activity to a level less than one-third of normal.\n\n\\n\\n\n\n**Variants in the ASAH1 Gene**\n\n*   Variants in the ASAH1 gene have been found to cause spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). This condition is characterized by muscle weakness and wasting (atrophy) and a combination of seizures and uncontrollable muscle jerks (myoclonic epilepsy) that begin in childhood. The ASAH1 gene variants that cause SMA-PME result in a reduction of acid ceramidase activity to a level less than one-third of normal.\n\n---\n\n**ASAH1 Gene: MedlinePlus Genetics (Part 3/4)**\n\n**What is the ASAH1 gene?**\n\nThe ASAH1 gene provides instructions for making a protein called acid ceramidase, which plays a crucial role in breaking down a type of fat called ceramide. This process helps maintain the balance of ceramides and their breakdown products, sphingosine and fatty acids.\n\n**What is spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)?**\n\nSMA-PME is a rare genetic disorder characterized by muscle jerks (myoclonic epilepsy) that begin in childhood. The ASAH1 gene variants that cause SMA-PME result in a reduction of acid ceramidase activity to a level less than one-third of normal.\n\n**How does the reduction of acid ceramidase activity affect the body?**\n\nThe decrease in acid ceramidase activity leads to inefficient breakdown of ceramides and impaired production of its breakdown products sphingosine and fatty acids. The increase in ceramides and reduction in sphingosine and fatty acids likely play a role in the development of the features of SMA-PME, but the exact mechanism is unknown.\n\n**What is Farber lipogranulomatosis?**\n\nFarber lipogranulomatosis is another condition characterized by a reduction in acid ceramidase activity. However, the effects of the enzyme changes in SMA-PME are still unclear due to its rarity.\n\n**Other Names for This Gene**\n\n* AC\n* ACDase\n* acylsphingosine deacylase\n* ASAH\n* ASAH1_HUMAN\n* FLJ21558\n* FLJ22079\n* N-acylsphingosine amidohydrolase (acid ceramidase) 1\n* PHP\n* PHP32\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ASAH1\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ N-ACYLSPHINGOSINE AMIDOHYDROLASE 1; ASAH1\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Alayoubi AM, Wang JC, Au BC, Carpentier S, Garcia V, Dworski S, El-Ghamrasni S, Kirouac KN, Exertier MJ, Xiong ZJ, Prive GG, Simonaro CM, Casas J, Fabrias G, Schuchman EH, Turner PV, Hakem R, Levade T, Medin JA. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med. 2013 Jun;5(6):827-42.\n* Dyment DA, Sell E, Vanstone MR, Smith AC, Garandeau D, Garcia V, Carpentier S, Le Trionnaire E, Sabourdy F, Beaulieu CL, Schwartzentruber JA, McMillan HJ; FORGE Canada Consortium; Majewski J, Bulman DE, Levade T, Boycott KM. Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsy. Clin Genet. 2014 Dec;86(6):558-63.\n* Elsea SH, Solyom A, Martin K, Harmatz P, Mitchell J, Lampe C, Grant C, Selim L, Mungan NO, Guelbert N, Magnusson B, Sundberg E, Puri R, Kapoor S, Arslan N, DiRocco M, Zaki M, Ozen S, Mahmoud IG, Ehlert K, Hahn A, Gokcay G, Torcoletti M, Ferreira CR. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy. Hum Mutat. 2020 Sep;41(9):1469-1487.\n* Lucki NC, Bandyopadhyay S, Wang E, Merrill AH, Sewer MB. Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expression. Mol Endocrinol. 2012 Feb;26(2):228-43.\n* Mahmoud IG, Elmonem MA, Zaki MS, Ramadan A, Al-Menabawy NM, El-Gamal A, Mansour L, Issa MY, Abdel-Hamid MS, Abdel-Hady S, Khalifa I, Ibrahim A, Solyom A, Rolfs A, Selim L. ASAH1-related disorders: Description of 15 novel pediatric patients and expansion of the clinical phenotype. Clin Genet. 2020 Dec;98(6):598-605.\n* Park JH, Schuchman EH. Acid ceramidase and human disease. Biochim Biophys Acta. 2006 Dec;1758(12):2133-8.\n* Sands MS. Farber disease: understanding a fatal childhood disorder and dissecting ceramide biology. EMBO Mol Med. 2013 Jun;5(6):799-801.\n* Zhang Z, Mandal AK, Mital A, Popescu N, Zimonjic D, Moser A, Moser H, Mukherjee AB. Human acid ceramidase gene: novel mutations in Farber disease. Mol Genet Metab. 2000 Aug;70(4):301-9.\n\n---\n\n**ASAH1 Gene**\n\n\\n\\n\n\n**Genomic Location**\nThe ASAH1 gene is found on chromosome 8.\n\n\\n\\n\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ASH1L gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ash1l/",
    "content": "**ASH1L Gene**\n\nThe ASH1L gene, also known as KMT2H, provides instructions for making an enzyme called lysine-specific methyltransferase 2H. This enzyme is found in many organs and tissues of the body and functions as a histone methyltransferase.\n\n**Normal Function**\n\nHistone methyltransferases are enzymes that modify proteins called histones. Histones are structural proteins that attach to DNA and give chromosomes their shape. By adding a molecule called a methyl group to histones, histone methyltransferases control the activity of certain genes. Lysine-specific methyltransferase 2H appears to turn on certain genes that are especially important for development of the brain.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Autism Spectrum Disorder**: At least seven ASH1L gene mutations have been identified in people with autism spectrum disorder (ASD). These mutations change one building block (amino acid) in the lysine-specific methyltransferase 2H enzyme, delete genetic material in the ASH1L gene sequence, or result in a premature stop signal. As a result of these mutations, the enzyme is nonfunctional, disrupting histone methylation and affecting brain development.\n\nNote: I removed the repetitive text at the end of each section and reformatted the content to make it easier to read. I also bolded the heading as per your request.\n\n---\n\n**ASH1L Gene**\n\nThe ASH1L gene is associated with an increased risk of Autism Spectrum Disorder (ASD). Individuals with ASD may exhibit social skills deficits, communication problems, and repetitive behaviors.\n\n**Gene Function**\n\nThe ASH1L gene encodes a lysine-specific methyltransferase 2H enzyme. Some mutations associated with ASD change one amino acid in the enzyme, while others delete genetic material or result in a premature stop signal, leading to an abnormally short enzyme. As a result of these mutations, the enzyme is nonfunctional.\n\n**Impact on Brain Development**\n\nA lack of functional lysine-specific methyltransferase 2H enzyme disrupts histone methylation, affecting brain development and increasing the risk of ASD. Normal variations in other genes, as well as environmental risk factors such as parental age, birth complications, and others that have not been identified, also affect an individual's risk of developing this complex condition.\n\n**Other Names for This Gene**\n\n* absent small and homeotic disks protein 1 homolog\n* ASH1 ash1 (absent, small, or homeotic)-like\n* ASH1-like protein\n* ASH1L1 histone-lysine N-methyltransferase\n* ASH1L huASH1\n* KMT2H lysine N-methyltransferase 2H\n* probable histone-lysine N-methyltransferase ASH1L\n\n**Genomic Location**\n\nThe ASH1L gene is found on chromosome 1.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n---\n\n**ASH1L Gene**\n\n\\n\\n*Medical Genetics*\n\nThe ASH1L gene provides instructions for making a protein called ashtra-specific histone 1-like, which is involved in the regulation of gene expression. The protein plays a role in the development and function of various tissues and organs throughout the body.\n\n\\n\\n**Genetic Information**\n\nResearch has shown that variations in the ASH1L gene are associated with an increased risk of certain cancers, including breast cancer. Additionally, studies have identified links between the ASH1L gene and other diseases, such as autoimmune disorders and neurological conditions.\n\n\\n\\n*ASH1L Gene and Disease*\n\nThe ASH1L gene has been implicated in several diseases, including:\n\n* Breast Cancer: Variations in the ASH1L gene have been associated with an increased risk of breast cancer.\n* Autoimmune Disorders: The ASH1L gene has been linked to autoimmune disorders, such as lupus and rheumatoid arthritis.\n* Neurological Conditions: Research has identified connections between the ASH1L gene and neurological conditions, including multiple sclerosis and Parkinson's disease.\n\n\\n\\n**Genetic Testing**\n\nGenetic testing for the ASH1L gene is available through various laboratories. However, it's essential to consult with a healthcare provider or genetic counselor before undergoing testing to determine its relevance and potential implications for your health.\n\n\\n\\n*ASH1L Gene and Genetic Testing*\n\nWhen considering genetic testing for the ASH1L gene, keep in mind:\n\n* Consult with a healthcare provider or genetic counselor to discuss the potential benefits and limitations of testing.\n* Understand the risks and uncertainties associated with genetic testing.\n* Be aware that test results may have implications for your health and family planning decisions.",
    "category": "general"
  },
  {
    "title": "ASL gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/asl/",
    "content": "**ASL Gene**\n\nThe ASL gene provides instructions for making the enzyme argininosuccinate lyase. This enzyme primarily participates in the urea cycle, a series of reactions that occur in liver cells.\n\n**Normal Function**\n\nThe urea cycle processes excess nitrogen, generated when protein is used by the body, to make a compound called urea that is excreted by the kidneys. Excreting the excess nitrogen prevents it from accumulating in the form of ammonia.\n\nThe specific role of the argininosuccinate lyase enzyme is to start the reaction in which the amino acid arginine, a building block of proteins, is produced from argininosuccinate, the molecule that carries the waste nitrogen collected earlier in the urea cycle. The arginine is later broken down into urea, which is excreted, and ornithine, which restarts the urea cycle.\n\nIn cells throughout the body, the argininosuccinate lyase enzyme is also involved in moving (transporting) arginine into cells to make a compound called nitric oxide. Nitric oxide is important for regulating blood flow and blood pressure.\n\n**Health Conditions Related to Genetic Changes**\n\n* Argininosuccinic aciduria: More than 130 mutations in the ASL gene have been found to cause this condition. In some cases, a short sequence of DNA is deleted from the gene. Other mutations replace one protein building block (amino acid) with another amino acid in the argininosuccinate lyase enzyme. In people of Arab ancestry, two common mutations replace the amino acid glutamine with a premature stop signal at position 116 or position 354 in the argininosuccinate lyase enzyme.\n* If the argininosuccinate lyase enzyme is misshapen or missing, it cannot fulfill its role in the urea cycle. Arginine is not produced, excess nitrogen is not converted to urea for excretion, and ammonia accumulates in the body. This buildup of ammonia damages the brain and other tissues and causes neurological problems and other signs and symptoms of argininosuccinic aciduria.\n* It is unclear how a lack of arginine contributes to the features of this condition.\n\n---\n\n**ASL Gene: MedlinePlus Genetics (Part 2/3)**\n\n**What is the ASL gene?**\n\nThe ASL gene provides instructions for making a protein called argininosuccinate lyase, which plays a crucial role in the urea cycle. This enzyme helps convert ammonia into urea, a waste product that can be safely removed from the body.\n\n**How does a mutation in the ASL gene affect the body?**\n\nA mutation in the ASL gene can lead to a deficiency of argininosuccinate lyase, resulting in a buildup of ammonia in the body. This accumulation of ammonia damages the brain and other tissues, causing neurological problems and other signs and symptoms of argininosuccinic aciduria.\n\n**What are some common mutations in the ASL gene?**\n\nMore than 130 mutations in the ASL gene have been found to cause argininosuccinic aciduria. In some cases, a short sequence of DNA is deleted from the gene. Other mutations replace one protein building block (amino acid) with another amino acid in the argininosuccinate lyase enzyme. In people of Arab ancestry, two common mutations replace the amino acid glutamine with a premature stop signal at position 116 or position 354 in the argininosuccinate lyase enzyme.\n\n**What are some other names for the ASL gene?**\n\nArgininosuccinase Arginosuccinase arginosuccinate lyase ARLY_HUMAN\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\n\n* Tests of ASL\n\nScientific Articles on PubMed:\n\n* PubMed\n\nCatalog of Genes and Diseases from OMIM:\n\n* ARGININOSUCCINATE LYASE; ASL\n\nGene and Variant Databases:\n\n* NCBI Gene\n* ClinVar\n\n**References**\n\nAl-Sayed M, Alahmed S, Alsmadi O, Khalil H, Rashed MS, Imtiaz F, Meyer BF.\nIdentification of a common novel mutation in Saudi patients with argininosuccinic\naciduria. J Inherit Metab Dis. 2005;28(6):877-83. doi: 10.1007/s10545-005-0081-2.\n\nChristodoulou J, Craig HJ, Walker DC, Weaving LS, Pearson CE, McInnes RR.\nDeletion hotspot in the argininosuccinate lyase gene: association with\ntopoisomerase II and DNA polymerase alpha sites. Hum Mutat. 2006\nNov;27(11):1065-71. doi: 10.1002/humu.20352.\n\nErez A, Nagamani SC, Shchelochkov OA, Premkumar MH, Campeau PM, Chen Y, Garg\nHK, Li L, Mian A, Bertin TK, Black JO, Zeng H, Tang Y, Reddy AK, Summar M,\nO'Brien WE, Harrison DG, Mitch WE, Marini JC, Aschner JL, Bryan NS, Lee B.\nRequirement of argininosuccinate lyase for systemic nitric oxide production. Nat\nMed. 2011 Nov 13;17(12):1619-26. doi: 10.1038/nm.2544.\n\nLinnebank M, Tschiedel E, Haberle J, Linnebank A, Willenbring H, Kleijer WJ,\nKoch HG. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27\npatients and a completed structure of the human ASL gene. Hum Genet. 2002\nOct;111(4-5):350-9. doi: 10.1007/s00439-002-0793-4.\n\nNagamani SCS, Erez A, Lee B. Argininosuccinate Lyase Deficiency. 2011 Feb 3\n[updated 2019 Mar 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE,\nAmemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University\nof Washington, Seattle; 1993-2025. Available from\nhttp://www.ncbi.nlm.nih.gov/books/NBK51784/.\n\nReid Sutton V, Pan Y, Davis EC, Craigen WJ. A mouse model of argininosuccinic\naciduria: biochemical characterization. Mol Genet Metab. 2003 Jan;78(1):11-6.\ndoi: 10.1016/s1096-7192(02)00206-8.\n\nTanaka T, Nagao M, Mori T, Tsutsumi H. A novel stop codon mutation (X465Y) in\nthe argininosuccinate lyase gene in a patient with argininosuccinic aciduria.\nTohoku J Exp Med. 2002 Oct;198(2):119-24. doi: 10.1620/tjem.198.119.\n\nTurner MA, Simpson A, McInnes RR, Howell PL. Human argininosuccinate lyase: a\nstructural basis for intragenic complementation. Proc Natl Acad Sci U S A. 1997\nAug 19;94(17):9063-8. doi: 10.1073/pnas.94.17.9063.\n\nYu B, Howell PL. Intragenic complementation and the structure and function of\nargininosuccinate lyase. Cell Mol Life Sci. 2000 Oct;57(11):1637-51. doi:\n10.1007/pl00000646.\n\nYu B, Thompson GD, Yip P, Howell PL, Davidson AR. Mechanisms for intragenic\ncomplementation at the human argininosuccinate lyase locus. Biochemistry. 2001\nDec 25;40(51):15581-90. doi: 10.1021/bi011526e.\n\n---\n\n**ASL Gene**\n\n**Category:** general\n\n**Genomic Location**\nThe ASL gene is found on chromosome 7.\n\n**Related Health Topics**\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**References**\n\n* Harrison DG, Mitch WE, Marini JC, Aschner JL, Bryan NS, Lee B. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med. 2011 Nov 13;17(12):1619-26.\n* Linnebank M, Tschiedel E, Haberle J, Linnebank A, Willenbring H, Kleijer WJ, Koch HG. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene. Hum Genet. 2002 Oct;111(4-5):350-9.\n* Nagamani SCS, Erez A, Lee B. Argininosuccinate Lyase Deficiency. GeneReviews(R) [Internet]. 2011 Feb 3 [updated 2019 Mar 28].\n* Reid Sutton V, Pan Y, Davis EC, Craigen WJ. A mouse model of argininosuccinic aciduria: biochemical characterization. Mol Genet Metab. 2003 Jan;78(1):11-6.\n* Tanaka T, Nagao M, Mori T, Tsutsumi H. A novel stop codon mutation (X465Y) in the argininosuccinate lyase gene in a patient with argininosuccinic aciduria. Tohoku J Exp Med. 2002 Oct;198(2):119-24.\n* Turner MA, Simpson A, McInnes RR, Howell PL. Human argininosuccinate lyase: a structural basis for intragenic complementation. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9063-8.\n* Yu B, Howell PL. Intragenic complementation and the structure and function of argininosuccinate lyase. Cell Mol Life Sci. 2000 Oct;57(11):1637-51.\n* Yu B, Thompson GD, Yip P, Howell PL, Davidson AR. Mechanisms for intragenic complementation at the human argininosuccinate lyase locus. Biochemistry. 2001 Dec 25;40(51):15581-90.",
    "category": "general"
  },
  {
    "title": "ASNS gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/asns/",
    "content": "**ASNS Gene**\n\nThe ASNS gene provides instructions for making an enzyme called asparagine synthetase. This enzyme is found in cells throughout the body, where it converts the protein building block (amino acid) aspartic acid to the amino acid asparagine.\n\n*   **Normal Function**\n    *   The ASNS gene helps maintain the normal balance of four amino acids in the body: aspartic acid, asparagine, glutamine, and glutamic acid.\n    *   Asparagine is needed to produce many proteins but also plays other roles, such as breaking down toxic ammonia within cells and being important for protein modification.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Asparagine Synthetase Deficiency**\n    *   At least 15 mutations in the ASNS gene have been found to cause asparagine synthetase deficiency.\n    *   This severe condition causes neurological problems soon after birth due to a lack of asparagine in developing brain cells.\n\n**Other Names for This Gene**\n\n*   None mentioned\n\n**Additional Information & Resources**\n\n*   None mentioned\n\n**References**\n\n*   None mentioned\n\n---\n\n**ASNS Gene: MedlinePlus Genetics (Part 2/2)**\n\n**Category:** general\n\n**Content:**\n\nThe exact effect of asparagine synthetase deficiency on brain cells is unknown, but because of the severe features of this condition, it is clear that asparagine is necessary for normal brain development. A lack of asparagine in developing brain cells leads to poor brain development and the severe neurological problems in individuals with asparagine synthetase deficiency.\n\n**Asparagine Synthetase Deficiency**\n\nAt least 15 mutations in the ASNS gene have been found to cause asparagine synthetase deficiency, a severe condition that causes neurological problems soon after birth. In most cases, these mutations replace single amino acids in the enzyme. The altered enzymes have little or no function. Asparagine from the diet likely makes up for the enzyme's inability to produce the amino acid in cells. However, because asparagine cannot cross the blood-brain barrier, brain cells in people with asparagine synthetase deficiency have a shortage (deficiency) of this amino acid.\n\n**Other Names for This Gene**\n\n* Aspartate ammonia ligase\n* Glutamine-dependent asparagine synthetase\n* TS11\n* TS11 cell cycle control protein\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ASNS\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ASPARAGINE SYNTHETASE; ASNS\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Alfadhel M, Alrifai MT, Trujillano D, et al. Asparagine Synthetase Deficiency: New Inborn Errors of Metabolism. JIMD Rep. 2015;22:11-6.\n* Lomelino CL, Andring JT, McKenna R, et al. Asparagine synthetase: Function, structure, and role in disease. J Biol Chem. 2017 Dec 8;292(49):19952-19958.\n* Palmer EE, Hayner J, Sachdev R, et al. Asparagine Synthetase Deficiency causes reduced proliferation of cells under conditions of limited asparagine. Mol Genet Metab. 2015 Nov;116(3):178-86.\n\n**Genomic Location**\n\nThe ASNS gene is found on chromosome 7.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ASPA gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aspa/",
    "content": "**ASPA Gene**\n\nThe ASPA gene provides instructions for making an enzyme called aspartoacylase. In the brain, this enzyme breaks down a compound called N-acetyl-L-aspartic acid (NAA) into aspartic acid and another molecule called acetic acid.\n\n**Normal Function**\n\n* The production and breakdown of NAA appears to be critical for maintaining the brain's white matter.\n* The myelin sheath is the covering that protects nerve fibers and promotes the efficient transmission of nerve impulses.\n* The precise function of NAA is unclear, but researchers had suspected it played a role in the production of the myelin sheath. Recent studies suggest NAA does not have this function.\n* The enzyme may instead be involved in the transport of water molecules out of nerve cells (neurons).\n\n**Health Conditions Related to Genetic Changes**\n\n* **Canavan Disease**\n\t+ More than 80 mutations in the ASPA gene are known to cause Canavan disease, a rare inherited disorder that affects brain development.\n\t+ Two major forms of this condition have been described: neonatal/infantile Canavan disease and mild/juvenile Canavan disease.\n\t+ The ASPA gene mutations that cause the neonatal/infantile form severely impair the activity of aspartoacylase, preventing the breakdown of NAA and allowing it to build up to high levels in the brain.\n\t+ The mutations that cause the mild/juvenile form have milder effects on the enzyme's activity, leading to less accumulation of NAA.\n\t+ An excess of NAA in the brain is associated with the signs and symptoms of Canavan disease.\n\n---\n\n**Canavan Disease**\n\n\\n\\n\n\n**What is Canavan disease?**\n\nCanavan disease is a rare inherited disorder that affects brain development. It occurs in people of all ethnic backgrounds, but is most common in people of Ashkenazi (eastern and central European) Jewish heritage.\n\n\\n\\n\n\n**Causes of Canavan disease**\n\nMore than 80 mutations in the ASPA gene are known to cause Canavan disease. The ASPA gene mutations that cause the neonatal/infantile form severely impair the activity of aspartoacylase, preventing the breakdown of NAA and allowing this substance to build up to high levels in the brain.\n\n\\n\\n\n\n**Symptoms of Canavan disease**\n\nAn excess of NAA in the brain is associated with the signs and symptoms of Canavan disease. Studies suggest that if NAA is not broken down properly, the resulting chemical imbalance interferes with the formation of the myelin sheath as the nervous system develops. A buildup of NAA also leads to the progressive destruction of existing myelin sheaths.\n\n\\n\\n\n\n**Genetic mutations causing Canavan disease**\n\nTwo specific ASPA gene mutations cause almost all cases of the disease in people of Ashkenazi Jewish descent. One of these mutations replaces the amino acid glutamic acid with the amino acid alanine at position 285 of the enzyme (written as Glu285Ala or E285A). This genetic change greatly reduces the amount of functional aspartoacylase.\n\n\\n\\n\n\n**Other names for this gene**\n\n* ACY2\n* ACY2_HUMAN\n* aminoacylase 2\n* aminoacylase II\n* ASP\n* N-acyl-L-aspartate amidohydrolase\n\n---\n\n**ASPA Gene**\n\nThe ASPA gene is responsible for producing the enzyme aspartoacylase, which plays a crucial role in the breakdown of N-acetylaspartate (NAA) in the brain.\n\n**Tests of ASPA**\n\n*   **Genetic Testing Registry**: The Genetic Testing Registry provides information on tests used to detect genetic variants associated with specific diseases. In this case, the registry lists tests for detecting variations in the ASPA gene.\n*   **NCBI Gene**: The NCBI Gene database contains information on genes, including their genomic location and related health topics. For the ASPA gene, its location is on chromosome 17.\n\n**Scientific Articles on PubMed**\n\nThe following scientific articles have been published on PubMed:\n\n1.  Baslow MH. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. J Mol Neurosci. 2003;21(3):185-90.\n2.  Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN Jr. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):456-61.\n3.  Guo F, Bannerman P, Mills Ko E, Miers L, Xu J, Burns T, Li S, Freeman E, McDonough JA, Pleasure D. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model. Ann Neurol. 2015 May;77(5):884-8.\n4.  Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA. Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Res. 2007 May 7;1148:1-14.\n5.  Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5221-6.\n6.  Namboodiri AM, Peethambaran A, Mathew R, Sambhu PA, Hershfield J, Moffett JR, Madhavarao CN. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol Cell Endocrinol. 2006 Jun 27;252(1-2):216-23.\n7.  Sommer A, Sass JO. Expression of aspartoacylase (ASPA) and Canavan disease. Gene. 2012 Sep 1;505(2):206-10.\n8.  Tacke U, Olbrich H, Sass JO, Fekete A, Horvath J, Ziyeh S, Kleijer WJ, Rolland MO, Fisher S, Payne S, Vargiami E, Zafeiriou DI, Omran H. Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease. Neuropediatrics. 2005 Aug;36(4):252-5.\n9.  Zano S, Wijayasinghe YS, Malik R, Smith J, Viola RE. Relationship between enzyme properties and disease progression in Canavan disease. J Inherit Metab Dis. 2013 Jan;36(1):1-6.\n10. Zeng BJ, Pastores GM, Leone P, Raghavan S, Wang ZH, Ribeiro LA, Torres P, Ong E, Kolodny EH. Mutation analysis of the aspartoacylase gene in non-Jewish patients with Canavan disease. Adv Exp Med Biol. 2006;576:165-73; discussion 361-3.\n11. Zeng BJ, Wang ZH, Torres PA, Pastores GM, Leone P, Raghavan SS, Kolodny EH. Rapid detection of three large novel deletions of the aspartoacylase gene in non-Jewish patients with Canavan disease. Mol Genet Metab. 2006 Sep-Oct;89(1-2):156-63.\n\n**Catalog of Genes and Diseases from OMIM**\n\nThe ASPA gene is associated with Canavan disease, a rare genetic disorder characterized by spongy degeneration of the brain.\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**: The NCBI Gene database contains information on genes, including their genomic location and related health topics. For the ASPA gene, its location is on chromosome 17.\n*   **ClinVar**: ClinVar is a freely available, public archive of reports of the relationships among human variation and phenotype (e.g., disease).\n\n---\n\n**ASPA Gene**\n\n**Genomic Location**\nThe ASPA gene is found on chromosome 17.\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n\\n\\n\n\n**Disclaimers**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ASPM gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/aspm/",
    "content": "**ASPM Gene**\n\nThe ASPM gene provides instructions for making a protein that is involved in cell division. This protein is found in cells and tissues throughout the body; however, it appears to be particularly important for the division of cells in the developing brain.\n\n**Normal Function**\n\n* The ASPM protein helps maintain the orderly division of early brain cells called neural progenitor cells.\n* By promoting the division of neural progenitor cells during early brain development, the ASPM protein helps determine the total number of neurons and the overall size of the brain.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Autosomal Recessive Primary Microcephaly (MCPH)**\n\t+ Mutations in the ASPM gene are the most common cause of MCPH.\n\t+ This condition is characterized by an abnormally small head and brain, intellectual disability, and delayed development.\n\t+ Almost all of the ASPM gene mutations responsible for MCPH reduce production of the ASPM protein.\n\t+ The protein that is produced is shorter than normal and is thought to be partly or wholly nonfunctional.\n\t+ A shortage of functional ASPM protein impairs cell division, especially in neural progenitor cells in the developing brain.\n\t+ As a result, fewer mature neurons are produced, and affected individuals are born with an unusually small brain.\n\n**Other Health Conditions**\n\n* **Age-Related Macular Degeneration**\n\t+ The ASPM gene is upregulated in age-related macular degeneration.\n\t+ However, the exact relationship between the ASPM gene and this condition is unclear.\n* **Cancers**\n\t+ The ASPM gene is upregulated in several types of cancer, including gliomas and hepatocellular carcinomas.\n\t+ However, the exact effects of the extra ASPM protein on cancer cells are unclear.\n\n---\n\n**ASPM Gene: MedlinePlus Genetics (Part 2/4)**\n\n**Microcephaly Primary Hereditary**\n\nThis condition is characterized by an abnormally small head and brain, intellectual disability, and delayed development. More than 80 mutations in the ASPM gene have been found to cause MCPH.\n\n**Almost All Mutations Reduce Production of ASPM Protein**\n\nThe protein that is produced is shorter than normal and is thought to be partly or wholly nonfunctional. A shortage of functional ASPM protein impairs cell division, especially in neural progenitor cells in the developing brain. As a result, fewer mature neurons are produced, and affected individuals are born with an unusually small brain.\n\n**Why Neural Progenitor Cells Are More Severely Affected**\n\nBecause the ASPM protein is found in cells throughout the body, it is unclear why ASPM gene mutations affect neural progenitor cells more severely than other cell types. Some researchers believe that neural progenitor cells are more sensitive than other types of cells to a shortage of the ASPM protein.\n\n**Other Names for This Gene**\n\n* abnormal spindle-like microcephaly-associated protein\n* asp (abnormal spindle) homolog, microcephaly associated (Drosophila)\n* ASPM_HUMAN\n* Calmbp1\n* FLJ10517\n* FLJ10549\n* FLJ43117\n* MCPH5\n\n---\n\n**ASPM Gene**\n\nThe ASPM gene is a crucial determinant of cerebral cortical size. Mutations in this gene have been associated with primary microcephaly, a condition characterized by a significantly reduced head circumference.\n\n**Scientific Articles on PubMed**\n\n*   Bond J, Roberts E, Mochida GH, Hampshire DJ, Scott S, Askham JM, Springell K, Mahadevan M, Crow YJ, Markham AF, Walsh CA, Woods CG. ASPM is a major determinant of cerebral cortical size. Nat Genet. 2002 Oct;32(2):316-20.\n*   Bond J, Scott S, Hampshire DJ, Springell K, Corry P, Abramowicz MJ, Mochida GH, Hennekam RC, Maher ER, Fryns JP, Alswaid A, Jafri H, Rashid Y, Mubaidin A, Walsh CA, Roberts E, Woods CG. Protein-truncating mutations in ASPM cause variable reduction in brain size. Am J Hum Genet. 2003 Nov;73(5):1170-7.\n*   Fish JL, Kosodo Y, Enard W, Paabo S, Huttner WB. Aspm specifically maintains symmetric proliferative divisions of neuroepithelial cells. Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10438-10443.\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   ABNORMAL SPINDLE-LIKE, MICROCEPHALY-ASSOCIATED; ASPM\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n**References**\n\n*   Bond J, Roberts E, Mochida GH, Hampshire DJ, Scott S, Askham JM, Springell K, Mahadevan M, Crow YJ, Markham AF, Walsh CA, Woods CG. ASPM is a major determinant of cerebral cortical size. Nat Genet. 2002 Oct;32(2):316-20.\n*   Bond J, Scott S, Hampshire DJ, Springell K, Corry P, Abramowicz MJ, Mochida GH, Hennekam RC, Maher ER, Fryns JP, Alswaid A, Jafri H, Rashid Y, Mubaidin A, Walsh CA, Roberts E, Woods CG. Protein-truncating mutations in ASPM cause variable reduction in brain size. Am J Hum Genet. 2003 Nov;73(5):1170-7.\n*   Fish JL, Kosodo Y, Enard W, Paabo S, Huttner WB. Aspm specifically maintains symmetric proliferative divisions of neuroepithelial cells. Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10438-10443.\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of ASPM\n\n---\n\n**ASPM Gene**\n\n\\n\\n\n\n*   **Genomic Location**: The ASPM gene is found on chromosome 1.\n*   **Related Health Topics**\n    *   Genes and Gene Therapy\n    *   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ASS1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/ass1/",
    "content": "**ASS1 Gene**\n\nThe ASS1 gene provides instructions for making an enzyme called argininosuccinate synthase 1. This enzyme participates in the urea cycle, which is a sequence of chemical reactions that takes place in liver cells.\n\n**Normal Function**\n\n* The urea cycle processes excess nitrogen that is generated as the body breaks down proteins.\n* The excess nitrogen is used to make a compound called urea, which is excreted from the body in urine.\n* Argininosuccinate synthase 1 is involved in the third step of the urea cycle. This step combines two protein building blocks (amino acids), citrulline and aspartate, to form a molecule called argininosuccinic acid.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Citrullinemia**: At least 118 mutations that cause type I citrullinemia have been identified in the ASS1 gene. Type I citrullinemia is a serious condition that usually appears in the first few days of life.\n* Symptoms include poor feeding, vomiting, seizures, and loss of consciousness.\n* Most of the mutations involved in type I citrullinemia change single amino acids in the argininosuccinate synthase 1 enzyme. These genetic changes likely alter the structure of the enzyme, impairing its ability to attach to molecules such as citrulline and aspartate.\n* A few mutations lead to the production of an abnormally short version of the enzyme that cannot effectively play its role in the urea cycle.\n\n**References**\n\n(Note: References are not included in this cleaned output)\n\n---\n\n**ASS1 Gene: MedlinePlus Genetics**\n\n**Category:** general\n\n**Content:**\nIn the case of type I citrullinemia, defects in the ASS1 gene lead to the accumulation of ammonia and other byproducts of the urea cycle in the bloodstream. This is because the liver is unable to process excess nitrogen into urea due to a disruption in the third step of the urea cycle.\n\n**Other Names for This Gene**\n\n* argininosuccinate synthetase 1\n* ASS\n* ASSY_HUMAN\n* Citrulline-aspartate ligase\n* CTLN1\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ASS1\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ARGININOSUCCINATE SYNTHETASE 1; ASS1\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML. Urea Cycle Disorders Overview. 2003 Apr 29 [updated 2017 Jun 22]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n* Diez-Fernandez C, Rufenacht V, Haberle J. Mutations in the Human Argininosuccinate Synthetase (ASS1) Gene, Impact on Patients, Common Changes, and Structural Considerations. Hum Mutat. 2017 May;38(5):471-484.\n* Gao HZ, Kobayashi K, Tabata A, Tsuge H, Iijima M, Yasuda T, Kalkanoglu HS, Dursun A, Tokatli A, Coskun T, Trefz FK, Skladal D, Mandel H, Seidel J, Kodama S, Shirane S, Ichida T, Makino S, Yoshino M, Kang JH, Mizuguchi M, Barshop BA, Fuchinoue S, Seneca S, Zeesman S, Knerr I, Rodes M, Wasant P, Yoshida I, De Meirleir L, Abdul Jalil M, Begum L, Horiuchi M, Katunuma N, Nakagawa S, Saheki T. Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients. Hum Mutat. 2003 Jul;22(1):24-34.\n* Haberle J, Pauli S, Linnebank M, Kleijer WJ, Bakker HD, Wanders RJ, Harms E, Koch HG. Structure of the human argininosuccinate synthetase gene and an improved system for molecular diagnostics in patients with classical and mild citrullinemia. Hum Genet. 2002 Apr;110(4):327-33.\n* Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem. 2003 May;270(9):1887-99.\n* Kose E, Unal O, Bulbul S, Gunduz M, Haberle J, Arslan N. Identification of three novel mutations in fourteen patients with citrullinemia type 1. Clin Biochem. 2017 Aug;50(12):686-689.\n* Quinonez SC, Lee KN. Citrullinemia Type I. 2004 Jul 7 [updated 2022 Aug 18]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\n\n---\n\n**ASS1 Gene**\n\n\\n\\n\n\n*   **Genomic Location**: The ASS1 gene is found on chromosome 9.\n*   **Related Health Topics**\n    *   Genes and Gene Therapy\n    *   Genetic Disorders\n\n\\n\\n\n\n**Understanding Genetics**\n\n*   What is DNA?\n*   What is a gene?\n*   What is a gene variant and how do variants occur?",
    "category": "general"
  },
  {
    "title": "AST Test: MedlinePlus Medical Test",
    "url": "https://medlineplus.gov/lab-tests/ast-test/",
    "content": "**AST Test**\n\nWhat is an AST test?\n\nAn AST blood test measures the amount of AST in your blood. This test is commonly used to help diagnose liver damage or disease.\n\nAST (aspartate aminotransferase) is an enzyme, a protein that speeds up certain chemical reactions in your body. It is found mainly in your liver but also in your heart, muscles, and other tissues. Usually, you will have low levels of AST in your blood. When your liver or other cells that contain AST are damaged, they release AST into your blood. This can lead to high AST levels in your blood.\n\nAn AST test may be ordered by itself but is often ordered as part of a group of liver function tests.\n\nOther names: SGOT test, serum glutamic oxaloacetic transaminase test; aspartate transaminase test\n\nWhat is it used for?\n\nAn AST blood test is often part of a routine blood screening to check the health of your liver. The test may help diagnose or monitor liver problems. It may also help diagnose other health conditions.\n\nWhy do I need an AST blood test?\n\nYou may get an AST blood test as part of your routine checkupor to monitor the treatment of a liver problem. You may also need a test if you have symptoms of liver damage, which may include:\n\n* Nausea and vomiting\n* Lack of appetite\n* Fatigue\n* Weakness\n* Jaundice, a condition that causes your skin and eyes to turn yellow\n* Swelling and/or pain in your abdomen(belly)\n* Swelling in your ankles and legs\n* Dark-colored urine (pee) and/or light-colored stool (poop)\n* Frequent itching\n\nEven if you don't have symptoms, your health care provider may order an AST blood test if you're more likely to develop liver disease because of:\n\n* A family history of liver disease\n* Alcohol use disorder (AUD)\n* Obesity\n* Diabetes\n* Taking certain medicines that can cause liver damage\n* Hepatitis or exposure to hepatitis\n\nWhat happens during an AST blood test?\n\nA health care professional will take a blood sample from a vein in your arm, using a small needle. After the needle is inserted, a small amount of blood will be collected into a test tube or vial. You may feel a little sting when the needle goes in or out. This usually takes less than five minutes.\n\nWill I need to do anything to prepare for the test?\n\nYou may need to stop taking certain medicines before the test, so tell your provider about everything you take. But don't stop taking any medicines unless your provider tells you to.\n\nAre there any risks to the test?\n\nThere is very little risk to having a blood test. You may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.\n\nWhat do the results mean?\n\nLow levels of AST in the blood are usually considered normal.\n\nHigh levels of AST in the blood may be due to liver disease or other liver problems. Other reasons you may have high levels of AST can include:\n\n* Hepatitis\n* Cirrhosis\n* Mononucleosis\n* Heart procedures or problems\n* Pancreatitis\n* Hemochromatosis (too much iron in the body)\n* Deep burns\n* Seizures\n* Use of drugs that are toxic to the liver, especially alcohol use\n* Surgery\n\nIf your results are not in the normal range, it doesn't always mean that you have a medical condition that needs treatment. Many things can affect your results, such as pregnancy, exercise, certain medicines, and your age or sex. Talk with your provider to learn what your results mean.\n\nLearn more about laboratory tests, reference ranges, and understanding results.\n\nIs there anything else I need to know about an AST blood test?\n\nYour health care provider may order an ALT blood testalong with your AST blood test. ALT stands for alanine transaminase, which is another type of liver enzyme. If you have high levels of AST and/or ALT, it may mean that you have some type of liver damage.\n\n---\n\n**AST Test: MedlinePlus Medical Test (Part 2/2)**\n\n**Category:** Health\n\nAre there any special instructions I need to follow before the test?\n\nYou may need to stop taking certain medicines before the test, so tell your provider about everything you take. But don't stop taking any medicines unless your provider tells you to.\n\nAn AST test is usually ordered with other blood tests. You usually need to fast (not eat or drink) for up to 12 hours before these tests. Your provider will let you know if there are any special instructions.\n\nAre there any risks to the test?\n\nThere is very little risk to having a blood test. You may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.\n\nWhat do the results mean?\n\nLow levels of AST in the blood are usually considered normal.\n\nHigh levels of AST in the blood may be due to liver disease or other liver problems. Other reasons you may have high levels of AST can include:\n\n* Hepatitis\n* Cirrhosis\n* Mononucleosis\n* Heart procedures or problems\n* Pancreatitis\n* Hemochromatosis (too much iron in the body)\n* Deep burns\n* Seizures\n* Use of drugs that are toxic to the liver, especially alcohol use\n* Surgery\n\nIf your results are not in the normal range, it doesn't always mean that you have a medical condition that needs treatment. Many things can affect your results, such as pregnancy, exercise, certain medicines, and your age or sex. Talk with your provider to learn what your results mean.\n\nIs there anything else I need to know about an AST blood test?\n\nYour health care provider may order an ALT blood test along with your AST blood test. ALT stands for alanine transaminase, which is another type of liver enzyme. If you have high levels of AST and/or ALT, it may mean that you have some type of liver damage.\n\n**References:**\n\n* American Liver Foundation\n* Cleveland Clinic: Health Library: Diagnostics & Testing\n* Lala V, Zubair M, Minter DA. Liver Function Tests.\n* Mayo Clinic\n* Merck Manual Consumer Version\n* Moriles KE, Zubair M, Azer SA. Alanine Aminotransferase (ALT) Test.\n* Nemours KidsHealth\n* Pathology Tests Explained\n* Testing.com",
    "category": "health"
  },
  {
    "title": "ASXL1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/asxl1/",
    "content": "**ASXL1 Gene**\n\nThe ASXL1 gene provides instructions for making a protein that is involved in a process known as chromatin remodeling. Chromatin is the complex of DNA and proteins that packages DNA into chromosomes. The structure of chromatin can be changed (remodeled) to alter how tightly DNA is packaged. When DNA is tightly packed, gene activity (expression) is lower than when DNA is loosely packed.\n\nThrough its role in chromatin remodeling, the ASXL1 protein regulates the expression of many genes, including a group of genes known as HOX genes, which play important roles in development before birth. The ASXL1 protein can turn on (activate) or turn off (repress) HOX genes depending on when they are needed.\n\nThe ASXL1 protein may have an additional role in gene regulation by signaling to molecules to add a methyl group (a process called methylation) to an area near a gene called the promoter region, which controls gene activity. When a promoter region is methylated, gene activity is repressed, and when a promoter region is not methylated, the gene is active.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Bohring-Opitz Syndrome**: More than 20 mutations in the ASXL1 gene have been found to cause Bohring-Opitz syndrome, a condition that causes abnormal head size and shape, distinctive facial features, joint abnormalities, intellectual disability, and other signs and symptoms. Most of the ASXL1 gene mutations that cause Bohring-Opitz syndrome create a premature stop signal in the instructions for making the ASXL1 protein, resulting in either an abnormally short, nonfunctional protein or a complete lack of ASXL1 protein.\n* **Systemic Mastocytosis**: MedlinePlus Genetics provides information about Systemic mastocytosis.\n\n---\n\n**ASXL1 Gene**\n\n**Cancers**\n\nMutations in the ASXL1 gene have been associated with cancerous conditions of blood-forming cells, such as acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome. These mutations are somatic, which means they are acquired during a person's lifetime and are present only in cells that give rise to cancer.\n\nThe mutations associated with these conditions are likely \"gain-of-function,\" which means that they lead to an overactive ASXL1 protein. Researchers believe that the overactive ASXL1 protein leads to poor regulation of gene activity. It is unclear how this altered gene regulation plays a role in the development of cancer, but it is likely that overactive genes promote the growth of cancers by allowing abnormal blood cells to grow and divide uncontrollably.\n\nThe ASXL1 gene mutations involved in these cancers are different from the ones that cause Bohring-Opitz syndrome (described above). People with Bohring-Opitz syndrome are not thought to have an increased risk of developing cancer.\n\n**Bohring-Opitz Syndrome**\n\nMore than 20 mutations in the ASXL1 gene have been found to cause Bohring-Opitz syndrome, a condition that causes abnormal head size and shape, distinctive facial features, joint abnormalities, intellectual disability, and other signs and symptoms. Most of the ASXL1 gene mutations that cause Bohring-Opitz syndrome create a premature stop signal in the instructions for making the ASXL1 protein, resulting in either an abnormally short, nonfunctional protein or a complete lack of ASXL1 protein.\n\nThese ASXL1 gene mutations are described as \"loss-of-function\" because they reduce the amount of functional ASXL1 protein available, which likely disrupts the regulation of the activity of HOX genes and other genes during development. Altered activity of HOX genes probably leads to the neurological and physical features of this condition.\n\n**Other Names for This Gene**\n\n* additional sex combs like 1\n* additional sex combs like transcriptional regulator 1\n* KIAA0978\n* putative Polycomb group protein ASXL1 isoform 1\n* putative Polycomb group protein ASXL1 isoform 2\n\n---\n\n**ASXL1 Gene**\n\n**Information & Resources**\n\nExpand Section\n\n* **Tests Listed in the Genetic Testing Registry**\n\t+ Tests of ASXL1\n* **Scientific Articles on PubMed**\n\t+ PubMed\n* **Catalog of Genes and Diseases from OMIM**\n\t+ ASXL TRANSCRIPTIONAL REGULATOR 1; ASXL1\n* **Gene and Variant Databases**\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\nExpand Section\n\n* Aravind L, Iyer LM. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. Cell Cycle. 2012 Jan 1;11(1):119-31.\n* Bohring A, Oudesluijs GG, Grange DK, Zampino G, Thierry P. New cases of Bohring-Opitz syndrome, update, and critical review of the literature. Am J Med Genet A. 2006 Jun 15;140(12):1257-63.\n* Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, de Vries P, Janssen I, van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wieczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, de Vries BB. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet. 2011 Jun 26;43(8):729-31.\n* Inoue D, Matsumoto M, Nagase R, Saika M, Fujino T, Nakayama KI, Kitamura T. Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. Exp Hematol. 2016 Mar;44(3):172-6.e1.\n* Magini P, Della Monica M, Uzielli ML, Mongelli P, Scarselli G, Gambineri E, Scarano G, Seri M. Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations. Am J Med Genet A. 2012 Apr;158A(4):917-21.\n* Russell B, Johnston JJ, Biesecker LG, Kramer N, Pickart A, Rhead W, Tan WH, Brownstein CA, Kate Clarkson L, Dobson A, Rosenberg AZ, Vergano SA, Helm BM, Harrison RE, Graham JM Jr. Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance. Am J Med Genet A. 2015 Sep;167A(9):2122-31.\n\n**Genomic Location**\n\nThe ASXL1 gene is found on chromosome 20.\n\n**Related Health Topics**\n\n* **Genes and Gene Therapy**\n* **Genetic Disorders**\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?",
    "category": "general"
  },
  {
    "title": "ATG16L1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atg16l1/",
    "content": "**ATG16L1 Gene**\n\nThe ATG16L1 gene provides instructions for making a protein that is required for a process called autophagy. Cells use this process to recycle worn-out cell parts and break down certain proteins when they are no longer needed. Autophagy also plays an important role in controlled cell death (apoptosis). Additionally, autophagy is involved in the body's inflammatory response and helps the immune system destroy some types of harmful bacteria and viruses.\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Crohn's Disease**: At least one variation in the ATG16L1 gene is associated with an increased risk of Crohn's disease, particularly a form of the disorder that affects the lower part of the small intestine (the ileum) and the colon. This increased risk has been found primarily in people of northern European ancestry.\n\n**Other Names for This Gene**\n\n*   APG16 autophagy 16-like\n*   APG16L\n*   ATG16 autophagy related 16-like 1 (S. cerevisiae)\n*   ATG16 autophagy related 16-like protein 1\n*   ATG16A\n*   ATG16L\n*   Autophagy 16-like 1\n*   Autophagy related 16-like 1\n*   Autophagy related 16-like 1 (S. cerevisiae)\n*   WD repeat domain 30\n*   WDR30\n\n---\n\n**ATG16L1 Gene**\n\nThe ATG16L1 gene is located on chromosome 2.\n\n**Scientific Articles on PubMed**\n\n*   **Boada-Romero E, Serramito-Gomez I, Sacristan MP, Boone DL, Xavier RJ, Pimentel-Muinos FX. The T300A Crohn's disease risk polymorphism impairs function of the WD40 domain of ATG16L1. Nat Commun. 2016 Jun 8;7:11821. doi: 10.1038/ncomms11821. Citation on PubMed or Free article on PubMed Central**\n*   **Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW 4th. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature. 2008 Nov 13;456(7219):259-63. doi: 10.1038/nature07416. Epub 2008 Oct 5. Citation on PubMed or Free article on PubMed Central**\n*   **Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Gunther S, Prescott NJ, Onnie CM, Hasler R, Sipos B, Folsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007 Feb;39(2):207-11. doi: 10.1038/ng1954. Epub 2006 Dec 31. Citation on PubMed**\n*   **Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS One. 2008;3(10):e3391. doi: 10.1371/journal.pone.0003391. Epub 2008 Oct 13. Citation on PubMed or Free article on PubMed Central**\n*   **Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007 May;39(5):596-604. doi: 10.1038/ng2032. Epub 2007 Apr 15. Citation on PubMed or Free article on PubMed Central**\n*   **Salem M, Ammitzboell M, Nys K, Seidelin JB, Nielsen OH. ATG16L1: A multifunctional susceptibility factor in Crohn disease. Autophagy. 2015 Apr 3;11(4):585-94. doi: 10.1080/15548627.2015.1017187. Citation on PubMed or Free article on PubMed Central**\n*   **Zhang HF, Qiu LX, Chen Y, Zhu WL, Mao C, Zhu LG, Zheng MH, Wang Y, Lei L, Shi J. ATG16L1 T300A polymorphism and Crohn's disease susceptibility: evidence from 13,022 cases and 17,532 controls. Hum Genet. 2009 Jun;125(5-6):627-31. doi: 10.1007/s00439-009-0660-7. Epub 2009 Apr 1. Citation on PubMed**\n*   **Zheng H, Ji C, Li J, Jiang H, Ren M, Lu Q, Gu S, Mao Y, Xie Y. Cloning and analysis of human Apg16L. DNA Seq. 2004 Aug;15(4):303-5. doi: 10.1080/10425170400004104. Citation on PubMed**\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   **AUTOPHAGY 16-LIKE 1; ATG16L1**\n\n**Gene and Variant Databases**\n\n*   **NCBI Gene**\n*   **ClinVar**\n*   **Tests Listed in the Genetic Testing Registry**\n    *   **Tests of ATG16L1**\n\n**Genomic Location**\n\nThe ATG16L1 gene is found on chromosome 2.\n\n**Related Health Topics**\n\n*   **Genes and Gene Therapy**\n*   **Genetic Disorders**\n\n---\n\n**ATG16L1 Gene**\n\n\\n\\n* **What is the ATG16L1 gene?**\n\t+ The ATG16L1 gene provides instructions for making a protein called autophagy-related protein 16-like 1. This protein plays a role in the process of autophagy, which helps eliminate and recycle damaged or dysfunctional cellular components.\n* **How does the ATG16L1 gene function?**\n\t+ The ATG16L1 gene is involved in the regulation of autophagy, a vital cellular process that helps maintain cellular homeostasis. Mutations in the ATG16L1 gene have been associated with an increased risk of developing Crohn's disease and other inflammatory disorders.\n* **What are the implications of ATG16L1 gene mutations?**\n\t+ Research has shown that individuals with mutations in the ATG16L1 gene are more susceptible to developing Crohn's disease, a type of inflammatory bowel disease. This highlights the importance of understanding the genetic factors contributing to this condition and potential therapeutic strategies.\n\n\\n\\n**Disclaimer:** The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ATL1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atl1/",
    "content": "**ATL1 Gene**\n\nThe ATL1 gene provides instructions for producing a protein called atlastin-1. Atlastin-1 is produced primarily in the brain and spinal cord (central nervous system), particularly in nerve cells (neurons) that extend down the spinal cord (corticospinal tracts). These neurons send electrical signals that lead to voluntary muscle movement.\n\n**Normal Function**\n\n*   The ATL1 gene provides instructions for producing a protein called atlastin-1.\n*   Atlastin-1 is produced primarily in the brain and spinal cord (central nervous system), particularly in nerve cells (neurons) that extend down the spinal cord (corticospinal tracts).\n*   These neurons send electrical signals that lead to voluntary muscle movement.\n*   In neurons, this protein is found mainly in the endoplasmic reticulum, which is a structure involved in protein processing and distribution.\n*   Atlastin-1 fuses together the network of tubules that make up the structure of the endoplasmic reticulum.\n*   Atlastin-1 is also active in compartments called axonal growth cones, which are located at the tip of neurons.\n*   The axonal growth cones direct the growth of specialized extensions, called axons, which transmit nerve impulses that signal muscle movement.\n*   Within axonal growth cones, atlastin-1 acts during development to help guide the growth of axons.\n\n**Health Conditions Related to Genetic Changes**\n\n*   Approximately 60 mutations in the ATL1 gene have been found to cause spastic paraplegia type 3A.\n*   This condition is characterized by muscle stiffness (spasticity) and weakness of the lower limbs (paraplegia), which begin in childhood.\n*   Most of the mutations that cause spastic paraplegia type 3A change one protein building block (amino acid) in the atlastin-1 protein.\n*   These mutations likely lead to abnormal activity of atlastin-1, which impairs the functioning of neurons, including the distribution of materials within these cells.\n*   This lack of functional atlastin-1 protein can also restrict the growth of axons.\n*   Within the long neurons of the corticospinal tracts, these problems can lead to cell death.\n*   As a result, the neurons are unable to transmit nerve impulses, particularly to other neurons and muscles in the lower extremities.\n*   This impaired nerve function leads to the signs and symptoms of spastic paraplegia type 3A.\n\n---\n\n**ATL1 Gene**\n\n**Spastic Paraplegia Type 3A**\n\nApproximately 60 mutations in the ATL1 gene have been found to cause spastic paraplegia type 3A. This condition is characterized by muscle stiffness (spasticity) and weakness of the lower limbs (paraplegia), which begin in childhood. Most of the mutations that cause spastic paraplegia type 3A change one protein building block (amino acid) in the atlastin-1 protein. These mutations likely lead to abnormal activity of atlastin-1, which impairs the functioning of neurons, including the distribution of materials within these cells. This lack of functional atlastin-1 protein can also restrict the growth of axons. Within the long neurons of the corticospinal tracts, these problems can lead to cell death. As a result, the neurons are unable to transmit nerve impulses, particularly to other neurons and muscles in the lower extremities. This impaired nerve function leads to the signs and symptoms of spastic paraplegia type 3A.\n\n**Hereditary Sensory Neuropathy Type ID**\n\nMutations in the ATL1 gene have been found to cause a condition called hereditary sensory neuropathy type ID. This condition is characterized by nerve abnormalities in the legs and feet (peripheral neuropathy). Many people with this condition experience prickling or tingling sensations (paresthesias), absent reflexes, weakness, and a reduced ability to feel pain. Affected individuals often get open sores (ulcers) on their feet, and because they cannot feel the pain of these sores, they may not seek immediate treatment. Without treatment, the ulcers can become infected and may require amputation of the surrounding area.\n\nAt least four ATL1 gene mutations have been found to cause hereditary sensory neuropathy type ID. These mutations impair nerve cell function and decrease transmission of nerve impulses, similar to the effects of ATL1 gene mutations that cause spastic paraplegia type 3A (described above). It is unclear why some ATL1 gene mutations cause hereditary sensory neuropathy type ID and others cause spastic paraplegia type 3A.\n\n**Other Names for This Gene**\n\nAD-FSP, ATLA1_HUMAN, atlastin, atlastin1, FSP1, GBP3, guanylate-binding protein 3\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry: Tests of ATL1\nScientific Articles on PubMed: PubMed\nCatalog of Genes and Diseases from OMIM: ATLASTIN GTPase 1; ATL1, NEUROPATHY, HEREDITARY SENSORY, TYPE ID; HSN1D\n\n---\n\n**ATL1 Gene**\n\n**What is the ATL1 gene?**\n\nThe ATL1 gene, also known as ATLASTIN GTPase 1, plays a crucial role in the development and maintenance of the nervous system. It encodes a protein called atlastin-1, which is involved in the formation of axons and the transport of molecules within nerve cells.\n\n**Genomic Location**\n\nThe ATL1 gene is located on chromosome 14.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Scientific Articles**\n\n* Byrnes LJ, Sondermann H. Structural basis for the nucleotide-dependent dimerization of the large G protein atlastin-1/SPG3A. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2216-21.\n* Ivanova N, Claeys KG, Deconinck T, Litvinenko I, Jordanova A, Auer-Grumbach M, Haberlova J, Lofgren A, Smeyers G, Nelis E, Mercelis R, Plecko B, Priller J, Zamecnik J, Ceulemans B, Erichsen AK, Bjorck E, Nicholson G, Sereda MW, Seeman P, Kremensky I, Mitev V, De Jonghe P. Hereditary spastic paraplegia 3A associated with axonal neuropathy. Arch Neurol. 2007 May;64(5):706-13.\n* Leonardis L, Auer-Grumbach M, Papic L, Zidar J. The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features. Eur J Neurol. 2012 Jul;19(7):992-8.\n* McCorquodale DS 3rd, Ozomaro U, Huang J, Montenegro G, Kushman A, Citrigno L, Price J, Speziani F, Pericak-Vance MA, Zuchner S. Mutation screening of spastin, atlastin, and REEP1 in hereditary spastic paraplegia. Clin Genet. 2011 Jun;79(6):523-30.\n* Moss TJ, Daga A, McNew JA. Fusing a lasting relationship between ER tubules. Trends Cell Biol. 2011 Jul;21(7):416-23.\n* Zhu PP, Soderblom C, Tao-Cheng JH, Stadler J, Blackstone C. SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development. Hum Mol Genet. 2006 Apr 15;15(8):1343-53.\n\n**Genetic Testing**\n\n* Tests of ATL1\n\n**References**\n\n* Byrnes LJ, Sondermann H. Structural basis for the nucleotide-dependent dimerization of the large G protein atlastin-1/SPG3A. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2216-21.\n* Ivanova N, Claeys KG, Deconinck T, Litvinenko I, Jordanova A, Auer-Grumbach M, Haberlova J, Lofgren A, Smeyers G, Nelis E, Mercelis R, Plecko B, Priller J, Zamecnik J, Ceulemans B, Erichsen AK, Bjorck E, Nicholson G, Sereda MW, Seeman P, Kremensky I, Mitev V, De Jonghe P. Hereditary spastic paraplegia 3A associated with axonal neuropathy. Arch Neurol. 2007 May;64(5):706-13.\n* Leonardis L, Auer-Grumbach M, Papic L, Zidar J. The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features. Eur J Neurol. 2012 Jul;19(7):992-8.\n* McCorquodale DS 3rd, Ozomaro U, Huang J, Montenegro G, Kushman A, Citrigno L, Price J, Speziani F, Pericak-Vance MA, Zuchner S. Mutation screening of spastin, atlastin, and REEP1 in hereditary spastic paraplegia. Clin Genet. 2011 Jun;79(6):523-30.\n* Moss TJ, Daga A, McNew JA. Fusing a lasting relationship between ER tubules. Trends Cell Biol. 2011 Jul;21(7):416-23.\n* Zhu PP, Soderblom C, Tao-Cheng JH, Stadler J, Blackstone C. SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development. Hum Mol Genet. 2006 Apr 15;15(8):1343-53.\n\n**Disclaimer**\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ATM gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atm/",
    "content": "**ATM Gene**\n\nThe ATM gene provides instructions for making a protein that is located primarily in the nucleus of cells, where it helps control the rate at which cells grow and divide. This protein also plays an important role in the normal development and activity of several body systems, including the nervous system and the immune system.\n\n**Normal Function**\n\n* The ATM protein assists cells in recognizing damaged or broken DNA strands.\n* DNA can be damaged by agents such as toxic chemicals or radiation.\n* Breaks in DNA strands also occur naturally when chromosomes exchange genetic material during cell division.\n* The ATM protein coordinates DNA repair by activating enzymes that fix the broken strands.\n* Efficient repair of damaged DNA strands helps maintain the stability of the cell's genetic information.\n\nBecause of its central role in cell division and DNA repair, the ATM protein is of great interest in cancer research.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Ataxia-telangiectasia**: Researchers have identified several hundred variants (also called mutations) in the ATM gene that cause ataxia-telangiectasia. This disorder is characterized by progressive difficulty with coordinating movements (ataxia) beginning in early childhood.\n* **Bladder cancer**\n* **Breast cancer**\n* **Melanoma**\n\n---\n\n**ATM Gene: MedlinePlus Genetics (Part 2/4)**\n\n**Other Cancers**\n\nResearch suggests that people who carry one altered copy of the ATM gene in each cell may have an increased risk of developing several other types of cancer. In particular, some studies have shown that cancers of the breast, stomach, bladder, pancreas, lung, and ovaries occur more frequently in ATM gene variant carriers than in people who do not carry these variants. The results of similar studies, however, have been conflicting. Additional research is needed to clarify which other types of cancer, if any, are associated with ATM gene variants.\n\n**Ataxia-Telangiectasia**\n\nResearchers have identified several hundred variants (also called mutations) in the ATM gene that cause ataxia-telangiectasia. This disorder is characterized by progressive difficulty with coordinating movements (ataxia) beginning in early childhood. People with this disorder have variants in both copies of the ATM gene in each cell. Most of these variants disrupt protein production, resulting in an abnormally small, nonfunctional version of the ATM protein. Cells without any functional ATM protein are hypersensitive to radiation and do not respond normally to DNA damage. Instead of activating DNA repair, the altered ATM protein allows variants to accumulate in other genes, which may cause cells to grow and divide in an uncontrolled way. This kind of unregulated cell growth can lead to the formation of cancerous tumors. In addition, ATM gene variants can allow cells to die inappropriately, particularly affecting cells in a part of the brain involved in coordinating movements (the cerebellum). This loss of brain cells causes the movement problems characteristic of ataxia-telangiectasia.\n\n**Bladder Cancer**\n\nMedlinePlus Genetics provides information about bladder cancer.\n\n**Breast Cancer**\n\nMedlinePlus Genetics provides information about breast cancer.\n\n**Melanoma**\n\nMedlinePlus Genetics provides information about melanoma.\n\n**Other Names for This Gene**\n\n* AT mutated\n* AT protein\n* AT1\n* ATA\n* Ataxia telangiectasia mutated\n* ATM_HUMAN\n* Human phosphatidylinositol 3-kinase homolog serine-protein kinase\n* ATM\n* TEL1\n* TELO1\n\n**Additional Information & Resources**\n\nMedlinePlus Genetics provides information about various health conditions, including those related to the ATM gene.\n\n---\n\n**ATM Gene**\n\nThe ATM gene plays a crucial role in maintaining genomic stability and preventing cancer. Mutations in the ATM gene are associated with an increased risk of breast cancer, as well as other types of cancer.\n\n**Scientific Articles on PubMed**\n\n*   Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006 Sep 25;25(43):5906-11.\n*   Bradbury JM, Jackson SP. ATM and ATR. Curr Biol. 2003 Jun 17;13(12):R468.\n*   Geoffroy-Perez B, Janin N, Ossian K, Lauge A, Croquette MF, Griscelli C, Debre M, Bressac-de-Paillerets B, Aurias A, Stoppa-Lyonnet D, Andrieu N. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer. 2001 Jul 15;93(2):288-93.\n*   Gumy-Pause F, Wacker P, Sappino AP. ATM gene and lymphoid malignancies. Leukemia. 2004 Feb;18(2):238-42.\n*   Hall J. The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. Cancer Lett. 2005 Sep 28;227(2):105-14.\n*   Kim JH, Kim H, Lee KY, Choe KH, Ryu JS, Yoon HI, Sung SW, Yoo KY, Hong YC. Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk. Hum Mol Genet. 2006 Apr 1;15(7):1181-6.\n*   Kitagawa R, Kastan MB. The ATM-dependent DNA damage signaling pathway. Cold Spring Harb Symp Quant Biol. 2005;70:99-109.\n*   Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst). 2004 Aug-Sep;3(8-9):889-900.\n*   Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res. 2005 Jan 6;569(1-2):123-32.\n*   Lavin MF, Kozlov S. DNA damage-induced signalling in ataxia-telangiectasia and related syndromes. Radiother Oncol. 2007 Jun;83(3):231-7.\n*   McKinnon PJ. ATM and ataxia telangiectasia. EMBO Rep. 2004 Aug;5(8):772-6.\n*   Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev. 2004 Feb;14(1):11-6.\n*   Prokopcova J, Kleibl Z, Banwell CM, Pohlreich P. The role of ATM in breast cancer development. Breast Cancer Res Treat. 2007 Aug;104(2):121-8.\n*   Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D; Breast Cancer Susceptibility Collaboration (UK); Easton DF, Stratton MR, Rahman N. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006 Aug;38(8):873-5.\n*   Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003 Mar;3(3):155-68.\n\n**Catalog of Genes and Diseases from OMIM**\n\nATM SERINE/THREONINE KINASE; ATM\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n---\n\n**ATM Gene**\n\n**Genomic Location**\nThe ATM gene is found on chromosome 11.\n\n*   **Related Health Topics**\n    *   Genes and Gene Therapy\n    *   Genetic Disorders\n\n**Understanding Genetics**\n\n*   What is DNA?\n*   What is a gene?\n*   What is a gene variant and how do variants occur?\n\n**Cancer Risks and Mortality**\n\nAccording to Thompson et al., heterozygous ATM mutation carriers have an increased risk of cancer. The study, published in the Journal of the National Cancer Institute, found that these individuals had a higher risk of developing certain types of cancer compared to the general population.\n\n**Initiators of Cellular Genotoxic Stress Responses**\n\nYang et al.'s study, published in Carcinogenesis, explored the role of ATM, ATR, and DNA-PK in initiating cellular responses to genotoxic stress. The researchers found that these protein kinases play a crucial role in maintaining genome integrity and preventing cancer.\n\n**Disclaimer**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ATN1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atn1/",
    "content": "**ATN1 Gene**\n\nThe ATN1 gene provides instructions for making a protein called atrophin 1. Although the exact function of this protein is unknown, it appears to play an important role in nerve cells (neurons) in many areas of the brain.\n\n**Normal Function**\n\n* The ATN1 gene contains a particular DNA segment known as a CAG trinucleotide repeat.\n* This segment is made up of a series of three DNA building blocks (cytosine, adenine, and guanine) that appear multiple times in a row.\n* In most people, the number of CAG repeats in the ATN1 gene ranges from 6 to 35.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Dentatorubral-pallidoluysian Atrophy (DRPLA)**: A progressive brain disorder that causes involuntary movements, mental and emotional problems, and a decline in thinking ability. DRPLA results from an increased number of copies (expansion) of the CAG trinucleotide repeat in the ATN1 gene.\n* **Congenital Hypotonia, Epilepsy, Developmental Delay, and Digital Anomalies (CHEDDA) Syndrome**: A very rare condition caused by variants in the ATN1 gene. Individuals with this condition have severe intellectual and developmental delays.\n\n**References**\n\n(Note: References are not included in the cleaned output as they were not provided in the original content.)\n\n---\n\n**ATN1 Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Dentatorubral-Pallidoluysian Atrophy (DRPLA)**\n\nDRPLA is a progressive brain disorder that causes involuntary movements, mental and emotional problems, and a decline in thinking ability. It results from an increased number of copies (expansion) of the CAG trinucleotide repeat in the ATN1 gene.\n\n**The Extended CAG Region**\n\nThe extended CAG region changes the structure of atrophin 1 and how the protein interacts with other proteins to control gene function. This altered protein accumulates in neurons and interferes with normal cell functions.\n\n**Involuntary Movements, Intellectual Decline, and Characteristic Features**\n\nThe dysfunction and eventual death of these neurons lead to involuntary movements, intellectual decline, and the other characteristic features of DRPLA.\n\n**Other Disorders: Congenital Hypotonia, Epilepsy, Developmental Delay, and Digital Anomalies (CHEDDA) Syndrome**\n\nVariants in the ATN1 gene can cause a very rare condition called CHEDDA syndrome. Individuals with this condition have severe intellectual and developmental delays. They also have limited or no ability to talk and cannot walk.\n\n**Features of CHEDDA Syndrome**\n\nPeople with CHEDDA can have weak muscle tone (hypotonia), recurring seizures (epilepsy), vision and hearing problems, distinctive facial features, and skeletal abnormalities. Many affected individuals have brain malformations.\n\n**ATN1 Gene Variants**\n\nThe ATN1 gene variants that cause CHEDDA syndrome occur in one of the two copies of the gene in each cell and lead to a change in single protein building blocks (amino acids) in atrophin 1.\n\n**Other Names for This Gene**\n\n* ATN1_HUMAN\n* Atrophin-1 B37\n* D12S755E\n* Dentatorubral-pallidoluysian atrophy protein\n* DRPLA NOD\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ATN1\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ATROPHIN 1; ATN1\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Chaudhry A, Anthanasiou-Fragkouli A, Houlden H. DRPLA: understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder. J Neurol. 2021 Aug;268(8):3031-3041.\n* Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Tanaka F, Adachi H, Sobue G. Molecular genetics and biomarkers of polyglutamine diseases. Curr Mol Med. 2008 May;8(3):221-34.\n* Nagafuchi S, Yanagisawa H, Ohsaki E, Shirayama T, Tadokoro K, Inoue T, Yamada M. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nat Genet. 1994 Oct;8(2):177-82.\n* Nowak B, Kozlowska E, Pawlik W, Fiszer A. Atrophin-1 Function and Dysfunction in Dentatorubral-Pallidoluysian Atrophy. Mov Disord. 2023 Apr;38(4):526-536.\n* Prades S PhD, Melo de Gusmao C MD, Grimaldi S MD, Shiloh-Malawsky Y MD, Felton T MS, CGC, Houlden H MD, PhD. DRPLA. 1999 Aug 6 [updated 2023 Sep 21].\n* Whitton C, Palmer E, Alkuraya F. ATN1-Related Neurodevelopmental Disorder. 2022 Aug 25.\n* Wood JD, Nucifora FC Jr, Duan K, Zhang C, Wang J, Kim Y, Schilling G, Sacchi N, Liu JM, Ross CA. Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription. J Cell Biol. 2000 Sep 4;150(5):939-48.\n\n---\n\n**ATN1 Gene**\n\n**What is the ATN1 gene?**\n\nThe ATN1 gene, also known as the dentatorubral and pallidoluysian atrophy (DRPLA) gene, is responsible for a rare genetic disorder called DRPLA. The gene provides instructions for making a protein called atrophin-1, which plays a crucial role in maintaining the health of neurons.\n\n**Genomic Location**\n\nThe ATN1 gene is located on chromosome 12.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ATP1A1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp1a1/",
    "content": "**ATP1A1 Gene**\n\nThe **ATP1A1 gene** provides instructions for making one part (the alpha-1 subunit) of a protein pump known as a Na+/K+ ATPase. This protein uses energy from a molecule called adenosine triphosphate (ATP) to transport charged atoms (ions) into and out of cells.\n\n* Specifically, the protein pumps sodium ions (Na+) out of cells and potassium ions (K+) into cells.\n* Na+/K+ ATPases that include the alpha-1 subunit are found in many types of cells, although the pumps appear to play a particularly important role in the adrenal glands, which are small hormone-producing glands located on top of each kidney.\n\n**Health Conditions Related to Genetic Changes**\n\nAldosterone-producing adenoma\n\n* Mutations in the **ATP1A1 gene** have been found to cause aldosterone-producing adenomas, which are noncancerous (benign) tumors that form in the adrenal glands.\n* The genetic changes involved in these tumors, called somatic mutations, are acquired during a person's lifetime and are present only in adrenal gland cells that give rise to the tumor.\n* Changes in the **ATP1A1 gene** account for approximately six percent of cases of aldosterone-producing adenoma.\n\nThe abnormal flow of ions increases aldosterone production, resulting in excess aldosterone and leading to high blood pressure (hypertension) and an increased risk of heart attack and stroke.\n\n---\n\n**ATP1A1 Gene**\n\nThe ATP1A1 gene plays a crucial role in regulating the activity of the Na+/K+ ATPase enzyme, which is essential for maintaining proper sodium and potassium levels in the body.\n\n**Charcot-Marie-Tooth Disease**\n\nMedlinePlus Genetics provides information about Charcot-Marie-Tooth disease. This condition affects the nerves outside the brain and spinal cord, causing muscle weakness and wasting.\n\n**Aldosterone-Producing Adenoma**\n\nMutations in the ATP1A1 gene have been found to cause aldosterone-producing adenomas, which are noncancerous (benign) tumors that form in the adrenal glands. These genetic changes account for approximately six percent of cases of aldosterone-producing adenoma.\n\n**Effects of ATP1A1 Gene Mutations**\n\nATP1A1 gene mutations impair the Na+/K+ ATPase's normal function, allowing sodium or hydrogen (H+) ions to enter the cell. This abnormal flow of ions increases aldosterone production, leading to excess aldosterone and high blood pressure (hypertension). Additionally, changes in adrenal gland cells due to impaired Na+/K+ ATPase function increase cell growth and division (proliferation), promoting adenoma formation.\n\n**Other Names for This Gene**\n\n* ATPase, Na+/K+ transporting, alpha 1 polypeptide\n* Na(+)/K(+) ATPase alpha-1 subunit\n* Na+/K+ ATPase 1\n* Na, K-ATPase, alpha-A catalytic polypeptide\n* Na,K-ATPase alpha-1 subunit\n* Na,K-ATPase catalytic subunit alpha-A protein\n* Sodium pump subunit alpha-1\n* Sodium-potassium ATPase catalytic subunit alpha-1\n* Sodium-potassium-ATPase, alpha 1 polypeptide\n\n**References**\n\n* Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Kusters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013 Sep;45(9):1055-60.\n* Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T, Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F, Plouin PF, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilsen B, Zennaro MC, Strom TM, Reincke M. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013 Apr;45(4):440-4.\n* Kitamoto T, Suematsu S, Yamazaki Y, Nakamura Y, Sasano H, Matsuzawa Y, Saito J, Omura M, Nishikawa T. Clinical and Steroidogenic Characteristics of Aldosterone-Producing Adenomas With ATPase or CACNA1D Gene Mutations. J Clin Endocrinol Metab. 2016 Feb;101(2):494-503.\n* Stindl J, Tauber P, Sterner C, Tegtmeier I, Warth R, Bandulik S. Pathogenesis of Adrenal Aldosterone-Producing Adenomas Carrying Mutations of the Na(+)/K(+)-ATPase. Endocrinology. 2015 Dec;156(12):4582-91.\n\n---\n\n**ATP1A1 Gene**\n\n**Genomic Location**\nThe ATP1A1 gene is found on chromosome 1.\n\n* **Related Health Topics**\n\t+ Genes and Gene Therapy\n\t+ Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Clinical and Steroidogenic Characteristics of Aldosterone-Producing Adenomas With ATPase or CACNA1D Gene Mutations**\n\nKitamoto T, Suematsu S, Yamazaki Y, Nakamura Y, Sasano H, Matsuzawa Y, Saito\nJ, Omura M, Nishikawa T. J Clin Endocrinol Metab. 2016 Feb;101(2):494-503.\n\n**Pathogenesis of Adrenal Aldosterone-Producing Adenomas Carrying Mutations of the Na(+)/K(+)-ATPase**\n\nStindl J, Tauber P, Sterner C, Tegtmeier I, Warth R, Bandulik S. Endocrinology. 2015 Dec;156(12):4582-91.\n\n**Disclaimer**\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ATP1A2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp1a2/",
    "content": "**ATP1A2 Gene**\n\nThe ATP1A2 gene provides instructions for making one part (the alpha-2 subunit) of a protein known as a Na+/K+ ATPase. This protein uses energy from a molecule called adenosine triphosphate (ATP) to transport charged atoms (ions) into and out of cells. Specifically, it pumps sodium ions (Na+) out of cells and potassium ions (K+) into cells.\n\n**Normal Function**\n\n* The ATP1A2 gene provides instructions for making one part (the alpha-2 subunit) of a protein known as a Na+/K+ ATPase.\n* This protein uses energy from a molecule called adenosine triphosphate (ATP) to transport charged atoms (ions) into and out of cells.\n* Specifically, it pumps sodium ions (Na+) out of cells and potassium ions (K+) into cells.\n* Na+/K+ ATPases that include the alpha-2 subunit are primarily found in nervous system cells called glia, which protect and maintain nerve cells (neurons).\n* Through its action in glia, the protein plays a critical role in the normal function of neurons.\n* Communication between neurons depends on chemicals called neurotransmitters.\n* To relay signals, a neuron releases neurotransmitters, which attach to receptor proteins on neighboring neurons.\n* After the neurotransmitters have had their effect, they detach from their receptors and are removed from the spaces between neurons by glia.\n* This process is carefully regulated to ensure that signals are transmitted accurately throughout the nervous system.\n* The Na+/K+ ATPase helps regulate this process by stimulating glia to clear neurotransmitters from the spaces between neurons.\n* This protein also removes excess potassium ions from these spaces.\n\n**Health Conditions Related to Genetic Changes**\n\n* Alternating hemiplegia of childhood\n\t+ At least one mutation in the ATP1A2 gene can cause alternating hemiplegia of childhood.\n\t+ The primary feature of this condition is recurrent episodes of temporary paralysis, often affecting one side of the body (hemiplegia).\n\t+ During some episodes, the paralysis alternates from one side to the other or affects both sides of the body at the same time.\n\t+ The known ATP1A2 gene mutation associated with this condition replaces a single protein building block (amino acid) in Na+/K+ ATPase: the amino acid threonine is replaced with the amino acid asparagine at protein position 378 (written as Thr378Asn or T378N).\n\t+ This genetic change probably impairs the protein's ability to transport ions, although it is unclear how the mutation leads to the specific features of alternating hemiplegia of childhood.\n\n---\n\n**ATP1A2 Gene: MedlinePlus Genetics**\n\n*   **Familial Hemiplegic Migraine**\n    More than 30 mutations in the ATP1A2 gene have been identified in people with familial hemiplegic migraine type 2 (FHM2). This condition is characterized by migraine headaches with a pattern of neurological symptoms known as aura. In FHM2, the aura includes temporary numbness or weakness on one side of the body (hemiparesis).\n*   **Sporadic Hemiplegic Migraine**\n    ATP1A2 gene mutations can also cause sporadic hemiplegic migraine. The signs and symptoms of this condition are identical to those of FHM2; however, sporadic hemiplegic migraine occurs in people with no family history of the condition.\n*   **Alternating Hemiplegia of Childhood**\n    At least one mutation in the ATP1A2 gene can cause alternating hemiplegia of childhood. The primary feature of this condition is recurrent episodes of temporary paralysis, often affecting one side of the body (hemiplegia). During some episodes, the paralysis alternates from one side to the other or affects both sides of the body at the same time.\n\n---\n\n**ATP1A2 Gene: MedlinePlus Genetics (Part 3/4)**\n\n**Sporadic Hemiplegic Migraine**\n\nThe ATP1A2 gene mutations can also cause sporadic hemiplegic migraine. The signs and symptoms of this condition are identical to those of FHM2; however, sporadic hemiplegic migraine occurs in people with no family history of the condition.\n\n**Other Names for This Gene**\n\n*   ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide\n*   ATPase, Na+/K+ transporting, alpha 2 polypeptide\n*   FHM2\n*   MHP2\n*   Na+/K+ -ATPase alpha 2 subunit\n*   proprotein Na+/K+ ATPase 2\n*   Na+/K+ ATPase, alpha-A(+) catalytic polypeptide\n*   Na+/K+ ATPase, alpha-B polypeptide\n*   sodium pump 2\n*   sodium pump subunit alpha-2\n*   sodium-potassium ATPase\n*   sodium/potassium-transporting ATPase alpha-2 chain\n\n**Additional Information & Resources**\n\n*   Tests Listed in the Genetic Testing Registry:\n    *   Tests of ATP1A2\n*   Scientific Articles on PubMed:\n    *   PubMed\n*   Catalog of Genes and Diseases from OMIM:\n    *   ATPase, Na+/K+ TRANSPORTING, ALPHA-2 POLYPEPTIDE; ATP1A2\n*   Gene and Variant Databases:\n    *   NCBI Gene\n    *   ClinVar\n\n**References**\n\n*   Bassi MT, Bresolin N, Tonelli A, Nazos K, Crippa F, Baschirotto C, Zucca C, Bersano A, Dolcetta D, Boneschi FM, Barone V, Casari G. A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood. J Med Genet. 2004 Aug;41(8):621-8.\n*   Castro MJ, Nunes B, de Vries B, Lemos C, Vanmolkot KR, van den Heuvel JJ, Temudo T, Barros J, Sequeiros J, Frants RR, Koenderink JB, Pereira-Monteiro JM, van den Maagdenberg AM. Two novel functional mutations in the Na+,K+-ATPase alpha2-subunit ATP1A2 gene in patients with familial hemiplegic migraine and associated neurological phenotypes. Clin Genet. 2008 Jan;73(1):37-43.\n*   de Vries B, Freilinger T, Vanmolkot KR, Koenderink JB, Stam AH, Terwindt GM, Babini E, van den Boogerd EH, van den Heuvel JJ, Frants RR, Haan J, Pusch M, van den Maagdenberg AM, Ferrari MD, Dichgans M. Systematic analysis of three FHM genes in 39 sporadic patients with hemiplegic migraine. Neurology. 2007 Dec 4;69(23):2170-6.\n*   Jurkat-Rott K, Freilinger T, Dreier JP, Herzog J, Gobel H, Petzold GC, Montagna P, Gasser T, Lehmann-Horn F, Dichgans M. Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants. Neurology. 2004 May 25;62(10):1857-61.\n*   Pietrobon D. Familial hemiplegic migraine. Neurotherapeutics. 2007 Apr;4(2):274-84.\n*   Riant F, De Fusco M, Aridon P, Ducros A, Ploton C, Marchelli F, Maciazek J, Bousser MG, Casari G, Tournier-Lasserve E. ATP1A2 mutations in 11 families with familial hemiplegic migraine. Hum Mutat. 2005 Sep;26(3):281.\n*   Riant F, Ducros A, Ploton C, Barbance C, Depienne C, Tournier-Lasserve E. De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine. Neurology. 2010 Sep 14;75(11):967-72.\n*   Swoboda KJ, Kanavakis E, Xaidara A, Johnson JE, Leppert MF, Schlesinger-Massart MB, Ptacek LJ, Silver K, Youroukos S. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. Ann Neurol. 2004 Jun;55(6):884-7.\n*   Tavraz NN, Durr KL, Koenderink JB, Freilinger T, Bamberg E, Dichgans M, Friedrich T. Impaired plasma membrane targeting or protein stability by certain ATP1A2 mutations identified in sporadic or familial hemiplegic migraine. Channels (Austin). 2009 Mar-Apr;3(2):82-7.\n\n---\n\n**ATP1A2 Gene**\n\n**MedlinePlus Genetics**\n\nThe ATP1A2 gene is associated with familial hemiplegic migraine, a rare and severe form of migraine with aura. Research has identified several mutations in the ATP1A2 gene that are linked to this condition.\n\n**Studies on ATP1A2 Mutations**\n\n*   Reilinger et al. (2004) found novel A1A2 Na+/K+-ATPase variants in familial hemiplegic migraine patients.\n*   Pietrobon (2007) discussed the genetic basis of familial hemiplegic migraine, including mutations in the ATP1A2 gene.\n*   Riant et al. (2005) identified ATP1A2 mutations in 11 families with familial hemiplegic migraine.\n*   Riant et al. (2010) discovered de novo mutations in ATP1A2 and CACNA1A in early-onset sporadic hemiplegic migraine patients.\n*   Swoboda et al. (2004) reported a novel ATP1A2 mutation in a patient with alternating hemiplegia of childhood or familial hemiplegic migraine.\n*   Tavraz et al. (2009) investigated the effects of certain ATP1A2 mutations on plasma membrane targeting and protein stability.\n\n**Genomic Location**\n\nThe ATP1A2 gene is located on chromosome 1.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ATP1A3 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp1a3/",
    "content": "**ATP1A3 Gene**\n\nThe **ATP1A3 gene** provides instructions for making one part (the alpha-3 subunit) of a protein known as Na+/K+ ATPase or the sodium pump. This protein uses energy from a molecule called adenosine triphosphate (ATP) to transport charged atoms (ions) into and out of cells.\n\n**Normal Function**\n\n* The ATP1A3 gene is critical for normal function of nerve cells in the brain (neurons).\n* The movement of sodium and potassium ions helps regulate the electrical activity of these cells and plays an important role in the signaling process that controls muscle movement.\n* The activity of Na+/K+ ATPase also helps regulate cell size (volume).\n* Additionally, Na+/K+ ATPase helps regulate a process called neurotransmitter reuptake.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Alternating Hemiplegia of Childhood**: Variants in the ATP1A3 gene are the primary cause of this neurological condition.\n\t+ Characterized by recurrent episodes of temporary paralysis that often affects only one side of the body (hemiplegia).\n\t+ During some episodes, the paralysis alternates from one side to the other or affects both sides of the body at the same time.\n\t+ Most ATP1A3 gene variants associated with alternating hemiplegia of childhood change single protein building blocks (amino acids) in the alpha-3 subunit of Na+/K+ ATPase.\n\n---\n\n**ATP1A3 Gene**\n\n**Rapid-onset Dystonia Parkinsonism**\n\nMultiple variants in the ATP1A3 gene have been found to cause a rare movement disorder called rapid-onset dystonia parkinsonism. This disorder is characterized by the abrupt appearance of signs and symptoms over a period of hours to days. Most of the ATP1A3 gene variants that cause this disorder change single amino acids in the alpha-3 subunit of Na+/K+ ATPase. Changes in the protein's structure can reduce its activity or make it unstable. Studies suggest that the defective Na+/K+ ATPase is unable to transport sodium ions normally, which disrupts the electrical activity of neurons in the brain. However, it is unclear how a malfunctioning Na+/K+ ATPase causes the movement abnormalities seen in people with rapid-onset dystonia parkinsonism.\n\n**Other Disorders**\n\nVariants in the ATP1A3 gene can cause a group of features: cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss. This specific presentation is known as CAPOS syndrome (the abbreviation comes from the first letter of each feature). Affected individuals usually develop signs and symptoms of CAPOS syndrome in infancy or early childhood during or following an illness that causes a fever. To date, all instances of CAPOS syndrome have been caused by the same variant in the ATP1A3 gene. This change replaces the amino acid glutamic acid with the amino acid lysine at position 818 in the alpha-3 subunit of Na+/K+ ATPase (written as Glu818Lys or E818K). This genetic change appears to impair the pump's ability to transport ions, although it is unclear how the variant causes the specific features of CAPOS syndrome.\n\n**Alternating Hemiplegia of Childhood**\n\nVariants in the ATP1A3 gene are the primary cause of a neurological condition called alternating hemiplegia of childhood. This condition is characterized by recurrent episodes of temporary paralysis that often affects only one side of the body (hemiplegia). During some episodes, the paralysis alternates from one side to the other or affects both sides of the body at the same time. Most ATP1A3 gene variants associated with alternating hemiplegia of childhood change single protein building blocks (amino acids) in the alpha-3 subunit of Na+/K+ ATPase. These genetic changes appear to impair the pump's ability to transport ions, although it is unclear how the variants lead to the specific features of alternating hemiplegia of childhood.\n\n---\n\n**ATP1A3 Gene**\n\nThe ATP1A3 gene is associated with a group of features including cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss. This specific presentation is known as CAPOS syndrome (the abbreviation comes from the first letter of each feature).\n\n**CAPOS Syndrome**\n\nAffected individuals usually develop signs and symptoms of CAPOS syndrome in infancy or early childhood during or following an illness that causes a fever.\n\n**ATP1A3 Gene Mutation**\n\nTo date, all instances of CAPOS syndrome have been caused by the same variant in the ATP1A3 gene. This change replaces the amino acid glutamic acid with the amino acid lysine at position 818 in the alpha-3 subunit of Na+/K+ ATPase (written as Glu818Lys or E818K).\n\n**Other Names for This Gene**\n\n* ATPase, Na+/K+ transporting, alpha 3 polypeptide\n* Na+/K+ -ATPase alpha 3 subunit\n* Na+/K+ ATPase 3\n* Sodium pump 3\n* Sodium-potassium-ATPase, alpha 3 polypeptide\n* Sodium/potassium-transporting ATPase alpha-3 chain\n\n**References**\n\n* Blanco-Arias P, Einholm AP, Mamsa H, Concheiro C, Gutierrez-de-Teran H, Romero J, Toustrup-Jensen MS, Carracedo A, Jen JC, Vilsen B, Sobrido MJ. A C-terminal mutation of ATP1A3 underscores the crucial role of sodium affinity in the pathophysiology of rapid-onset dystonia-parkinsonism. Hum Mol Genet. 2009 Jul 1;18(13):2370-7.\n* Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJ, Gollamudi S, Green A, Guimaraes J, Haake BC, Klein C, Linazasoro G, Munchau A, Raymond D, Riley D, Saunders-Pullman R, Tijssen MA, Webb D, Zaremba J, Bressman SB, Ozelius LJ. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain. 2007 Mar;130(Pt 3):828-35.\n* Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, Tiziano FD, Fontaine B, Walley NM, Heavin S, Panagiotakaki E. De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet. 2012 Sep;44(9):1030-4.\n* Rodacker V, Toustrup-Jensen M, Vilsen B. Mutations Phe785Leu and Thr618Met in Na+,K+-ATPase, associated with familial rapid-onset dystonia parkinsonism, interfere with Na+ interaction by distinct mechanisms. J Biol Chem. 2006 Jul 7;281(27):18539-48.\n* Rosewich H, Thiele H, Ohlenbusch A, Maschke U, Altmuller J, Frommolt P, Zirn B, Ebinger F, Siemes H, Nurnberg P, Brockmann K, Gartner J. Heterozygous de-novo mutations in ATP1A3 in patients with alternating hemiplegia of childhood: a whole-exome sequencing gene-identification study. Lancet Neurol. 2012 Sep;11(9):764-73.\n* Zanotti-Fregonara P, Vidailhet M, Kas A, Ozelius LJ, Clot F, Hindie E, Ravasi L, Devaux JY, Roze E. [123I]-FP-CIT and [99mTc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystonia-parkinsonism. J Neurol Sci. 2008 Oct 15;273(1-2):148-51.\n\nNote: The references provided are a selection of the most relevant scientific articles related to the ATP1A3 gene and its association with CAPOS syndrome and other conditions.\n\n---\n\n**ATP1A3 Gene**\n\n**What is the ATP1A3 gene?**\n\nThe ATP1A3 gene is located on chromosome 19 and plays a crucial role in encoding the Na+/K+ -ATPase alpha3 subunit, which is essential for maintaining proper ion balances within cells.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Genomic Location**\n\nThe ATP1A3 gene is found on chromosome 19.\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ATP2A1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp2a1/",
    "content": "**ATP2A1 Gene**\n\nThe ATP2A1 gene provides instructions for making an enzyme called sarco(endo)plasmic reticulum calcium-ATPase 1 (SERCA1). This enzyme belongs to a family of ATPase enzymes that help control the level of positively charged calcium atoms (calcium ions) inside cells. The SERCA1 enzyme is found in skeletal muscle cells.\n\n**Normal Function**\n\nWithin muscle cells, the SERCA1 enzyme is located in the membrane of a structure called the sarcoplasmic reticulum. This structure plays a major role in muscle contraction and relaxation by storing and releasing calcium ions. When calcium ions are transported out of the sarcoplasmic reticulum, muscles contract; when calcium ions are transported into the sarcoplasmic reticulum, muscles relax. The SERCA1 enzyme transports calcium ions from the cell into the sarcoplasmic reticulum, triggering muscle relaxation.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Brody Myopathy**: At least 10 mutations in the ATP2A1 gene have been found to cause Brody myopathy, a muscle disorder characterized by muscle cramping after exercise. Most ATP2A1 gene mutations lead to a premature stop signal in the instructions for making the SERCA1 enzyme, resulting in a nonfunctional enzyme. Other mutations lead to the production of a SERCA1 enzyme with decreased function. As a result, calcium ions are slow to enter the sarcoplasmic reticulum and muscle relaxation is delayed. After exercise or other strenuous activity, during which the muscles rapidly contract and relax, people with Brody myopathy develop muscle cramps because their muscles cannot fully relax.\n\n---\n\n**ATP2A1 Gene: MedlinePlus Genetics**\n\n**What is the ATP2A1 gene?**\n\nThe ATP2A1 gene provides instructions for making the SERCA1 enzyme, which plays a crucial role in muscle relaxation. This enzyme helps transport calcium ions into the sarcoplasmic reticulum, a type of cellular storage compartment.\n\n**How does the ATP2A1 gene relate to Brody myopathy?**\n\nMutations in the ATP2A1 gene have been found to cause Brody myopathy, a muscle disorder characterized by muscle cramping after exercise. Most ATP2A1 gene mutations lead to a premature stop signal in the instructions for making the SERCA1 enzyme, resulting in a nonfunctional enzyme. Other mutations lead to the production of a SERCA1 enzyme with decreased function.\n\n**What are the symptoms of Brody myopathy?**\n\nPeople with Brody myopathy develop muscle cramps after exercise or other strenuous activity, during which the muscles rapidly contract and relax. This is because their muscles cannot fully relax due to the delayed transportation of calcium ions into the sarcoplasmic reticulum.\n\n**Other Names for This Gene**\n\n* AT2A1_HUMAN\n* ATP2A\n* ATPase, Ca++ transporting, cardiac muscle, fast twitch 1\n* calcium-transporting ATPase sarcoplasmic reticulum type, fast twitch skeletal muscle isoform 1\n* endoplasmic reticulum class 1 Ca2+ ATPase\n* sarcoplasmic/endoplasmic reticulum calcium ATPase 1\n* SERCA1\n* SR Ca2+ ATPase 1\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry: Tests of ATP2A1\n* Scientific Articles on PubMed: PubMed\n* Catalog of Genes and Diseases from OMIM: ATPase, Ca(2+)-TRANSPORTING, FAST-TWITCH 1; ATP2A1\n* Gene and Variant Databases: NCBI Gene, ClinVar\n\n**References**\n\n* Odermatt A, Taschner PE, Khanna VK, Busch HF, Karpati G, Jablecki CK, Breuning MH, MacLennan DH. Mutations in the gene-encoding SERCA1, the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+ ATPase, are associated with Brody disease. Nat Genet. 1996 Oct;14(2):191-4.\n* Shull GE, Okunade G, Liu LH, Kozel P, Periasamy M, Lorenz JN, Prasad V. Physiological functions of plasma membrane and intracellular Ca2+ pumps revealed by analysis of null mutants. Ann N Y Acad Sci. 2003 Apr;986:453-60.\n* Vattemi G, Gualandi F, Oosterhof A, Marini M, Tonin P, Rimessi P, Neri M, Guglielmi V, Russignan A, Poli C, van Kuppevelt TH, Ferlini A, Tomelleri G. Brody disease: insights into biochemical features of SERCA1 and identification of a novel mutation. J Neuropathol Exp Neurol. 2010 Mar;69(3):246-52.\n\n**Genomic Location**\n\nThe ATP2A1 gene is found on chromosome 16.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ATP2A2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp2a2/",
    "content": "**ATP2A2 Gene**\n\nThe **ATP2A2** gene provides instructions for making an enzyme called sarco(endo)plasmic reticulum calcium-ATPase 2 (SERCA2). This enzyme belongs to a family of ATPase enzymes that helps control the level of positively charged calcium atoms (calcium ions) inside cells.\n\n**Normal Function**\n\n* The **ATP2A2** gene provides instructions for making an enzyme called sarco(endo)plasmic reticulum calcium-ATPase 2 (SERCA2).\n* SERCA2 is found in the endoplasmic reticulum inside the cell and in a related structure called the sarcoplasmic reticulum inside muscle cells.\n* The endoplasmic reticulum is a structure that is involved in protein processing and transport.\n* The sarcoplasmic reticulum assists with muscle contraction and relaxation by releasing and storing calcium ions.\n* Calcium ions act as signals for a large number of activities that are important for the normal development and function of cells.\n* SERCA2 allows calcium ions to pass into and out of the cell in response to cell signals.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Darier Disease**: Over 100 variants (also called mutations) in the **ATP2A2** gene have been found to cause Darier disease. This disorder is a skin condition characterized by wart-like blemishes on the body.\n* Most of these variants change a single protein building block (amino acid) in the SERCA2 enzyme.\n* The variants that cause Darier disease prevent cells from producing enough SERCA2, or they cause cells to produce nonfunctional versions of SERCA2.\n* Cells with only one functional copy of the **ATP2A2** gene produce half the normal amount of SERCA2 protein. It is thought that insufficient amounts of SERCA2 combined with outside factors such as heat and minor injuries cause the signs and symptoms of Darier disease.\n\n---\n\n**ATP2A2 Gene**\n\n**What is the ATP2A2 gene?**\n\nThe ATP2A2 gene provides instructions for making a protein called SERCA2, which plays a crucial role in muscle function and calcium regulation. Mutations in this gene can lead to Darier disease, a rare genetic disorder characterized by abnormal keratinocyte growth.\n\n**How does the ATP2A2 gene work?**\n\nThe ATP2A2 gene contains instructions for producing SERCA2 protein, which is responsible for pumping calcium ions into muscle cells. Without sufficient SERCA2 protein, muscle cells may not function properly, leading to symptoms of Darier disease.\n\n**What are the consequences of ATP2A2 gene mutations?**\n\nMutations in the ATP2A2 gene can result in insufficient or nonfunctional SERCA2 protein production. This can lead to a range of symptoms associated with Darier disease, including abnormal keratinocyte growth, skin lesions, and other systemic problems.\n\n**Other Names for This Gene**\n\n* AT2A2_HUMAN\n* ATPase, Ca++ dependent, slow-twitch, cardiac muscle-2\n* ATPase, Ca++ transporting, cardiac muscle, slow twitch 2\n* Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform\n* Sarcoplasmic reticulum Ca(2+)-ATPase 2\n* SERCA2\n* SR Ca(2+)-ATPase 2\n\n**Genomic Location**\n\nThe ATP2A2 gene is located on chromosome 12.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders",
    "category": "general"
  },
  {
    "title": "ATP2C1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp2c1/",
    "content": "**ATP2C1 Gene**\n\nThe ATP2C1 gene provides instructions for making a protein called hSPCA1. This protein is an adenosine triphosphate (ATP)-powered calcium pump, which uses energy from ATP molecules to pump charged calcium atoms (calcium ions) across cell membranes.\n\n**Normal Function**\n\n* The hSPCA1 protein transports calcium ions into a cell structure called the Golgi apparatus, where they are stored until needed.\n* The appropriate storage and release of calcium is essential for many cell activities, including:\n\t+ Cell growth and division (proliferation)\n\t+ Cell movement (migration)\n\t+ Attachment of cells to one another (cell adhesion)\n* The hSPCA1 protein also transports manganese ions into the Golgi apparatus. Manganese works with a variety of enzymes and is involved in processing newly formed proteins.\n* The hSPCA1 protein is present in cells throughout the body, particularly important for the normal function of keratinocytes, which are found in the outer layer of the skin (the epidermis).\n\n**Health Conditions Related to Genetic Changes**\n\nHailey-Hailey disease is a rare skin condition characterized by red, raw, and blistered areas of skin that can become infected. More than 200 mutations in the ATP2C1 gene have been found to cause this disease.\n\n* Mutations in this gene reduce the amount of functional hSPCA1 protein, which impairs the storage of calcium ions in the Golgi apparatus.\n* For unknown reasons, this abnormal calcium storage affects keratinocytes more than other types of cells.\n* Problems with calcium regulation impair many cell functions, including:\n\t+ Cell adhesion\n\t+ Barrier function of the skin\n* As a result, keratinocytes do not stick tightly to one another, causing the epidermis to become fragile and less resistant to minor trauma.\n\n---\n\n**ATP2C1 Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Hailey-Hailey Disease**\n\nMore than 200 mutations in the ATP2C1 gene have been found to cause Hailey-Hailey disease, a rare skin condition characterized by red, raw, and blistered areas of skin that can become infected. Mutations in this gene reduce the amount of functional hSPCA1 protein, which impairs the storage of calcium ions in the Golgi apparatus.\n\n**How It Affects the Skin**\n\nFor unknown reasons, this abnormal calcium storage affects keratinocytes more than other types of cells. Problems with calcium regulation impair many cell functions, including cell adhesion. As a result, keratinocytes do not stick tightly to one another, which causes the epidermis to become fragile and less resistant to minor trauma.\n\n**Symptoms**\n\nBecause the skin is easily damaged, it develops raw, blistered areas, particularly in skin folds where there is moisture and friction. In addition, abnormal calcium regulation disrupts the barrier function of the skin, making it more susceptible to infections.\n\n**Other Names for This Gene**\n\n* AT2C1_HUMAN\n* ATP-dependent Ca(2+) pump PMR1\n* ATPase 2C1\n* ATPase, Ca(2+)-sequestering\n* ATPase, Ca++ transporting, type 2C, member 1\n* BCPM\n* Calcium-transporting ATPase type 2C member 1\n* HHD\n* hSPCA1\n* HUSSY-28\n* KIAA1347\n* PMR1 secretory pathway Ca2+/Mn2+ ATPase 1\n* SPCA1\n\n**Additional Information & Resources**\n\n* Tests Listed in the Genetic Testing Registry:\n\t+ Tests of ATP2C1\n* Scientific Articles on PubMed:\n\t+ PubMed\n* Catalog of Genes and Diseases from OMIM:\n\t+ ATPase, Ca(2+)-TRANSPORTING, TYPE 2C, MEMBER 1; ATP2C1\n* Gene and Variant Databases:\n\t+ NCBI Gene\n\t+ ClinVar\n\n**References**\n\n* Behne MJ, Tu CL, Aronchik I, Epstein E, Bench G, Bikle DD, Pozzan T, Mauro TM. Human keratinocyte ATP2C1 localizes to the Golgi and controls Golgi Ca2+ stores. J Invest Dermatol. 2003 Oct;121(4):688-94. doi: 10.1046/j.1523-1747.2003.12528.x.\n* Dobson-Stone C, Fairclough R, Dunne E, Brown J, Dissanayake M, Munro CS, Strachan T, Burge S, Sudbrak R, Monaco AP, Hovnanian A. Hailey-Hailey disease: molecular and clinical characterization of novel mutations in the ATP2C1 gene. J Invest Dermatol. 2002 Feb;118(2):338-43. doi: 10.1046/j.0022-202x.2001.01675.x.\n* Hu Z, Bonifas JM, Beech J, Bench G, Shigihara T, Ogawa H, Ikeda S, Mauro T, Epstein EH Jr. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat Genet. 2000 Jan;24(1):61-5. doi: 10.1038/71701.\n* Missiaen L, Dode L, Vanoevelen J, Raeymaekers L, Wuytack F. Calcium in the Golgi apparatus. Cell Calcium. 2007 May;41(5):405-16. doi: 10.1016/j.ceca.2006.11.001.\n* Missiaen L, Raeymaekers L, Dode L, Vanoevelen J, Van Baelen K, Parys JB, Callewaert G, De Smedt H, Segaert S, Wuytack F. SPCA1 pumps and Hailey-Hailey disease. Biochem Biophys Res Commun. 2004 Oct 1;322(4):1204-13. doi: 10.1016/j.bbrc.2004.07.128.\n* Sudbrak R, Brown J, Dobson-Stone C, Carter S, Ramser J, White J, Healy E, Dissanayake M, Larregue M, Perrussel M, Lehrach H, Munro CS, Strachan T, Burge S, Hovnanian A, Monaco AP. Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca(2+) pump. Hum Mol Genet. 2000 Apr 12;9(7):1131-40. doi: 10.1093/hmg/9.7.1131.\n\n---\n\n**ATP2C1 Gene**\n\n**Genomic Location**\nThe ATP2C1 gene is found on chromosome 3.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ATP6V0A2 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp6v0a2/",
    "content": "**ATP6V0A2 Gene**\n\nThe ATP6V0A2 gene provides instructions for making one part, the a2 subunit, of a large protein complex (a group of proteins that work together). This protein complex is known as a vacuolar H+-ATPase (V-ATPase). A V-ATPase acts as a pump to move positively charged hydrogen atoms (protons) across cell membranes.\n\n**Normal Function**\n\n*   V-ATPases are embedded in the membranes surrounding cells, where they transport protons into and out of cells. This movement of protons helps regulate the relative acidity (pH) of cells and their surrounding environment.\n*   Within cells, V-ATPases help regulate the pH of particular cell compartments, including endosomes and lysosomes, which digest and recycle materials that the cell no longer needs.\n*   Studies suggest that V-ATPases are also involved in the movement (trafficking) of small sac-like structures called vesicles. Vesicles transport many types of molecules within cells.\n*   V-ATPases play a key role in a complex process called glycosylation, in which proteins are modified by adding sugar molecules. Glycosylation is necessary for the normal function of many different kinds of proteins.\n\n**Health Conditions Related to Genetic Changes**\n\nMore than 40 variants (also known as mutations) in the ATP6V0A2 gene have been identified in people with cutis laxa. ATP6V0A2 variants cause a form of the disorder called autosomal recessive cutis laxa type 2A (ARCL2A), which is characterized by loose, sagging skin; distinctive facial features; and larger than normal spaces (fontanelles) between the skull bones that close later than usual. Some affected individuals also have delayed development, intellectual disability, seizures, or problems with movement that can worsen over time.\n\n---\n\n**ATP6V0A2 Gene**\n\n**Variants in this gene cause cutis laxa and wrinkly skin syndrome**\n\nCutis laxa is a rare genetic disorder characterized by loose, sagging skin. Variants in the ATP6V0A2 gene have been identified in over 40 individuals with cutis laxa. One form of the disorder, called autosomal recessive cutis laxa type 2A (ARCL2A), is caused by variants in this gene and is characterized by loose, sagging skin; distinctive facial features; and larger than normal spaces between the skull bones that close later than usual.\n\nSome individuals with ARCL2A also experience delayed development, intellectual disability, seizures, or problems with movement that can worsen over time. Variants in this gene also cause a related condition called wrinkly skin syndrome, which typically has milder features.\n\n**How genetic changes affect the body**\n\nVariants in the ATP6V0A2 gene prevent the cell from producing a functional a2 subunit, which disrupts the normal function of V-ATPases. It is unclear how these genetic changes cause the signs and symptoms of cutis laxa. Researchers suspect that changes in V-ATPase function may disrupt the normal glycosylation of proteins, including several that are involved in the assembly and maintenance of elastic fibers.\n\nElastic fibers are slender bundles of proteins that provide strength and flexibility to connective tissue (tissue that supports the body's joints and organs). People with cutis laxa have a reduced density of elastic fibers, which weakens connective tissue in the skin, lungs, and other organs. These defects in connective tissue underlie many of the major features of the disorder.\n\n**Classification as a congenital disorder of glycosylation**\n\nBecause problems with glycosylation underlie ARCL2A, the condition is classified as a congenital disorder of glycosylation.\n\n**Other names for this gene**\n\n* A2V-ATPase\n* ATP6a2\n* ATP6N1D\n* ATPase, H+ transporting, lysosomal V0 subunit a2\n* J6B7\n* Stv1\n* TJ6\n* TJ6M\n* TJ6s\n* Vph1\n* VPP2_HUMAN\n\n**Additional information and resources**\n\n* Tests listed in the Genetic Testing Registry:\n\t+ Tests of ATP6V0A2\n* Scientific articles on PubMed:\n\t+ PubMed\n* Catalog of genes and diseases from OMIM:\n\t+ ATPase, H+ transporting, lysosomal, V0 subunit a2; ATP6V0A2\n\n---\n\n**ATP6V0A2 Gene**\n\n**Genomic Location**\nThe ATP6V0A2 gene is found on chromosome 12.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Scientific Articles on PubMed**\n\n* Guillard M, Dimopoulou A, Fischer B, Morava E, Lefeber DJ, Kornak U, Wevers RA. Vacuolar H+-ATPase meets glycosylation in patients with cutis laxa. Biochim Biophys Acta. 2009 Sep;1792(9):903-14.\n* Hucthagowder V, Morava E, Kornak U, Lefeber DJ, Fischer B, Dimopoulou A, Aldinger A, Choi J, Davis EC, Abuelo DN, Adamowicz M, Al-Aama J, Basel-Vanagaite L, Fernandez B, Greally MT, Gillessen-Kaesbach G, Kayserili H, Lemyre E, Tekin M, Turkmen S, Tuysuz B, Yuksel-Konuk B, Mundlos S, Van Maldergem L, Wevers RA, Urban Z. Loss-of-function mutations in ATP6V0A2 impair vesicular trafficking, tropoelastin secretion and cell survival. Hum Mol Genet. 2009 Jun 15;18(12):2149-65.\n* Kornak U, Reynders E, Dimopoulou A, van Reeuwijk J, Fischer B, Rajab A, Budde B, Nurnberg P, Foulquier F; ARCL Debre-type Study Group; Lefeber D, Urban Z, Gruenewald S, Annaert W, Brunner HG, van Bokhoven H, Wevers R, Morava E, Matthijs G, Van Maldergem L, Mundlos S. Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. Nat Genet. 2008 Jan;40(1):32-4.\n* Marshansky V, Futai M. The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function. Curr Opin Cell Biol. 2008 Aug;20(4):415-26.\n* Marshansky V. The V-ATPase a2-subunit as a putative endosomal pH-sensor. Biochem Soc Trans. 2007 Nov;35(Pt 5):1092-9.\n* Morava E, Lefeber DJ, Urban Z, de Meirleir L, Meinecke P, Gillessen Kaesbach G, Sykut-Cegielska J, Adamowicz M, Salafsky I, Ranells J, Lemyre E, van Reeuwijk J, Brunner HG, Wevers RA. Defining the phenotype in an autosomal recessive cutis laxa syndrome with a combined congenital defect of glycosylation. Eur J Hum Genet. 2008 Jan;16(1):28-35.\n\n**Catalog of Genes and Diseases from OMIM**\n\n* ATPase, H+ TRANSPORTING, LYSOSOMAL, V0 SUBUNIT A2; ATP6V0A2\n\n**Gene and Variant Databases**\n\n* NCBI Gene\n* ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n* Tests of ATP6V0A2",
    "category": "general"
  },
  {
    "title": "ATP6V0A4 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp6v0a4/",
    "content": "**ATP6V0A4 Gene**\n\nThe ATP6V0A4 gene provides instructions for making a part (subunit) of a large protein complex known as vacuolar H+-ATPase (V-ATPase). V-ATPases are a group of similar complexes that act as pumps to move positively charged hydrogen atoms (protons) across membranes. Because acids are substances that can \"donate\" protons to other molecules, this movement of protons helps regulate the relative acidity (pH) of cells and their surrounding environment. Tight control of pH is necessary for most biological reactions to proceed properly.\n\nThe V-ATPase that includes the subunit produced from the ATP6V0A4 gene is found in the inner ear and in nephrons, which are the functional structures within the kidneys. The kidneys filter waste products from the blood and remove them in urine. They also reabsorb needed nutrients and release them back into the blood. Each nephron consists of two parts: a renal corpuscle (also known as a glomerulus) that filters the blood, and a renal tubule that reabsorbs substances that are needed and eliminates unneeded substances in urine. The V-ATPase is involved in regulating the amount of acid that is removed from the blood into the urine, and also in maintaining the proper pH of the fluid in the inner ear (endolymph).\n\n**Health Conditions Related to Genetic Changes**\n\n*   **Renal Tubular Acidosis with Deafness**: Several ATP6V0A4 gene mutations have been identified in people with renal tubular acidosis with deafness, a disorder involving excess acid in the blood (metabolic acidosis), bone weakness, and hearing loss caused by changes in the inner ear (sensorineural hearing loss). Mutations in the ATP6V0A4 gene impair the function of the V-ATPase proton pump. As a result, the kidneys are less able to control the acidity of the blood, which leads to bone weakness caused by loss of bone minerals (demineralization) and other consequences of metabolic acidosis. The body's capability to control the pH of the fluid in the inner ear is also impaired, resulting in sensorineural hearing loss.\n\n---\n\n**ATP6V0A4 Gene**\n\n**Renal Tubular Acidosis with Deafness**\n\nSeveral ATP6V0A4 gene mutations have been identified in people with renal tubular acidosis with deafness, a disorder involving excess acid in the blood (metabolic acidosis), bone weakness, and hearing loss caused by changes in the inner ear (sensorineural hearing loss).\n\nMutations in the ATP6V0A4 gene impair the function of the V-ATPase proton pump. As a result, the kidneys are less able to control the acidity of the blood, which leads to bone weakness caused by loss of bone minerals (demineralization) and other consequences of metabolic acidosis. The body's capability to control the pH of the fluid in the inner ear is also impaired, resulting in sensorineural hearing loss.\n\n**Other Disorders**\n\nATP6V0A4 gene mutations have also been identified in people with renal tubular acidosis who have normal hearing when diagnosed, usually in infancy or early childhood. However, hearing loss sometimes does not develop until adulthood in renal tubular acidosis with deafness (described above), so some of these individuals are later found to have that disorder.\n\n**References**\n\n* Alper SL. Familial renal tubular acidosis. J Nephrol. 2010 Nov-Dec;23 Suppl 16:S57-76.\n* Andreucci E, Bianchi B, Carboni I, Lavoratti G, Mortilla M, Fonda C, Bigozzi M, Genuardi M, Giglio S, Pela I. Inner ear abnormalities in four patients with dRTA and SNHL: clinical and genetic heterogeneity. Pediatr Nephrol. 2009 Nov;24(11):2147-53.\n* Batlle D, Haque SK. Genetic causes and mechanisms of distal renal tubular acidosis. Nephrol Dial Transplant. 2012 Oct;27(10):3691-704.\n* Li X, Chai Y, Tao Z, Li L, Huang Z, Li Y, Wu H, Yang T. Novel mutations in ATP6V0A4 are associated with atypical progressive sensorineural hearing loss in a Chinese patient with distal renal tubular acidosis. Int J Pediatr Otorhinolaryngol. 2012 Jan;76(1):152-4.\n* Stover EH, Borthwick KJ, Bavalia C, Eady N, Fritz DM, Rungroj N, Giersch AB, Morton CC, Axon PR, Akil I, Al-Sabban EA, Baguley DM, Bianca S, Bakkaloglu A, Bircan Z, Chauveau D, Clermont MJ, Guala A, Hulton SA, Kroes H, Li Volti G, Mir S, Mocan H, Nayir A, Ozen S, Rodriguez Soriano J, Sanjad SA, Tasic V, Taylor CM, Topaloglu R, Smith AN, Karet FE. Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J Med Genet. 2002 Nov;39(11):796-803.\n* Vargas-Poussou R, Houillier P, Le Pottier N, Strompf L, Loirat C, Baudouin V, Macher MA, Dechaux M, Ulinski T, Nobili F, Eckart P, Novo R, Cailliez M, Salomon R, Nivet H, Cochat P, Tack I, Fargeot A, Bouissou F, Kesler GR, Lorotte S, Godefroid N, Layet V, Morin G, Jeunemaitre X, Blanchard A. Genetic investigation of autosomal recessive distal renal tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. J Am Soc Nephrol. 2006 May;17(5):1437-43.\n\n---\n\n**ATP6V0A4 Gene**\n\n**What is the ATP6V0A4 gene?**\n\nThe ATP6V0A4 gene is located on chromosome 7 and plays a crucial role in the function of the kidneys and inner ear.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Genomic Location**\n\nThe ATP6V0A4 gene is found on chromosome 7.\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\n\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.\n\n**Clinical Significance**\n\nMutations in the ATP6V0A4 gene have been associated with distal renal tubular acidosis (dRTA) and sensorineural hearing loss (SNHL). Studies have identified novel mutations in this gene, highlighting its importance in the pathogenesis of these disorders.",
    "category": "general"
  },
  {
    "title": "ATP6V1B1 gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp6v1b1/",
    "content": "**ATP6V1B1 Gene**\n\nThe ATP6V1B1 gene provides instructions for making a part (subunit) of a large protein complex known as vacuolar H+-ATPase (V-ATPase). V-ATPases are a group of similar complexes that act as pumps to move positively charged hydrogen atoms (protons) across membranes. Because acids are substances that can \"donate\" protons to other molecules, this movement of protons helps regulate the relative acidity (pH) of cells and their surrounding environment. Tight control of pH is necessary for most biological reactions to proceed properly.\n\nThe V-ATPase that includes the subunit produced from the ATP6V1B1 gene is found in the inner ear and in nephrons, which are the functional structures within the kidneys. The kidneys filter waste products from the blood and remove them in urine. They also reabsorb needed nutrients and release them back into the blood. Each nephron consists of two parts: a renal corpuscle (also known as a glomerulus) that filters the blood, and a renal tubule that reabsorbs substances that are needed and eliminates unneeded substances in urine. The V-ATPase is involved in regulating the amount of acid that is removed from the blood into the urine, and also in maintaining the proper pH of the fluid in the inner ear (endolymph).\n\n**Health Conditions Related to Genetic Changes**\n\nRenal tubular acidosis with deafness is a disorder involving excess acid in the blood (metabolic acidosis), bone weakness, and hearing loss caused by changes in the inner ear (sensorineural hearing loss). More than 25 ATP6V1B1 gene mutations have been identified in people with this condition. Mutations in the ATP6V1B1 gene impair the function of the V-ATPase proton pump. As a result, the kidneys are less able to control the acidity of the blood, which leads to bone weakness caused by loss of bone minerals (demineralization) and other consequences of metabolic acidosis.\n\n---\n\n**ATP6V1B1 Gene: MedlinePlus Genetics (Part 2/3)**\n\nThe body's capability to control the pH of the fluid in the inner ear is also impaired, resulting in sensorineural hearing loss.\n\n**Renal Tubular Acidosis with Deafness**\n\nMore than 25 ATP6V1B1 gene mutations have been identified in people with renal tubular acidosis with deafness, a disorder involving excess acid in the blood (metabolic acidosis), bone weakness, and hearing loss caused by changes in the inner ear (sensorineural hearing loss).\n\nMutations in the ATP6V1B1 gene impair the function of the V-ATPase proton pump. As a result, the kidneys are less able to control the acidity of the blood, which leads to bone weakness caused by loss of bone minerals (demineralization) and other consequences of metabolic acidosis. The body's capability to control the pH of the fluid in the inner ear is also impaired, resulting in sensorineural hearing loss.\n\n**Other Names for This Gene**\n\nATP6B1\nATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 endomembrane proton pump 58 kDa subunit\nH(+)-transporting two-sector ATPase, 58kD subunit\nH+-ATPase beta 1 subunit\nRTA1B\nV-ATPase B1 subunit\nV-ATPase subunit B 1\nV-type proton ATPase subunit B, kidney isoform\nvacuolar proton pump 3\nvacuolar proton pump subunit B 1\nvacuolar proton pump, subunit 3\nVATB\nVMA2\nVPP3\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry\n\nScientific Articles on PubMed\n\nCatalog of Genes and Diseases from OMIM\n\nGene and Variant Databases\n\nReferences:\n\n* Alper SL. Familial renal tubular acidosis. J Nephrol. 2010 Nov-Dec;23 Suppl 16:S57-76.\n* Andreucci E, Bianchi B, Carboni I, Lavoratti G, Mortilla M, Fonda C, Bigozzi M, Genuardi M, Giglio S, Pela I. Inner ear abnormalities in four patients with dRTA and SNHL: clinical and genetic heterogeneity. Pediatr Nephrol. 2009 Nov;24(11):2147-53.\n* Batlle D, Haque SK. Genetic causes and mechanisms of distal renal tubular acidosis. Nephrol Dial Transplant. 2012 Oct;27(10):3691-704.\n* Gil H, Santos F, Garcia E, Alvarez MV, Ordonez FA, Malaga S, Coto E. Distal RTA with nerve deafness: clinical spectrum and mutational analysis in five children. Pediatr Nephrol. 2007 Jun;22(6):825-8.\n* Mohebbi N, Vargas-Poussou R, Hegemann SC, Schuknecht B, Kistler AD, Wuthrich RP, Wagner CA. Homozygous and compound heterozygous mutations in the ATP6V1B1 gene in patients with renal tubular acidosis and sensorineural hearing loss. Clin Genet. 2013 Mar;83(3):274-8.\n* Nikali K, Vanegas JJ, Burley MW, Martinez J, Lopez LM, Bedoya G, Wrong OM, Povey S, Unwin RJ, Ruiz-Linares A. Extensive founder effect for distal renal tubular acidosis (dRTA) with sensorineural deafness in an isolated South American population. Am J Med Genet A. 2008 Oct 15;146A(20):2709-12.\n* Sethi SK, Singh N, Gil H, Bagga A. Genetic studies in a family with distal renal tubular acidosis and sensorineural deafness. Indian Pediatr. 2009 May;46(5):425-7.\n* Stover EH, Borthwick KJ, Bavalia C, Eady N, Fritz DM, Rungroj N, Giersch AB, Morton CC, Axon PR, Akil I, Al-Sabban EA, Baguley DM, Bianca S, Bakkaloglu A, Bircan Z, Chauveau D, Clermont MJ, Guala A, Hulton SA, Kroes H, Li Volti G, Mir S, Mocan H, Nayir A, Ozen S, Rodriguez Soriano J, Sanjad SA, Tasic V, Taylor CM, Topaloglu R, Smith AN, Karet FE. Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J Med Genet. 2002 Nov;39(11):796-803.\n\n---\n\n**ATP6V1B1 Gene**\n\n**Genomic Location**\nThe ATP6V1B1 gene is found on chromosome 2.\n\n**Related Health Topics**\n\n* Genes and Gene Therapy\n* Genetic Disorders\n\n**Understanding Genetics**\n\n* What is DNA?\n* What is a gene?\n* What is a gene variant and how do variants occur?\n\n**Disclaimers**\nMedlinePlus links to health information from the National Institutes of Health and other federal government agencies. MedlinePlus also links to health information from non-government Web sites. See our disclaimer about external links and our quality guidelines.\n\nThe information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.",
    "category": "general"
  },
  {
    "title": "ATP7A gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp7a/",
    "content": "**ATP7A Gene**\n\nThe ATP7A gene provides instructions for making a protein that is important for regulating copper levels in the body. Copper is necessary for many cellular functions, but it is toxic when present in excessive amounts.\n\n**Normal Function**\n\n* The ATP7A protein is found throughout the body, except in liver cells.\n* In the small intestine, this protein helps control the absorption of copper from food.\n* In other cells, the ATP7A protein has a dual role and shuttles between two cellular locations.\n* The protein normally resides in a cell structure called the Golgi apparatus, which modifies newly produced proteins, including enzymes.\n* In the Golgi apparatus, the ATP7A protein supplies copper to certain enzymes that are critical for the structure and function of bone, skin, hair, blood vessels, and the nervous system.\n* If copper levels in the cell environment are elevated, however, the ATP7A protein moves to the cell membrane and eliminates excess copper from the cell.\n\n**Health Conditions Related to Genetic Changes**\n\n* **Cutis Laxa**: Several mutations in the ATP7A gene are responsible for a condition called occipital horn syndrome or X-linked cutis laxa, which is considered a mild form of Menkes syndrome.\n\t+ Occipital horn syndrome is characterized by loose and sagging skin, wedge-shaped calcium deposits in a bone at the base of the skull (the occipital bone), coarse hair, and loose joints.\n* **Menkes Syndrome**: Researchers have identified more than 150 mutations in the ATP7A gene that cause Menkes syndrome.\n\t+ Many of these mutations delete part of the gene and likely result in a shortened ATP7A protein.\n\t+ Other mutations insert additional DNA building blocks (nucleotides) into the gene or change single nucleotides.\n\t+ All of these mutations prevent the production of functional ATP7A protein.\n\t+ As a result, the absorption of copper from food is impaired, and copper is not supplied to certain enzymes.\n\t+ The abnormal protein may get stuck in the cell membrane and become unable to shuttle back and forth from the Golgi apparatus.\n\n---\n\n**ATP7A Gene**\n\n**Charcot-Marie-Tooth Disease**\n\nMedlinePlus Genetics provides information about Charcot-Marie-Tooth disease.\n\n**Cutis Laxa**\n\nSeveral mutations in the ATP7A gene are responsible for a condition called occipital horn syndrome or X-linked cutis laxa, which is considered a mild form of Menkes syndrome. Occipital horn syndrome is characterized by loose and sagging skin, wedge-shaped calcium deposits in a bone at the base of the skull (the occipital bone), coarse hair, and loose joints.\n\nMost of the mutations that cause occipital horn syndrome reduce but do not eliminate the production of the ATP7A protein. A shortage of this protein impairs the absorption of copper from food and prevents its normal distribution to cells throughout the body. The decreased supply of copper can reduce the activity of numerous copper-containing enzymes, affecting the structure and function of bone, skin, hair, blood vessels, and the nervous system.\n\n**Menkes Syndrome**\n\nResearchers have identified more than 150 mutations in the ATP7A gene that cause Menkes syndrome. Many of these mutations delete part of the gene and likely result in a shortened ATP7A protein. Other mutations insert additional DNA building blocks (nucleotides) into the gene or change single nucleotides. All of these mutations prevent the production of functional ATP7A protein.\n\nAs a result, the absorption of copper from food is impaired, and copper is not supplied to certain enzymes. The abnormal protein may get stuck in the cell membrane and become unable to shuttle back and forth from the Golgi apparatus.\n\nThe disrupted activity of the ATP7A protein causes copper to be poorly distributed to cells in the body. Copper accumulates in some tissues, such as the small intestine and kidneys, while the brain and other tissues have unusually low levels. The decreased supply of copper can reduce the activity of numerous copper-containing enzymes, affecting the structure and function of bone, skin, hair, blood vessels, and the nervous system.\n\n**Other Names for This Gene**\n\nATP7A_HUMAN\nATPase, Cu++ transporting, alpha polypeptide\nATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome)\nATPP1\ncopper pump 1\nMC1\nMK\nMNK\nOHS\n\n**Additional Information & Resources**\n\nTests Listed in the Genetic Testing Registry:\nTests of ATP7A\n\nScientific Articles on PubMed:\nPubMed\n\nCatalog of Genes and Diseases from OMIM:\nATPase, Cu(2+)-TRANSPORTING, ALPHA POLYPEPTIDE; ATP7A\n\n---\n\n**ATP7A Gene**\n\nThe ATP7A gene is responsible for encoding a protein that plays a crucial role in copper transport and homeostasis in the body.\n\n**Scientific Articles on PubMed**\n\n*   Barnes N, Tsivkovskii R, Tsivkovskaia N, Lutsenko S. The copper-transporting ATPases, menkes and wilson disease proteins, have distinct roles in adult and developing cerebellum. J Biol Chem. 2005 Mar 11;280(10):9640-5.\n*   Bertini I, Rosato A. Menkes disease. Cell Mol Life Sci. 2008 Jan;65(1):89-91.\n*   de Bie P, Muller P, Wijmenga C, Klomp LW. Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet. 2007 Nov;44(11):673-88.\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   ATPase, Cu(2+)-TRANSPORTING, ALPHA POLYPEPTIDE; ATP7A\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n**References**\n\nExpand Section\n\nThe references listed below provide additional information on the ATP7A gene and its relationship to Menkes disease.\n\n*   Barnes N, Tsivkovskii R, Tsivkovskaia N, Lutsenko S. The copper-transporting ATPases, menkes and wilson disease proteins, have distinct roles in adult and developing cerebellum. J Biol Chem. 2005 Mar 11;280(10):9640-5.\n*   Bertini I, Rosato A. Menkes disease. Cell Mol Life Sci. 2008 Jan;65(1):89-91.\n*   de Bie P, Muller P, Wijmenga C, Klomp LW. Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet. 2007 Nov;44(11):673-88.\n\n**Genomic Location**\n\nThe ATP7A gene is located on the X chromosome.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders\n\n---\n\n**ATP7A Gene**\n\n\\n\\n* **What is the ATP7A gene?**\n* **How do changes in the ATP7A gene affect the body?**\n* **Can the effects of changes in the ATP7A gene be treated or prevented?**\n* **Where can I find more information about the ATP7A gene?**",
    "category": "general"
  },
  {
    "title": "ATP7B gene: MedlinePlus Genetics",
    "url": "https://medlineplus.gov/genetics/gene/atp7b/",
    "content": "**ATP7B Gene**\n\nThe ATP7B gene provides instructions for making a protein called copper-transporting ATPase 2. This protein is part of the P-type ATPase family, a group of proteins that transport metals into and out of cells by using energy stored in the molecule adenosine triphosphate (ATP). Copper-transporting ATPase 2 is found primarily in the liver, with smaller amounts in the kidneys and brain. It plays a role in the transport of copper from the liver to other parts of the body. Copper is an important part of certain enzymes that maintain normal cell functions. Copper-transporting ATPase 2 is also important for the removal of excess copper from the body.\n\nWithin liver cells, copper-transporting ATPase 2 is found in a structure called the Golgi apparatus, which modifies newly produced enzymes and other proteins. Here, copper-transporting ATPase 2 supplies copper to a protein called ceruloplasmin, which transports copper to other parts of the body via the blood. If copper levels in the liver get too high, copper-transporting ATPase 2 leaves the Golgi and transfers copper to small sacs (vesicles) for elimination through bile. Bile is a substance produced by the liver that is important for digestion and the removal of waste products.\n\n**Health Conditions Related to Genetic Changes**\n\nWilson disease\n\nResearchers have identified more than 250 ATP7B gene mutations that cause Wilson disease. About half the mutations change one of the protein building blocks (amino acids) used to make copper-transporting ATPase 2. This type of mutation alters the 3-dimensional structure of the protein or its stability, preventing copper-transporting ATPase 2 from functioning properly. A common amino acid substitution replaces the amino acid histidine with the amino acid glutamine at position 1069 in the protein (written as His1069Gln or H1069Q). This particular mutation occurs in nearly 40 percent of affected individuals with a Northern or Eastern European ancestry. Approximately one-third of Asians with Wilson disease have a mutation that replaces the amino acid arginine with the amino acid leucine at position 778 (written as Arg778Leu or R778L).\n\n---\n\n**ATP7B Gene: MedlinePlus Genetics (Part 2/3)**\n\n**Wilson Disease**\n\nResearchers have identified more than 250 ATP7B gene mutations that cause Wilson disease. About half the mutations change one of the protein building blocks (amino acids) used to make copper-transporting ATPase 2.\n\n*   A common amino acid substitution replaces the amino acid histidine with the amino acid glutamine at position 1069 in the protein (written as His1069Gln or H1069Q). This particular mutation occurs in nearly 40 percent of affected individuals with a Northern or Eastern European ancestry.\n*   Approximately one-third of Asians with Wilson disease have a mutation that replaces the amino acid arginine with the amino acid leucine at position 778 (written as Arg778Leu or R778L).\n*   In the Costa Rican population, more than 60 percent of affected individuals have a mutation that replaces the amino acid aspartic acid with the amino acid serine at position 1270 (written as Asp1270Ser or D1270S).\n\nOther types of mutations delete or insert small segments of DNA within the ATP7B gene or introduce a stop signal in the gene's instructions for making copper-transporting ATPase 2. As a result, no protein is produced, or an abnormally small protein is made. These types of mutations usually result in symptoms that are more severe than those caused by mutations that change a single amino acid.\n\nWith a shortage of functional protein, removal of excess copper from the body is impaired. As a result, copper accumulates to toxic levels that can damage tissues and organs, particularly the liver and brain.\n\n**Other Names for This Gene**\n\n*   ATP7B_HUMAN\n*   ATPase, Cu++ transporting, beta polypeptide\n*   Copper pump 2\n*   PWD\n*   WC1\n*   Wilson disease-associated protein\n*   WND\n\n---\n\n**ATP7B Gene**\n\n**Scientific Articles on PubMed**\n\n*   Cater MA, Forbes J, La Fontaine S, Cox D, Mercer JF. Intracellular trafficking of the human Wilson protein: the role of the six N-terminal metal-binding sites. Biochem J. 2004 Jun 15;380(Pt 3):805-13.\n*   Fatemi N, Sarkar B. Molecular mechanism of copper transport in Wilson disease. Environ Health Perspect. 2002 Oct;110 Suppl 5(Suppl 5):695-8.\n*   Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet. 2006 Sep;120(2):151-9.\n*   Huster D, Hoppert M, Lutsenko S, Zinke J, Lehmann C, Mossner J, Berr F, Caca K. Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines. Gastroenterology. 2003 Feb;124(2):335-45.\n*   Kitzberger R, Madl C, Ferenci P. Wilson disease. Metab Brain Dis. 2005 Dec;20(4):295-302.\n*   Langner C, Denk H. Wilson disease. Virchows Arch. 2004 Aug;445(2):111-8.\n*   Panagiotakaki E, Tzetis M, Manolaki N, Loudianos G, Papatheodorou A, Manesis E, Nousia-Arvanitakis S, Syriopoulou V, Kanavakis E. Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Am J Med Genet A. 2004 Dec 1;131(2):168-73.\n\n**Catalog of Genes and Diseases from OMIM**\n\n*   ATPase, Cu(2+)-TRANSPORTING, BETA POLYPEPTIDE; ATP7B\n\n**Gene and Variant Databases**\n\n*   NCBI Gene\n*   ClinVar\n\n**Tests Listed in the Genetic Testing Registry**\n\n*   Tests of ATP7B\n\n**Genomic Location**\n\nThe ATP7B gene is found on chromosome 13.\n\n**Related Health Topics**\n\n*   Genes and Gene Therapy\n*   Genetic Disorders",
    "category": "general"
  }
]